

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 16:02:08 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Washington Times Corona virus interviw
Attachments: RE: Interview request: Wuhan coronavirus, Washington Times

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 15:13:22 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD Radio Free Asia Interview (taped)
Attachments: RE: Dr Fauci interview

Thank you. Would like to film for both our radio and social media (Facebook and Youtube).
Looking forward to hearing from you.

Carmen Wu
Broadcaster
Cantonese Service

Radio Free Asia
2025 M Street NW Ste. 300
Washington, DC 20036
Telephone - (202) 530-4016

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 17:38:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- ABC local news Corona on Camera (Taped)
Attachments: RE: Media Request: Wuhan coronavirus/ABC7 TV (in office, on camera)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 14:17:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - NPR's daily news show, 1A (Live Hit 10:20 am ET)
Attachments: RE: Radio interview request (NPR/1A): Tuesday, January 28, 10:30 - 11am ET

My name is Stacia Brown, and I'm a producer for NPR's daily news show, 1A. I'm writing to see if you might be able to join us for an on-air discussion about the coronavirus tomorrow. We're planning a "latest updates" and fact-check conversation for a 10:30 - 11am segment tomorrow, January 28. If you'd be able to join us in studio at WAMU on American University's campus, we'd be honored to have you back as a guest.

Thank you for considering this request!

Sincerely,

Stacia Brown

Producer, 1A

WAMU 88.5 | 4401 Connecticut Ave NW, Washington, DC 20008
202.885.1296 (o)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 17:54:26 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Pre-Brief: GPMB Mtg w/ Nicki Lurie & Jerry Keusch
Attachments: RE: time to discuss GPMB, RE: time to discuss GPMB

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 18:26:54 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CBS Evening News Nora O'Donnell (taped on Camera at 5:00 pm ET)
Attachments: Fwd: Adam Verdugo, Adam Verdugo.vcf, ATT00001.txt

Andrew Verdugo -on site contact Cell is (b) (6) – CALL ANDREW UPON ARRIVAL AND HE WILL MEET IN LOBBY

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 18:13:03 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: NewsMax Live Hit 7:20 pm ET - 7:30 pm ET
Attachments: RE: Wuhan interview with Dr. Fauci

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 14:33:19 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: -Interview with WIRED re Corona virus
Attachments: FW: Wired article on Wuhan coronavirus, RE: Wired article on Wuhan coronavirus, RE: Wired article on Wuhan coronavirus, FW: Wired article on Wuhan coronavirus

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 16:51:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD CNBC Taped or Live on Camera
Attachments: RE: CNBC

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 19:29:14 +0000
To: Jeremy Farrar;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Is there a cell number to reach you? or best number?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar <(b) (6)>
Sent: Wednesday, January 29, 2020 2:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET

I could not make it until 5pm CET today. But next few days also OK.

From: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)> on behalf of "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Wednesday, 29 January 2020 at 18:54
To: Jeremy Farrar <(b) (6)>
Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Dr Fauci is in back to back meetings but hopes to be able to step out and call you between 3:00 pm ET – 4:00 pm ET. Is that time ok and what is the best number to reach you at that time?

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)
Sent: Wednesday, January 29, 2020 1:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET

Tony - Would be very keen to hear your personal views on n-CoV. If you have 5 mins for a phone call.
Best wishes Jeremy

From: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Date: Wednesday, 29 January 2020 at 16:44
To: Michael RYAN (b) (6); "Redfield, Robert R. (CDC/OD)" (b) (6); (b) (6); (b) (6); (b) (6), David Heymann (b) (6); (b) (6); "Chris.Elias"; (b) (6), Richard Hatchett (b) (6); Jeremy Farrar (b) (6); (b) (6); (b) (6); (b) (6); "COX, Paul Michael" (b) (6); SHOC <shoc@who.int>, "GREIN, Thomas" (b) (6); "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>, "Marston, Hilary (NIH/NIAID) [E]" (b) (6); **Cc:** "GHEBREYESUS, Tedros Adhanom" (b) (6), Bernhard Schwartländer (b) (6); (b) (6); "MINHAS, Raman" (b) (6);
Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Mike:

I am sorry but I have an important meeting with Secretary Azar that is a prep meeting for another important meeting at the White House. These overlap with the 19:00 CET time frame of your call. Unless something changes I cannot be on the call. If that is the case, I will ask Hilary Marston from my staff to fill in for me and report back to me. Please send the call in information to my Special Assistant, Patty Conrad, and me just in case something changes.

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. <(b) (6)>
Sent: Wednesday, January 29, 2020 10:45 AM
To: Redfield, Robert R. (CDC/OD) (b) (6)
(b) (6); David Heymann (b) (6)
Chris.Elias <(b) (6)> (b) (6)
(b) (6); Fauci, Anthony
(NIH/NIAID) [E] <(b) (6)> (b) (6)
(b) (6) COX, Paul Michael (b) (6); SHOC <shoc@who.int>; GREIN, Thomas
(b) (6)
Cc: GHEBREYESUS, Tedros Adhanom (b) (6); SCHWARTLANDER, Bernhard F.
(b) (6); MINHAS, Raman (b) (6)
Subject: Informal coronavirus teleconference, 29 January, 19.00 CET

Dear colleagues,

Dr Tedros would like to take the opportunity to informally discuss with you the ongoing 2019 novel coronavirus.

We are planning to host a teleconference today at 19.00 CET and will provide a dial-in number with a passcode.

If you face any difficulties with the dial-in number, please provide us with a contact number and we will attempt to dial you in.

Best,

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 18:47:26 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: Daily Caller Skype interview
Attachments: RE: FW: Interview request: The Daily Caller, Wuhan coronavirus, RE: FW: Interview request: The Daily Caller, Wuhan coronavirus

My cell number is (b) (6). We will add you on Skype tomorrow and contact you with via the username below. Thank you!

The Skype username is (b) (6)

Maranda Finney
The Daily Caller
(b) (6)
maranda@dailycaller.com
Topic: Wuhan coronavirus
Deadline: Thursday

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 17:51:03 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CSPAN Podcast Taped 20 minutes Corona virus w/ Steve Scully
Attachments: RE: C-SPAN Interview Request , RE: C-SPAN Interview Request , RE: C-SPAN Interview Request

Yes, we can confirm for 12:30pmET for the interview. This will be done by landline and taped on our end.

If you need to reach me the best number is [REDACTED] (b) (6)

My name is Shannon Rice, I'm a producer at C-SPAN. Jenn Ruff from Washington Journal passed me on your contact info and says hello! We were hoping that Dr. Fauci might have some time this week to do TAPED podcast on the Coronavirus & disease outbreaks in general. It would be for our podcast The Weekly. It would be 20-25 minutes in length. No calls, just a conversation between him and our host Steve Scully.

We can either do it on the phone or if he is available we can arrange a car for him to come to the studio here on Capitol Hill. Might he have any time this week?

Thank you so much.

Shannon Rice
C-SPAN Radio
Producer, Washington Today & The Weekly Podcast
202-626-4841

From: (b) (6)
Sent: Thu, 23 Jan 2020 08:55:11 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: Coronavirus and Davos

Thanks, Francis.

> On Jan 23, 2020, at 8:51 AM, Collins, Francis (NIH/OD) [E] <(b) (6)> wrote:

>

> Thanks for all this updated info, Tony. I had a premonition that Lally Weymouth would call on me at the Washington Post luncheon (in front of numerous US Cabinet members, Ivanka, and several heads of state). Sure enough, she did. I think I did a decent job of relating what we currently know about coronavirus, and what we don't know yet.

>

> If there are press calls about what the US is doing, I will refer them to you. I'm ccing John.

>

> FC

>

> -----Original Message-----

> From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

> Sent: Thursday, January 23, 2020 6:56 AM

> To: Collins, Francis (NIH/OD) [E] <(b) (6)>

> Subject: RE: Coronavirus and Davos

>

> Anecdotal data suggest that most transmissions occur when transmitter is late in the infection, i.e. clinically ill. However, some anecdotal data suggest that early transmission does occur to some degree. The man in Seattle who travelled to Wuhan cannot remember coming into contact with anyone who appeared ill. Regarding mAbs, we have them against SARS and MERS and are hoping that there is some cross-reactivity of the anti-SARS Abs with nCov. However, it is difficult at this time to test since we do not yet have isolates of nCov; we only have sequence. As soon as we get isolated we can test.

>

> -----Original Message-----

> From: Collins, Francis (NIH/OD) [E] <(b) (6)>

> Sent: Thursday, January 23, 2020 5:50 AM

> To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

> Subject: Coronavirus and Davos

>

> Hi again,

> Was just part of a discussion with Hatchett, Farrar, WHO rep (Tedros not here), Berkley, Stoffels. Big issue seems to be whether transmissibility happens early or late in the course of infection. Obviously late would be much better for public health measures. Your read on current data?

> Any effort on developing MAb at NIH?

> FC

>

> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 15:26:13 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD TENATIVE - CNN New Day (Live Hit: 6 am hour)
Attachments: RE: Request from CNN's New Day

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 13:55:09 +0000
To: Secretary Scheduler (OS/IOS)
Subject: Accepted: HOLD: AMA updates on Coronavirus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 20:19:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - WTOP Live hit at 12:10 pm ET
Attachments: RE: WTOP Request

Hoping Dr. Fauci can is available is join us tomorrow morning or early afternoon to discuss the WHO declaring a public emergency for the coronavirus.

We could pretape the interview at 8:30am or he could join us live at 10:40a, 11:10a, or 12:10p.

Thanks!

Joslyn Chesson
Editor
WTOP News
(202) 895-5060

From: (b) (6)
Sent: Sat, 25 Jan 2020 15:16:59 -0500
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: Fwd: Prospective Intern, Interested in Your Research

Please handle
Sent from my iPhone

Begin forwarded message:

From: (b) (6)
Date: January 25, 2020 at 1:39:13 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: **Prospective Intern, Interested in Your Research**

Howdy Dr. Anthony S. Fauci,

I have recently completed the SIP application to be considered for a summer internship through the NIH. Upon searching for potential labs to contact I quickly found your name and was intrigued by your work and the potential to be considered as an intern in your research group. I apologize if this is not standard protocol, I definitely feel some apprehension towards reaching out to such esteemed scientists but the recommendation given upon submission of the application was that I reach out to researchers, as you all are the deciding factor in the placement of interns.

I am a senior Animal Science, Entomology, and Public Health student at (b) (6) who will be attending (b) (6) as a Masters Student, studying Epidemiology, in the Fall of 2020.

I am very interested in the research interests listed under your profile, specifically concerning your work on understanding the molecular mechanisms of immune dysfunction caused by HIV infection as well as the references to your work, in the news, concerning the Wuhan Coronavirus. (b) (6)

(b) (6)
I believe a lab such as yours could be beneficial in preparing me for success in these endeavors!

I have spent my undergraduate career working in a CDC Excellence Center lab under (b) (6)

(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)

I would love to get in contact with you concerning the potential to be involved in your research!

I appreciate your time,

(b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 16:48:49 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Podcast with Newt Gingrich
Attachments: RE: Guest for Coronavirus podcast episode, RE: Guest for Coronavirus podcast episode

Hello Dr. Fauci -- My name is Tamera, I handle the booking for Newt Gingrich's Podcast, [Newt's World](#). It is a non-partisan show where Newt gives historical context behind people and events. We launched last February and have 2.5 millions downloads to date with new episodes each Sunday. We are working on an episode of the podcast centered around "The Coronavirus" where you might discuss **The Global viruses** [Novel Coronavirus 2019 (nCoV-2019),SARS,MERS,Bird Flu] and **What Can Be Done to Prevent the Next Epidemic?**

If interested, Newt would interview you on Thursday, February 6th, where you would call in to the studio. The podcast would air Sunday, February 9th.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 18:57:18 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Masur, Henry (NIH/CC/CCMD) [E]; Burton, Deborah (NIH/CC/CCMD) [E]; Shyamasundaran Kottillil (b) (6); Barasch, Kimberly (NIH/NIAID) [C]; Lerner, Andrea (NIH/NIAID) [E]; Eisinger, Robert (NIH/NIAID) [E]
Subject: Update on HIV, HBV, OUD with Drs Masur and kottillil
Attachments: RE: Update on HIV, HBV, OUD, Update on HIV, HBV, OUD with Drs Masur and kottillil

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 19:23:55 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: AFP On Camera Interview Corona virus (taped)
Attachments: RE: Interview request: AFP, Wuhan coronavirus

From: (b) (6)
Sent: Sun, 26 Jan 2020 15:19:59 -0500
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Wuhan coronavirus

(b) (5)

On Jan 26, 2020, at 3:08 PM, Marston, Hilary (NIH/NIAID) [E]
(b) (6) wrote:

ASF: (b) (5)

From: "Buchholz, Ulla (NIH/NIAID) [E]" <(b) (6)>
Date: Sunday, January 26, 2020 at 1:25 PM
To: Hilary Marston (b) (6)
Cc: "Cohen, Jeffrey (NIH/NIAID) [E]" (b) (6)
Subject: Wuhan coronavirus

Dear Hilary,

In 2003/2004, a small group in the lab of Peter Collins rapidly generated parainfluenza virus vaccine candidates expressing SARS S, please see attached publications. We used a bovine/human parainfluenza virus type 3 vector (B/HPIV3) which contains internal proteins of bovine PIV3; its surface glycoproteins F and HN are derived from human PIV3. In the African green monkey model, a single intranasal dose of B/HPIV3 expressing the S protein of SARS CoV S induced high levels of SARS CoV neutralizing antibodies. After SARS CoV challenge, all control animals shed SARS CoV, while no SARS CoV shedding was detected in the B/HPIV3/SARS-S immunized NHPs.

This vector is also being used to express versions of the respiratory syncytial virus fusion protein. The RSV F expressing version of B/HPIV3 has been evaluated in Phase 1 studies, and shown to be safe in PIV3-seronegative infants and children.

(b) (5)

Thank you,
Ulla

--

Ursula Buchholz, PhD
Senior Associate Scientist
RNA Viruses Section
Laboratory of Infectious Diseases
NIAID, NIH
Bldg. 50, Rm. 6503
50 South Drive, MSC 8007
Bethesda, MD 20892

Phone: (b) (6)

Fax: (301) 480-1268

email: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

<

<

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 20:13:56 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: RAI Italy TV Coronavirus interview (taped on camera)
Attachments: RE: ON AIR: Interview request: coronavirus/profile | RAI Italy

Erika Esposito (Producer)

RAI Italy

(b) (6) | booking@gvgusa.com

Reporter: Claudio Paglira

Subject: coronavirus, ASF profile

Hi Patty,

Italy's national TV network would like to produce a segment on their evening news broadcast profiling Dr. Fauci's work on coronavirus and infectious disease control generally. The crew is based in NYC and can come to campus at Dr. Fauci's earliest convenience anytime after Feb 5. They anticipate needing 30 min for an interview with 20 min for set-up in his office.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 17:55:17 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E]
Subject: HOLD Hill.TV Corona Interview - taped via Skype 1:00 -1:15pm
Attachments: RE: Hill.TV Interview Request, RE: Hill.TV Interview Request

From: (b) (6)
Sent: Sun, 26 Jan 2020 16:56:42 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Ayesha from FOX 5

Sent from my iPhone

Begin forwarded message:

From: Ayesha Khan <Aisha.Khan@FOXTV.COM>
Date: January 26, 2020 at 4:53:10 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Subject: Ayesha from FOX 5

Hello Dr. Fauci,

Reporter Ayesha Khan from FOX 5. Are you by any chance available for another on camera interview regarding three people who are currently being investigated for possibly showing signs of the Coronavirus in Virginia? Two in Central and one in No. Va.

I can be reached on my cell at (b) (6).
Thanks so much!
Ayesha

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 13:53:30 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CNN New Day (Live Hit: 6:28 am ET)
Attachments: Fwd: Request from CNN's New Day, RE: Request from CNN's New Day

From: (b) (6)
Sent: Tue, 28 Jan 2020 12:41:40 -0500
To: Howard Bauchner
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Quick follow-up.

Wonderful! Thanks for sending.

On Jan 28, 2020, at 11:10 AM, Howard Bauchner <Howard.Bauchner@jamanetwork.org> wrote:

Tony – see below!

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

Late yesterday I had the privilege of interviewing Tony Fauci about the coronavirus epidemic. A follow-up of his VP that we published.

Had 1000 folks listening in while we live streamed it (Mike tells me that is good).

More exciting it has had 70,000 views on the various outlets – see below.

Not sure there is anyone in the world who could provide as erudite a description of SARs, MER, and this new outbreak than Tony.

HCB

From: Eman Aly
Sent: Tuesday, January 28, 2020 9:19 AM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Cc: Michael Berkwits <Michael.Berkwits@jamanetwork.org>
Subject: Links to Livestream

Twitter: <https://www.pscp.tv/w/1vOGwolpLBbGB>

Youtube: https://www.youtube.com/watch?v=3qlagdc_luM

Facebook: <https://business.facebook.com/jamajournal/videos/179944506555011/>

.....

Eman H. Aly

Manager – Social Communications & Digital Channel Strategy

JAMA Network™

330 N Wabash Ave, Ste 39300, Chicago, IL 60611

T 312-464-4259 M (b) (6)

eman.al@jamanetwork.org

jamanetwork.com

Skype: eman.al

Twitter: [@EmanMSW](https://twitter.com/EmanMSW)

Twitter: [@JAMANetwork](https://twitter.com/JAMANetwork)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 00:59:40 +0000
To: NIAID OD AM
Subject: FW: Coronavirus Preparedness Summit & Workshop- Call for Speakers

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: events@cov-s.com <events@cov-s.com>
Sent: Wednesday, January 29, 2020 10:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Coronavirus Preparedness Summit & Workshop- Call for Speakers

Dear Dr. Fauci,

It is my sincere pleasure to invite you to speak at the upcoming Coronavirus Preparedness Summit & Workshop planned for this June 17th to 19th in Washington, DC.

With expected 300 delegates from local, state, federal, and abroad, the 3-day event will bring together Public Health Officials, Emergency Preparedness Leaders, Academia, Business, Public and Private Sector Partners.

The 2019-nCoV Summit will provide a platform for public health officials and community stakeholders to come together, to network and exchange preparedness and response efforts. Special emphasis will be placed on identifying the responsibilities of various stakeholders in order to improve global communication coordination and collaboration.

Topics include:

- Delivery of Vaccine and Antiviral Medication
- Mass Fatality Management Planning
- Preparing Communities Strategies; Local Partnership and Participation
- Benefit-Risk Assessment: Public Health, Industry and Regulatory Perspectives
- Prevention Education Efforts and Risk Communication
- Command, Control and Management

- Emergency Response Management
- Business-Based Planning
- Community-Based Planning

I greatly appreciate your consideration of this request.

Best Regards,

Edna Santos
(703) 651-2092
events@cov-s.com
Events Coordinator

CORONAVIRUS **PREPAREDNESS**

SUMMIT & WORKSHOP

WASHINGTON, DC JUNE 17-19, 2020

Syllabusx

11250 Roger Bacon Drive #10, Reston, VA 20190

From: [REDACTED] (b) (6)
Sent: Tue, 28 Jan 2020 13:23:05 -0500
To: Corey MD, Larry
Subject: Re: [EXTERNAL] FW: Patient with coronavirus

Thanks

On Jan 28, 2020, at 10:21 AM, Corey MD, Larry <[REDACTED] (b) (6)> wrote:

Interesting email from Davide Corti [REDACTED] (b) (4)

Helen how is the patient doing ?

Sent from my iPhone

Begin forwarded message:

From: Davide Corti [REDACTED] (b) (6)
Date: January 28, 2020 at 7:00:05 AM PST
To: Skip Virgin [REDACTED] (b) (6)>
Cc: "Corey MD, Larry" [REDACTED] (b) (6)>
Subject: Re: [EXTERNAL] FW: Patient with coronavirus

Hi!
Thanks for sharing these infos.



Best,
Davide
<PastedGraphic-8.tiff>

Davide Corti, PhD
SVP, Antibody Research
Humabs BioMed SA | a subsidiary of Vir Biotechnology
Via dei Gaggini 3 | 6500 Bellinzona | Switzerland

On Jan 28, 2020, at 5:23 AM, Skip Virgin [REDACTED] (b) (6)> wrote:

Larry

(b) (4)

Davide please comment

Skip

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158
he/him/his

From: Corey MD, Larry (b) (6) >
Sent: Monday, January 27, 2020 4:49 PM
To: Skip Virgin (b) (6)
Subject: RE: [EXTERNAL] FW: Patient with coronavirus

(b) (4), (b) (6)

From: Skip Virgin (b) (6)
Sent: Monday, January 27, 2020 3:26 PM
To: Corey MD, Larry (b) (6)
Subject: RE: [EXTERNAL] FW: Patient with coronavirus

You are a god

(b) (6), (b) (4)

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158

he/him/his

From: Corey MD, Larry (b) (6)
Sent: Monday, January 27, 2020 1:13 PM
To: Skip Virgin (b) (6); George Scangos (b) (6)
Subject: [EXTERNAL] FW: Patient with coronavirus

(b) (4), (b) (6)

From: Helen Y Chu (b) (6)
Sent: Sunday, January 26, 2020 9:11 PM
To: Corey MD, Larry (b) (6)
Cc: Boeckh, Michael (b) (6)
Subject: Re: Patient with coronavirus

Thank you, Larry, understood.

(b) (6), (b) (4)

(b) (6), (b) (4)

Helen Y. Chu, MD MPH
Division of Allergy & Infectious Diseases
chulab.org

Our lab has moved to a new location in South Lake Union

From: "Corey MD, Larry" <(b) (6)>
Date: Sunday, January 26, 2020 at 1:42 PM
To: Helen Y Chu (b) (6)
Cc: "Boeckh, Michael" (b) (6)>
Subject: RE: Patient with coronavirus

Helen

(b) (4)

From: Helen Y Chu (b) (6) >
Sent: Sunday, January 26, 2020 10:27 AM
To: Mascola, John (NIH/VRC) [E] (b) (6) >; Anna Wald (b) (6); Suhana, Tina (NIH/VRC) [E] (b) (6) >
Cc: Corey MD, Larry (b) (6) >; McElrath, Julie (b) (6) >; Kathleen Neuzil (b) (6) >; Wesley C. Van Voorhis <(b) (6)>; Graham, Barney (NIH/VRC) [E] (b) (6) >; Corbett, Kizzmekia (NIH/VRC) [E] (b) (6); Morabito, Kaitlyn (NIH/VRC) [E] (b) (6) >; Bok, Karin (NIH/VRC) [E] (b) (6) >; Stein, Judy (NIH/VRC) [C] (b) (6) >; Ledgerwood, Julie (NIH/NIAID) [E] (b) (6) >; Chen, Grace (NIH/NIAID) [E] (b) (6) >; Marston, Hilary (NIH/NIAID) [E] (b) (6) >; Austin, Sarah (NIH/NIAID) [E] <(b) (6)>; Jay A. Shendure (b) (6)
Subject: Re: Patient with coronavirus

Dear John,
That sounds perfect. We will wait to hear from you about setting up a call as soon as possible.

Helen

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Sunday, January 26, 2020 10:18 AM
To: Anna Wald; Suhana, Tina (NIH/VRC) [E]
Cc: Corey MD, Larry; Helen Y Chu; Julie McElrath; Kathleen Neuzil; Wesley C. Van Voorhis; Graham, Barney (NIH/VRC) [E]; Corbett, Kizzmekia (NIH/VRC) [E]; Morabito, Kaitlyn (NIH/VRC) [E]; Bok, Karin (NIH/VRC) [E]; Stein, Judy (NIH/VRC) [C]; Ledgerwood, Julie (NIH/NIAID) [E]; Chen, Grace (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Austin, Sarah (NIH/NIAID) [E]
Subject: RE: Patient with coronavirus

Great.

Helen – I just talked to Barney who will be out of town next week, but suggested we proceed with a call. Kaitlyn Morabito is coordinating efforts for his lab and our clinical staff now also copied.

So lets wait to get confirmation for Hilary Marson from Tony's office – and then Tina can find time for a call.

(b) (4)

John

From: Anna Wald (b) (6)
Sent: Sunday, January 26, 2020 12:56 PM
To: Mascola, John (NIH/VRC) [E] (b) (6)
Cc: Corey MD, Larry <(b) (6)>; Helen Y Chu (b) (6); Julie McElrath (b) (6); Kathleen Neuzil (b) (6); Wesley C. Van Voorhis (b) (6); Graham, Barney (NIH/VRC) [E] (b) (6); Corbett, Kizzmekia (NIH/VRC) [E] (b) (6); Morabito, Kaitlyn (NIH/VRC) [E] (b) (6); Bok, Karin (NIH/VRC) [E] (b) (6); Stein, Judy (NIH/VRC) [C] (b) (6)>
Subject: Re: Patient with coronavirus

Dear John,

That sounds perfect. While I would like to remain in the loop, I am teaching in subSaharan Africa for the next 2 weeks so calls may be hard to coordinate with my schedule and I don't want to delay the discussions. Please go ahead and work with Helen directly- I know she is excited to collaborate. Helen and I will talk so she can update me.

Please don't hesitate to call my cell if there is anything we should discuss.

Best, Anna

Anna Wald, MD, MPH

Head of Allergy and Infectious Diseases Division
Professor of Medicine, Laboratory Medicine & Epidemiology, University of Washington

tel. (b) (6)
fax. 206/520-4371
University of Washington Virology Research Clinic
<http://depts.washington.edu/herpes/>

PHYSICAL LOCATION:
908 Jefferson St, Suite 11NJ-1166, Seattle, WA 98104

MAILING ADDRESS:

Harborview Medical Center, 325 9th Ave, Box #359928, Seattle, WA 98104

Privileged, confidential or patient identifiable information may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipient, or if the message has been addressed to you in error, do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply e-mail, and then destroy all copies of the message and any attachments.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Sunday, January 26, 2020 9:49:31 AM
To: Anna Wald (b) (6)
Cc: Corey MD, Larry (b) (6); Helen Y Chu (b) (6); Julie McElrath (b) (6); Kathleen Neuzil (b) (6); Wesley C. Van Voorhis (b) (6); Graham, Barney (NIH/VRC) [E] (b) (6); Corbett, Kizzmekia (NIH/VRC) [E] (b) (6); Morabito, Kaitlyn (NIH/VRC) [E] (b) (6); Bok, Karin (NIH/VRC) [E] (b) (6); Stein, Judy (NIH/VRC) [C] (b) (6)
Subject: RE: Patient with coronavirus

Dear Anna,

Thank you for this important email. We have had discussion with CDC leadership that NIAID/NIH should be primarily involved here. I'm copying the NIH POC, Dr. Hillary Marston, special assistant to Dr. Fauci.

(b) (4)

Of note, Dr. Barney Graham and several of his lab are leading our CoV vaccine and antibody efforts. Barney's lab has been working for several years on CoV spike protein and can produce stabilized versions that can be used as vaccine immunogens and protein probes to isolate antibodies. He is making these available to CDC and others.

Hilary, with help from Karin Bock on our end, can help set up a call, which I suggest would first be between your group and our NIH staff.

Thank you,

John R. Mascola, M.D.
Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
email: (b) (6)
office tel: (b) (6)

From: Anna Wald [REDACTED] (b) (6) >

Sent: Sunday, January 26, 2020 12:02 PM

To: Mascola, John (NIH/VRC) [E] [REDACTED] (b) (6)

Cc: Corey MD, Larry [REDACTED] (b) (6) >; Helen Y Chu [REDACTED] (b) (6); Julie McElrath [REDACTED] (b) (6); Kathleen Neuzil <[REDACTED] (b) (6)>; Wesley C. Van Voorhis [REDACTED] (b) (6)

Subject: Patient with coronavirus

Dear Dr. Mascola,

[REDACTED] (b) (4), (b) (6)

I am heading to the airport in few hours for a trip to Kenya so will not be on email. However, if anyone is trying to reach me, my cell phone is [REDACTED] (b) (6).

Thank you, Anna

Anna Wald, MD, MPH

Head of Allergy and Infectious Diseases Division,
Professor of Medicine, Laboratory Medicine & Epidemiology,
University of Washington

tel. 206/520-4340
fax. 206/520-4371
University of Washington Virology Research Clinic
<http://depts.washington.edu/herpes/>
pronouns: she/her/hers

PHYSICAL LOCATION:
908 Jefferson St, Suite 11NJ-1166, Seattle, WA 98104

MAILING ADDRESS:
Harborview Medical Center, 325 9th Ave, Box #359928, Seattle, WA 98104

Privileged, confidential or patient identifiable information may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipients. If you are not the intended recipient, or if the message has been addressed to you in error, do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply e-mail, and then destroy all copies of the message and any attachments.

<PastedGraphic-8.tiff>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 12:45:05 +0000
To: NIAID OD AM
Subject: FW: Question

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Wednesday, January 22, 2020 7:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Question

Just quoted you on Fox and Friends.

We want to know if you might be interested in coming to NYU to give Grand Rounds sometime over the next several weeks - on this coronavirus and vaccine candidate.

Grand Rounds are Wednesday mornings at 8 AM

It would be a great honor and pleasure to have you here.

We would of course cover all expenses and your fee.

Hope you will consider.

Marc

Sent from my iPhone

On Jan 22, 2020, at 5:52 AM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

[EXTERNAL]

Marc:

You certainly can quote me.

Best regards,

Tony

From: Siegel, Marc <Marc.Siegel@nyulangone.org>

Sent: Tuesday, January 21, 2020 10:30 PM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)

Subject: Re: Question

thanks Tony!

hope I can quote you!

From: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)

Sent: Tuesday, January 21, 2020 10:00:21 PM

To: Siegel, Marc

Subject: RE: Question

[EXTERNAL]

Marc:

Thanks for the note. We are already working on a vaccine for the 2019 n-CoV. We have the sequence of the virus and are employing an mRNA vaccine platform in collaboration with the Moderna Company. We hope to have the candidate in Phase 1 trials within 3 months. You might remember that we actually developed a DNA vaccine for SARS (another coronavirus pathogen) several years ago and brought it through Phase 1 trials showing safety and immunogenicity. We never developed it further since the SARS outbreak was completely stopped by good public health measures. Bottom line is that there is a good chance that over time, we will develop a vaccine for this virus.

Best regards,

Tony

-----Original Message-----

From: Siegel, Marc <Marc.Siegel@nyulangone.org>

Sent: Tuesday, January 21, 2020 4:41 PM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)

Subject: Question

Tony

Any chance of a vaccine for this coronavirus?

I believe they were testing one in dogs.

Marc

Sent from my iPhone

From: (b) (6)
Sent: Tue, 28 Jan 2020 13:26:48 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

No down side in re-affirming statement

On Jan 28, 2020, at 1:22 PM, Collins, Francis (NIH/OD) [E] <(b) (6)> wrote:

Hi Tony,

See below. NIH signed the 2016 statement. Do you see any negatives in re-affirming this?

Francis

From: Jeremy Farrar <(b) (6)>
Sent: Tuesday, January 28, 2020 1:17 PM
To: (b) (6)
(b) (6)
(b) (6); Casey, Christine G. (CDC/DDPHSS/CSELS/OD) (b) (6);
(b) (6);
(b) (6) Mark J Walport (b) (6)
Charlotte Watts (b) (6)
Collins, Francis (NIH/OD) [E] <(b) (6)> (b) (6)
(b) (6) Dzau, Victor J. (b) (6); Paul Stoffels
(b) (6); George Gao (b) (6); Maria Van kerkhove (b) (6);
Redfield, Robert R. (CDC/OD) (b) (6) Fiona Watt - UKRI MRC (b) (6);
(b) (6) Barbara Kerstiens (b) (6);
(b) (6); Mercedes TATAY (b) (6) Rebecca GRAIS
(b) (6) Julie Gerberding
(b) (6) Venkayya, Rajeev (b) (6)
Cc: Josie Golding (b) (6); Teresa Miller de Vega
(b) (6); David Carr (b) (6); Jeremy Farrar
(b) (6)>
Subject: Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

Dear All,

Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

I am writing to ask your organisation to recommit to a joint statement to rapid and open sharing of research data and findings relevant to the coronavirus (2019-nCoV) outbreak in China. The text of the joint statement follows below. Please do also share with others who may not be on this list.

This statement updates the 2016 [joint statement on data sharing in public health emergencies](#), to which your organisation was a signatory.

In light of the urgent global health threat presented by this outbreak, we are asking signatories to reaffirm their commitment to these principles and pledge to also ensure research findings of relevance are shared rapidly with WHO. This statement reflects the public commitments already made by several leading journals over the last few days. It is aimed at researchers globally, and is necessary because of the unprecedented speed and number of research papers in response to the outbreak.

We plan to publish this statement before the end of the day on Thursday 30 January, so please let us know by 14:00 GMT on Thursday if you would like to sign.

Please reply to my colleague David Carr at Wellcome (d.carr@wellcome.ac.uk), who will also be happy to answer any questions you have.

With best wishes,

Jeremy Farrar

PROPOSED JOINT STATEMENT

Sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

The outbreak of the novel coronavirus in China (2019-nCoV) represents a significant and urgent threat to global health.

We call on researchers, journals and funders to ensure that research findings and data relevant to this outbreak are shared rapidly and openly to inform the public health response and help save lives.

We affirm our commitment to the principles set out in the 2016 [Statement on data sharing in public health emergencies](#), and pledge to ensure that the World Health Organization has rapid access to emerging findings that could aid the global response.

Specifically, we commit to work together to ensure:

- all peer-reviewed research publications relevant to the outbreak are made immediately open access

- research findings relevant to the outbreak are shared immediately with the WHO upon journal submission, with author approval
- research findings are made available via preprint servers at or before journal submission, or via platforms that make papers openly accessible before peer review – with clear statements regarding the availability of underlying data
- interim and final research data relating to the outbreak are shared as rapidly and widely as possible, including with public health and research communities and the WHO
- journals are clear that data or preprints shared ahead of submission will not pre-empt its publication in these journals

We will apply the principles of this statement to similar outbreaks in the future where there is a significant public health benefit to ensuring data is shared widely and rapidly. We urge others to make the same commitments. If your organisation is committed to supporting these principles, please contact us (d.carr@wellcome.ac.uk) and we will add your organisation to the list of signatories

SIGNATORIES TO THE STATEMENT ON EBOLA

- Academy of Finland
- Academy of Medical Sciences, UK
- Bernhard Nocht Institute for Tropical Medicine
- Bill and Melinda Gates Foundation
- Biotechnology and Biological Sciences Research Council (BBSRC)
- The British Medical Journal (BMJ)
- Bulletin of the World Health Organization
- Calouste Gulbenkian Foundation – Gulbenkian Science Institute
- Canadian Institutes of Health Research
- The Centers for Disease Control and Prevention (to include Morbidity and Mortality Weekly Report [MMWR])
- Chinese Academy of Sciences
- Chinese Centre for Disease Control and Prevention
- The Department of Biotechnology, Government of India
- The Department for International Development (DFID)
- Deutsche Forschungsgemeinschaft (DFG)
- eLife
- EcoHealth Alliance
- The Economic and Social Research Council (ESRC)
- EMBO Press
- F1000
- Fondation Mérieux
- Fundação Oswaldo Cruz (Fiocruz)
- The Global Health Network
- Global Virus Network
- GlaxoSmithKline (GSK)
- The Institut Pasteur

- Instituto Butantan, Brazil
- Instituto Nacional de Salud, Peru
- International Severe Respiratory and emerging Infection Consortium (ISARIC)
- International Society for Infectious Diseases
- Japan Agency for Medical Research and Development (AMED)
- The JAMA Network
- The Lancet
- Médecins du Monde/Doctors of the World (MdM/DoW)
- Médecins Sans Frontières/Doctors Without Borders (MSF)
- Microbide Limited
- National Academy of Medicine
- National Institutes of Health, USA
- National Institute for Infectious Diseases Lazzaro Spallanzani (INMI), Italy
- National Science Foundation, USA
- The New England Journal of Medicine (NEJM)
- PLOS
- ProMED
- Research Ideas and Outcomes (RIO) Journal
- The Rockefeller University Press
- The Royal Society
- SAB Biotherapeutics
- Science Journals
- ScienceOpen
- South African Medical Research Council
- Springer Nature
- Thieme Publishers
- UK Medical Research Council
- Universidade Jean Piaget de Capo Verde
- USAID
- Wellcome Trust
- ZonMw – The Netherlands Organisation for Health Research and Development

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 16:24:12 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Washington Post on camera interview re Wuhan
Attachments: Media Request: Wuhan coronavirus/WashPost VIDEO, RE: Media Request: Wuhan coronavirus/WashPost VIDEO

Reporter: Amber Ferguson, video editor

Organization: Washington Post, video

Phone #(s): 202-334-4194 (Desk) (b) (6) (cell) amber.ferguson@washpost.com

Subject: Coronavirus, how to control outbreaks, how they have been controlled in past

Deadline: Loose—early week of Feb. 3

Spokesperson: NIAID Director Dr. Anthony S. Fauci

Expected place of publication (print, online, broadcast): online video story on WashPost.com

Expected date of publication/airing: unknown

Expected prominence (e.g. front page, Sunday, evening/morning show, etc.):

Key messages/talking points:

Additional information:

Patty,

She wants to come with camera to ASF office later this week or early next to film a video story. Please see her message to me below.

Hello Anne,

My name is Amber Ferguson and I'm a video producer/editor at The Washington Post. We are working on a video about how infectious diseases spread and if containment practices work. We would like to interview Dr. Fauci on-camera about the coronavirus and get his thoughts on past infectious outbreaks. We would be able to come to NIH. Could we schedule this for this Wednesday or Thursday or anytime early next week? Please let me know if you have any questions and if we can set up an interview.

Thank you,
Amber

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 19:37:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Radio Free Asia Coronavirus Taped on Camera
Attachments: RE: Dr Fauci interview

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 15:27:41 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FOX Corona Interview Neal Cavuto (LIVE HIT 10:25 am ET)
Attachments: Media Request: Wuhan coronavirus/Fox Cavuto LIVE weekend show, Corona virus interview with Dr Fauci for Saturday

Yes, we're confirmed for 10:25AM ET tomorrow.

The on-site contact is: Bryan McCarthy who can be reached at (b) (6)

We are on floor 5 at 400 North Capitol NW

I'll be in NYC, but can also be reached with any questions at (b) (6)

From: Ciniglio, Brianna <brianna.ciniglio@FOXNEWS.COM>
Sent: Thursday, January 23, 2020 9:50 AM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Subject: Fox News Cavuto Saturday Request

Good morning,

I work on Neil Cavuto's weekend show on Fox News. I am reaching out to see if Director Fauci would be available to join our show this Saturday at any point between 10AM-12PM ET to discuss the coronavirus. We will be live from NYC, but can arrange a remote interview. Please let me know if there's any way we can make something work.

Thank you,

Brianna Ciniglio
Booker, "Cavuto LIVE"
Fox News Channel
Office: (212)-301-5051
Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 22:55:05 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CORONAVIRUS UPDATE TO IC DIRECTORS (8 am -8:15 am)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 17:50:10 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: Shanghai Media Skype interview re Coronovirus
Attachments: Coronavirus interview with Dr. Fauci, Interview request: Wuhan coronavirus, Shanghai Media Group

Marat Sadana
Shanghai Media Group

(b) (6)

(b) (6)

Topic: Wuhan pneumonia
Deadline: Wednesday 1/22 COB

Hi Patty,

This is a student reporter who is working for Shanghai Media Group's video division, PearVideo. (See attached earlier email exchange—their info checks out, and the video will likely be broadcast here: <https://www.pearvideo.com/>) They'd like to set up a 20-minute Skype interview with Dr. Fauci, which will be taped for later broadcast. They'd like to do this ASAP (no solid deadline, but would need to do today or tomorrow). They sent the following questions:

1. Could you briefly introduce for us about what's special about 2019-nCoronavirus?
2. any possible speculation about the source of infection 2019-nCoronavirus?(animals?)
3. How transmissible 2019-nCoronavirus could be? What are the possible routes of infection?
4. 2019-nCoronavirus is confirmed to possibly transmit from people to people. What does this mean? Any further possible serious effect?
5. It is said NIH has begun to develop vaccine. How soon we could have it?
6. Any suggestion for public? How can we protect ourselves from 2019-nCoronavirus so far?

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 12:37:20 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - FOX Business Coronavirus Interview (LIVE HIT: 5:10 pm ET)
Attachments: Re: [EXTERNAL] FW: Fox Business Interview Request

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 15:45:36 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- Fox Business News - Corona virus Interview (LIVE HIT TBD)
Attachments: Fauci interview request

Hope all is well.

We've worked together when I was at AJE and CGTN AMERICA. I moved to FBN in NYC!

I am reaching out to you to check the availability of Dr Fauci for an interview tomorrow 01/23 sometime between 10a-12pmET to talk about the coronavirus. This is a 5min LIVE hit for our show, Varney & CO. The name of the anchor is Stuart. We can book NIH TV studios.

Can he accommodate?

<https://www.foxbusiness.com/technology/china-coronavirus-vaccine-outbreak-wuhan-virus-in-china>

Please let me know.

Joana

Joana Godinho | **Fox Business Network**
Coordinating Booker, Varney & Co.

1211 Avenue of the Americas New York, NY 10036

E: joana.godinho@foxbusiness.com O: 212-601-2941 C: (b) (6) (work) | C: (b) (6) (personal)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 20:37:06 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Akinso, Woleola (NIH/OD) [E];Akinso, Woleola (NIH/OD) [E];Akinso, Woleola (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: PRe-Tape with Brett Baer Corona)Taped on camera)
Attachments: RE: Bret Baier Request for Anthony Fauci, PRe-Tape with Brett Baer Corona)Taped on camera)

My name is Ashley Moir and I'm the booker for "Special Report w/ Bret Baier" at Fox News Channel in Washington, DC.

Bret was wondering if Dr. Fauci would be available to join us on the show in the 6pm hour this coming Monday, January 27 to discuss the latest with the Coronavirus.

Please get back to me at your earliest convenience. Thank you for considering!

Best,
Ashley

Ashley Koerber Moir
Booking Producer
Special Report w/ Bret Baier
Fox News Channel – DC Bureau
(b) (6) (cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 14:07:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: House E&C Member briefing on coronavirus
Attachments: RE: Please advise: E&C full committee briefing

E&C staff would like to have the full committee, Member-level briefing on Coronavirus on Thursday morning (Jan. 30) starting at 9:45am

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 23:13:44 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: Yahoo online skype interview (Live hit 2:00 pm - 2:15 pm ET)
Attachments: FW: (Monday, 2-3 p.m.?) Yahoo Finance TV interview request -- Dr. Anthony
Fauci

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 14:21:53 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Fox Bus NEws w/ David Asman Live Hit: TBD
Attachments: RE: [EXTERNAL] FW: Fox Business Interview Request, RE: [EXTERNAL] FW: Fox Business Interview Request, ON-CAMERA -- Interview request: Wuhan virus

Haley.Gillman@FOXNEWS.COM

Subject: Wuhan coronavirus

Organization: Fox News Channel Fox Business Network

Specific Outlet Show: Bulls and Bears

Taped or live: Live at 5:12 p.m. Jan. 30

Deadline: Today Jan. 30

Reporter: David Asman (program host, doing interview)

Producer: Haley Gillman

Phone #(s) or e-mail: 646-468-1720 haley.gillman@foxnews.com

Agency spokesperson: NIAID Director Dr. Anthony S. Fauci

Expected place of publication: Fox News program Bulls and Bears

Expected date of publication/airing: Jan. 30 at 5:12 pm ET

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 00:07:35 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers [REDACTED] (b) (6); Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Science Vs New Coronavirus

Let us discuss whether we can do this during the coming week.

From: Wendy Zukerman <wzukerman@spotify.com>
Sent: Saturday, January 25, 2020 12:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Science Vs New Coronavirus

Dear Anthony, This is Wendy from Science Vs - we interviewed you last year about our episode on Pandemics, thank you so much. **More than 500,000 people heard the episode.**

With the new Wuhan coronavirus - we'd like to do a quick, follow up interview. What's happening? Where did this come from? (Snakes?) How worried should we be?

Is there any chance you're available early next week? We'd need around 30 minutes.

Thank you

Wendy

Sent from my iPhone

On Oct 8, 2019, at 1:17 PM, Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)> wrote:

Some flu vaccines (relatively small proportion) are grown in cells as opposed to eggs. This is somewhat more reliable but not really faster. A very small percentage are developed through recombinant DNA technology and this is faster. We are trying to convert much more to the recombinant vaccine platforms but we are not there yet.

On Oct 8, 2019, at 6:21 PM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:

Thanks - regarding the question about growing vaccine in chicken eggs. Do we have alternate (non-chicken egg/ faster) technology available right now, but it hasn't been rolled out? Or, do we need to develop better vaccine making technology?

thank you so much.

On Tue, Oct 8, 2019 at 2:02 AM Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)> wrote:
Rough estimate assuming a conservative 20% infection rate and a 2% mortality I would estimate 1.5 million deaths in the USA and ~35 million global.

On Oct 8, 2019, at 12:53 AM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:

Thank you!! And if we've been going back and forth on what our final "death toll" should be. We're assuming highly contagious, with a 2% mortality rate, vaccine arrives around 6 months in, episode ends at 7 months. Do you think 2 million in the US would make sense? And worldwide, 33, 35 million or 40 million?

On Mon, Oct 7, 2019 at 4:04 PM Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)> wrote:
Pandemics will occur and we cannot "prevent" them, but we can mitigate their impact and prevent worst case scenarios. There are several ways to do this. Three of the most important are: 1) improve global surveillance so that we can get a head start on response such as development of a vaccine. 2) improve vaccine platform technology and manufacturing capabilities to allow rapid development of vaccines. 3) stockpile readily deliverable interventions such as respirators, antivirals and antibiotics for bacterial complications.

On Oct 7, 2019, at 9:35 AM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:

Hi Tony, We're almost out of the woodwork with all the fact checking! Thank you for your time. Quick question. **What are the top three things can we do now to help prevent a worst case scenario flu pandemic?**

Best, Wendy

--

Wendy Zukerman
Host and Executive Producer
[Science Vs podcast](#)
wzukerman@spotify.com

[REDACTED] (b) (6)

--

Wendy Zukerman
Host and Executive Producer
[Science Vs podcast](#)
wzukerman@spotify.com

[REDACTED] (b) (6)

--

Wendy Zukerman
Host and Executive Producer
[Science Vs podcast](#)
wzukerman@spotify.com

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 01:15:46 +0000
To: Lipkin, Ian W.
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: 2020 Foreign Language

Great! I am anxious to learn of your impression.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lipkin, Ian W. (b) (6)
Sent: Thursday, January 23, 2020 7:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: 2020 Foreign Language

Tony,
I've been invited to China by the central govt. details to follow

On Jan 23, 2020, at 6:05 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Thanks, Ian.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lipkin, Ian W. (b) (6)

Sent: Wednesday, January 22, 2020 10:43 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: 2020 Foreign Language

Tony,

See translation of Mandarin text regarding age and baseline medical status in the 17 Wuhan CoV fatalities.

Ian

As of 24:00 on January 22, our committee had received a total of 571 confirmed cases of pneumonia of new coronavirus infection in 25 provinces (autonomous regions, municipalities) in China, including 95 severe cases and 17 deaths (all from Hubei Province). A total of 393 suspected cases were reported in 13 provinces (autonomous regions and municipalities).


At 00:00 on the 22nd, 24 provinces (autonomous regions and municipalities) reported 131 new confirmed cases and 8 new deaths, including 5 males and 3 females. 13 provinces (autonomous regions and municipalities) reported 257 new suspected cases. A total of 25 provinces (autonomous regions and municipalities) reported the epidemic.


Confirmed cases reported overseas: 1 case in Hong Kong, China, 1 case in Macau, 1 case in Taiwan, China; 1 case in the United States, 1 case in Japan, 3 cases in Thailand, and 1 case in South Korea.


At present, 5897 close contacts have been traced, 969 people have been released from medical observation, and 4928 people are still receiving medical observation.

Introduction of 17 deaths


(b) (6)










foreign language









W. Ian Lipkin, MD
John Snow Professor of Epidemiology and Director
Center for Infection and Immunity
Mailman School of Public Health

Professor of Pathology and Neurology
College of Physicians & Surgeons
Columbia University
722 West 168th Street, 17th Floor
New York, NY 10032

Voice: (b) (6)

Fax: (212) 342-9044

Email: (b) (6)

Administrative Coordinator

(b) (6)

Voice: (b) (6)

Email: (b) (6)

www.cii.columbia.edu

Follow CII on Twitter: CII_Columbia | Facebook: CII.Columbia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 23:22:59 +0000
To: Paules, Catharine;Marston, Hilary (NIH/NIAID) [E]
Subject: n-CoV manuscript
Attachments: Coronavirus manuscript-first draft 1-20-2020 - with Fauci tracked changes.docx,
Coronavirus manuscript-first draft 1-20-2020 - Clean copy.docx

I am attaching 2 copies of the manuscript with my tracked changes showing and a clean copy

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:36:40 +0000
To: Dzau, Victor J.; 'GPMB Secretariat'; As Sy Elhadj; Brundtland Gro Harlem; Chris.Elias; Farrar Jeremy; Fore Henrietta; Gao Fu; Gashumba Diane; Kaag Sigrid; Ilona Kickbusch; Suzuki Yasuhiro; Vega Morales Jeanette; Vega Morales Jeanette; VijayRaghavan Krishnaswamy; 'Skvortsova Veronika'
Cc: MAHJOUR, Jaouad; MINHAS, Raman; Toomas Palu; Pate Muhamed; RYAN, Michael J.; SCHWARTLANDER, Bernhard F.; Alex Harris; Alveberg, Benedikte Louise; Chiaki NOGUCHI; Esveld Marja; Esveld Marja; Esveld Marja; Gonggrijp Mette; Julie.HALL; Kanarek, Morgan; Marston, Hilary (NIH/NIAID) [E]; Omar Abdi; Amelie RIOUX; Tore Godal; GABEDAVA, Tsira; ROSS, Alex; Banks Lynn; Block, Bruce; Conrad Jane; Conrad, Patricia (NIH/NIAID) [E]; Del Sol Dinia; Diao Fay; Gahungu Zacharie; Harikumar M K; Harikumar M K; Kabagire Christine; KITA Yosuke; Steven T. Smith; Miller de Vega Teresa; MURIUKI, Hilda Wairimu; Muzenda Sindiso; Sarah Belmir; YU Bai; Kirsi Madi (b) (6); 'Oleg Sonin'; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus
Attachments: Draft GPMB Statement_nCOV_28Jan_for Bd member review NIAID.docx

Looks fine. Please see my comments in attached document.

Thanks,

Tony

From: Dzau, Victor J. <(b) (6)>
Sent: Tuesday, January 28, 2020 11:46 PM
To: 'GPMB Secretariat' <gpmbsecretariat@who.int>; As Sy Elhadj (b) (6); Brundtland Gro Harlem <(b) (6)>; Chris.Elias (b) (6) Farrar Jeremy (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Fore Henrietta (b) (6) Gao Fu (b) (6); Gashumba Diane (b) (6) Kaag Sigrid (b) (6) Ilona Kickbusch (b) (6); Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6); 'Skvortsova Veronika' (b) (6)
Cc: MAHJOUR, Jaouad <(b) (6)>; MINHAS, Raman (b) (6); Toomas Palu (b) (6); Pate Muhamed (b) (6); RYAN, Michael J. (b) (6) SCHWARTLANDER, Bernhard F. (b) (6) Alex Harris (b) (6); Alveberg, Benedikte Louise (b) (6); Chiaki NOGUCHI (b) (6); Esveld Marja <(b) (6)>; Esveld Marja <(b) (6)>; Esveld Marja <(b) (6)>; Gonggrijp Mette (b) (6); Julie.HALL <(b) (6)>; Kanarek, Morgan (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6) Omar Abdi (b) (6); Amelie RIOUX (b) (6); Tore Godal (b) (6); GABEDAVA, Tsira (b) (6); ROSS, Alex (b) (6); Banks Lynn (b) (6); Block, Bruce (b) (6); Conrad Jane (b) (6) Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Del Sol Dinia (b) (6) Diao Fay (b) (6) Gahungu Zacharie (b) (6); Harikumar M K (b) (6) Harikumar M K (b) (6); Kabagire Christine <(b) (6)>; KITA Yosuke

(b) (6) Steven T. Smith (b) (6)>; Miller de Vega Teresa
(b) (6); MURIUKI, Hilda Wairimu (b) (6)>; Muzenda Sindiso
(b) (6) Sarah Belmir (b) (6)>; YU Bai (b) (6)>; Kirsi Madi
(b) (6); 'Oleg Sonin ' (b) (6)

Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

The message is clear and appropriate. I support it.

From: GPMB Secretariat <gpmbscretariat@who.int>

Sent: Tuesday, January 28, 2020 7:09 AM

To: As Sy Elhadj (b) (6)>; Brundtland Gro Harlem (b) (6)>; Dzau, Victor J. <(b) (6)>; Chris.Elias (b) (6); Farrar Jeremy (b) (6)>; Fauci Anthony <(b) (6)> Fore Henrietta (b) (6); Gao Fu (b) (6)>; Gashumba Diane (b) (6); Kaag Sigrid (b) (6); Ilona Kickbusch (b) (6)>; Suzuki Yasuhiro (b) (6)>; Vega Morales Jeanette (b) (6)>; Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)>; 'Skvortsova Veronika' (b) (6)
Cc: MAHJOUR, Jaouad (b) (6)>; MINHAS, Raman (b) (6)>; Toomas Palu (b) (6); Pate Muhamed (b) (6)>; RYAN, Michael J. (b) (6)>; SCHWARTLANDER, Bernhard F. (b) (6)>; Alex Harris (b) (6)>; Alveberg, Benedikte Louise (b) (6); Chiaki NOGUCHI (b) (6)>; Esveld Marja (b) (6)>; Esveld Marja (b) (6) Esveld Marja (b) (6)>; Gonggrijp Mette (b) (6)>; Julie.HALL <(b) (6)>; Kanarek, Morgan (b) (6)>; Marston Hilary (b) (6) Omar Abdi (b) (6)>; Amelie RIOUX (b) (6)>; Tore Godal (b) (6)>; GABEDAVAL, Tsira (b) (6)>; ROSS, Alex (b) (6)>; Banks Lynn (b) (6)>; Block, Bruce (b) (6)>; Conrad Jane (b) (6); Conrad Patricia <(b) (6)> Del Sol Dinia (b) (6)>; Diao Fay (b) (6); Gahungu Zacharie (b) (6)>; Harikumar M K (b) (6)>; Harikumar M K (b) (6)>; Kabagire Christine (b) (6)>; KITA Yosuke (b) (6)>; 'Steve Smith' <(b) (6)>; Miller de Vega Teresa (b) (6)>; MURIUKI, Hilda Wairimu <(b) (6)>; Muzenda Sindiso (b) (6); Sarah Belmir (b) (6)>; YU Bai (b) (6); Kirsi Madi (b) (6); 'Oleg Sonin ' (b) (6)>

Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

Importance: High

Dear Board members,

Thank you to all who participated in yesterday's teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries' (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than 1700 Wednesday 29 January, Geneva time

Thank you very much.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 01:10:59 +0000
To: Redfield, Robert R. (CDC/OD)
Subject: FW: CNN: Top NIH doctor wants China to invite US disease detectives to inspect Wuhan coronavirus data <https://cnn.it/36pifVH>

FYI

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Sunday, January 26, 2020 8:04 PM
Subject: CNN: Top NIH doctor wants China to invite US disease detectives to inspect Wuhan coronavirus data <https://cnn.it/36pifVH>

7 hr 26 min ago

Top NIH doctor wants China to invite US disease detectives to inspect Wuhan coronavirus data

From CNN Health's Elizabeth Cohen



Tom

Williams/CQ-Roll Call/Getty Images

The United States' top infectious disease doctor wants a team of disease detectives from the US Centers for Disease Control and Prevention to go to China and check on crucial questions about [how the Wuhan coronavirus is spreading](#).

But there's one problem: China first has to invite the CDC.

"Up to now, to my knowledge, we have not been invited," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the US National Institutes of Health.

A CDC spokesperson was not immediately available to comment on Sunday. NIH and CDC are separate divisions of the US Department of Health and Human Services.

On Sunday, Ma Xiaowei, China's health minister, told reporters that the virus could spread before someone develops symptoms. If so, that means the virus will spread much more quickly than expected. Ma did not explain how Chinese authorities arrived at this conclusion.

"The implications for this are so important that in my mind it's absolutely critical that we ourselves see the data, because what goes on over there has implications for what happens here," Fauci said. Fauci said that CDC disease detectives would need to see precisely how Chinese health authorities have gathered their data.

"To my knowledge, we have not seen the precise minute, granular data and how they collected it," he said. "We need to get to the real bottom line of how they collected their data and see if it's valid."

"The Chinese have good people. I don't want to impugn their capabilities," Fauci added. "But when it's something as important as this, our people who are trained epidemiologists need to go over their data and the best way to do that is go there and see how they're collecting it."

He added that to his knowledge, the Chinese did not tell US health authorities that the virus could spread before someone is symptomatic, a crucial aspect of any disease investigation. He said he learned about it after reading a CNN reporter's email.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 02:02:08 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Our NIAID supported SARS receptor binding domain vaccine (from China)
Attachments: hvi-10-648.pdf, nihms436421.pdf, nihms906599.pdf, Shi ZL_Cross-neutraliz SL-CoV by anti-SARS-CoV antibodies_Sci China_Life Sci_2017.pdf

As per prior e-mail. See attachments.

From: Hotez, Peter Jay (b) (6) >
Sent: Monday, January 20, 2020 8:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) > Stemmy, Erik (NIH/NIAID) [E] (b) (6)
Cc: Bottazzi, Maria Elena (b) (6); Hotez, Peter Jay (b) (6) >
Subject: Re: Our NIAID supported SARS receptor binding domain vaccine (from China)

Dear Tony and Erik, I hope it's OK I'm emailing you directly, but given the emerging situation I thought it would be wise. (b) (4)

(b) (4)



Warm regards, Peter

Peter Hotez, MD, PhD, FASTMH, FAAP

Dean, National School of Tropical Medicine

Professor, Departments of Pediatrics, Molecular Virology & Microbiology

Co-Head, Section of Pediatric Tropical Medicine

Health Policy Scholar

Baylor College of Medicine

Texas Children's Hospital Endowed Chair of Tropical Pediatrics
Co-Director, Texas Children's Hospital Center for Vaccine Development

University Professor

Department of Biology, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study

Senior Fellow, Scowcroft Institute of International Affairs

Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University

Adjunct Professor, University of Texas, School of Public Health

Founding Editor-in-Chief, PLoS Neglected Tropical Diseases

E-mail: (b) (6)

Twitter: (b) (6)

Skype: (b) (6)

Website: (b) (6)

Amazon Author Center: <https://www.amazon.com/Peter-J.-Hotez/e/B001HPIC48>

Like us on Facebook <https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/>

Executive Assistant: (b) (6)

(b) (6)

Phone (b) (6)



BAYLOR
UNIVERSITY

From: Hotez, Peter Jay <(b) (6)>
Sent: Monday, January 20, 2020 7:17 PM
To: Anthony (NIH/NIAID) [E] Fauci <(b) (6)>
<(b) (6)>
Cc: Bottazzi, Maria Elena <(b) (6)>; Hotez, Peter Jay <(b) (6)>
Subject: Our NIAID supported SARS receptor binding domain vaccine (from China)

Dear Tony and Erik, I hope it's OK I'm emailing you directly, but given the emerging situation I thought it would be wise. (b) (4)

(b) (4)

Warm regards, Peter

Peter Hotez, MD, PhD, FASTMH, FAAP

Dean, National School of Tropical Medicine

Professor, Departments of Pediatrics, Molecular Virology & Microbiology

Co-Head, Section of Pediatric Tropical Medicine

Health Policy Scholar

Baylor College of Medicine

Texas Children's Hospital Endowed Chair of Tropical Pediatrics
Co-Director, [Texas Children's Hospital Center for Vaccine Development](#)

University Professor

Department of Biology, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study

Senior Fellow, Scowcroft Institute of International Affairs

Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University

Adjunct Professor, University of Texas, School of Public Health

Founding Editor-in-Chief, PLoS Neglected Tropical Diseases

E-mail: (b) (6)

Twitter: (b) (6)

Skype: (b) (6)

Website: (b) (6)

Amazon Author Center: <https://www.amazon.com/Peter-J.-Hotez/e/B001HPIC48>

Like us on Facebook <https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/>

Executive Assistant: (b) (6)

(b) (6)

Phone: [REDACTED] (b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 01:17:29 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: question from a reporter about Dx mention in JAMA article

Please respond for me. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Thursday, January 23, 2020 6:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: question from a reporter about Dx mention in JAMA article

As I mentioned, I would just say a number of diagnostic developers are exploring use in their platform. Since none have publicly announced their plans, we would not want to get ahead of their planning.

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, January 23, 2020 1:09 PM
To: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: FW: question from a reporter about Dx mention in JAMA article

See question below.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Madeleine Johnson <madeleine.johnson@genomeweb.com>

Sent: Thursday, January 23, 2020 12:16 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: question from a reporter about Dx mention in JAMA article

Dear Dr. Fauci, My name is Madeleine Johnson and I am a reporter at GenomeWeb.com and 360Dx.com covering diagnostic technologies.

I'm writing a short feature story on companies and agencies developing diagnostic tests for 2019-nCoV. I noted in your *JAMA* Viewpoint article today that you and your co-authors refer to this as well.*

So far, I am aware of RT-qPCR tests developed by CDC, a lab in Germany, Co-Diagnostics, and BGI, and the possibility of rapid sequencing-based testing being developed by Oxford Nanopore. Are you aware of any others that you can disclose, on or off the record?

Also, I imagine that a rapid, near-patient diagnostic test would be the ideal in outbreak control. Are you aware of any pan-coronavirus tests that could be adapted for screening, or any sign that specific point of care molecular diagnostic platform developers are working on rapid MDx for use in airports or ERs, etc?

I am sure you are extremely busy, but even a few brief comments via email would be amazing! I am hoping to run a story later this afternoon (~3PM Eastern) but can also add to it once it is published online, if needed.

Thanks so much! Madeleine

*"For example, platform diagnostic modalities are being rapidly adapted to include 2019-nCoV, allowing early recognition and isolation of cases."

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:37:15 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

Thanks!

From: Marston, Hilary (NIH/NIAID) [E] (b) (6) >
Sent: Tuesday, January 28, 2020 6:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Steven T. Smith (b) (6) Handley, Gray (NIH/NIAID) [E] (b) (6)
Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

Consolidated comments from me and from Steve Smith.

From: GPMB Secretariat <gpmbscretariat@who.int>
Sent: martes, 28 de enero de 2020 9:09
To: As Sy Elhadj <(b) (6)>; Brundtland Gro Harlem (b) (6); Dzau Victor (b) (6); Chris.Elias (b) (6); Farrar Jeremy <(b) (6)>; Fauci Anthony <(b) (6)> Fore Henrietta (b) (6); Gao Fu (b) (6); Gashumba Diane (b) (6); Kaag Sigrid (b) (6); Ilona Kickbusch (b) (6); Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6); 'Skvortsova Veronika' (b) (6)
Cc: MAHJOUR, Jaouad (b) (6); MINHAS, Raman (b) (6); Toomas Palu (b) (6); Pate Muhamed (b) (6); RYAN, Michael J. (b) (6); SCHWARTLANDER, Bernhard F. (b) (6); Alex Harris (b) (6); Alveberg, Benedikte Louise (b) (6) Chiaki NOGUCHI (b) (6); Esveld Marja (b) (6); Esveld Marja (b) (6); Gonggrijp Mette (b) (6); Julie.HALL (b) (6); Kanarek Morgan (b) (6); Marston Hilary (b) (6); Omar Abdi (b) (6); Amelie RIOUX (b) (6); Tore Godal (b) (6); GABEDAVA, Tsira (b) (6); ROSS, Alex (b) (6); Banks Lynn (b) (6); Block Bruce (b) (6); Conrad Jane (b) (6); Conrad Patricia <(b) (6)> Del Sol Dinia (b) (6); Diao Fay (b) (6); Gahungu Zacharie (b) (6); Harikumar M K (b) (6); Harikumar M K (b) (6); Kabagire Christine (b) (6); KITA Yosuke (b) (6); 'Steve Smith' (b) (6); Miller de Vega Teresa (b) (6)

(b) (6)>; MURIUKI, Hilda Wairimu (b) (6)>; Muzenda Sindiso
(b) (6)>; Sarah Belmir (b) (6)>; YU Bai (b) (6)>; Kirsi Madi
(b) (6); 'Oleg Sonin ' (b) (6)>

Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

Importance: High

Dear Board members,

Thank you to all who participated in yesterday's teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries' (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than 1700 Wednesday 29 January, Geneva time

Thank you very much.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:41:34 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Wuhan coronavirus treatment candidate

Please respond to this person. Thanks.

From: Beitler, Jeremy R. [REDACTED] (b) (6)
Sent: Wednesday, January 29, 2020 12:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Wuhan coronavirus treatment candidate

Dear Dr. Fauci:

I am a physician-scientist at Columbia University and study human acute respiratory distress syndrome (ARDS). I am not a virologist. However, I read with interest your JAMA viewpoint on Wuhan 2019 nCoV and noted a potential prophylaxis/treatment that was not mentioned but that may be of interest.

From my ARDS research, I am familiar with a recent GSK study of recombinant human angiotensin-converting enzyme-2 (rhACE2) for ARDS (NCT01597635), for which it showed some promise. Regardless, it may be an effective treatment for Wuhan coronavirus.

As you noted, ACE2 is a main binding site for SARS. In lab models, soluble ACE2 appears effective at inhibiting propagation of SARS. Early published data for Wuhan CoV suggest it also may bind to ACE2 (Xu et al. Science China Life Sciences 2020:53). If Wuhan CoV indeed binds to ACE2, then rhACE2 might be effective at attenuating illness severity or blocking transmission. Given the established safety profile of rhACE2 from the prior GSK human trials, it seems to me an excellent candidate therapy for prophylaxis (not ideal in the studied iv formulation) or treatment if the Wuhan nCoV outbreak continues to grow.

I imagine you and others have already thought of this. Since I do not recall seeing it in the JAMA paper, I thought it worth sharing only because it is a treatment potentially immediately ready for testing.

Thank you for considering,

Jeremy

Cell: [REDACTED] (b) (6)

Jeremy R. Beitler, MD, MPH
Assistant Professor
Director of Clinical Research
Center for Acute Respiratory Failure

Columbia University

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 11:07:14 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Interview Invitation on coronavirus outbreak in China

They will send a crew.

From: [REDACTED] (b) (6)
Sent: Monday, January 20, 2020 11:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Subject: Interview Invitation on coronavirus outbreak in China

Dear Dr. Fauci,

I'm Youyou Wang from Hong Kong Phoenix TV, Washington DC bureau. I would like to invite you for a TV interview on coronavirus outbreak in China.

The situation in China is very fluid. We would really appreciate if you could share some insights on coronavirus. Your expertise in this area would be extremely valuable for our audience at this critical moment.

Please kindly let us know if you could accept our invitation, and your earliest availability. We could come to NIH earlier to set up for the interview.

Looking forward to hearing back from you!

Best regards,

--

王又又 | Youyou WANG

Correspondent

Washington D.C. Bureau | Phoenix Satellite Television

Phone: +1(202)715-0352 | Fax: +1(202)715-1374

Mobile: [REDACTED] (b) (6) | E-mail: wangyouyou@phoenixtv.com

101 Constitution Ave NW | Suite 920 EAST | Washington DC 20001

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:23:31 +0000
To: Janet Tobias; Conrad, Patricia (NIH/NIAID) [E]
Cc: Rancourt, Anne (NIH/NIAID) [E]
Subject: RE: Coronavirus and interview for the film

Patty:

Please set something up for me to have a conversation with Janet.

Thanks,

Tony

From: Janet Tobias <janet@ikanamedia.com>
Sent: Sunday, January 26, 2020 9:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> Conrad, Patricia (NIH/NIAID) [E]
<(b) (6)>
Cc: Rancourt, Anne (NIH/NIAID) [E] <(b) (6)>
Subject: Coronavirus and interview for the film

Dear Tony and Patty: I know you must be extremely busy. I talked to Anne last week and told her I was going to write to you both to put in place an interview in

(b) (4)

Janet

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:42:04 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Possible Coronavirus cure

Please respond to this person.

From: Austin Avino [REDACTED] (b) (6)
Sent: Wednesday, January 29, 2020 12:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Possible Coronavirus cure

My name is austin avino. I am not a dr. Or a med student. I have been doing research on coronavirus and know it can be in both animals and humans. Through further research i found out that there is one animal in particular that has almost an immunity to all deseases some professionals have discovered. The shark. They have squalimine that years ago was tested against cancer but was not sucessful. Coronavirus is a respitory disease and i have been thinking whats the best way to get medicine in the lungs. There is a squalamine inhalant that has been tested on rats to treat certain strands of pneumonia. After several days of being applied 2 doses of the inhalant daily the percentage of the pneumonia bacteria droped. I do not know if this would work or not but it would be worth finding a cure for a disease without a cure at the moment. Lab testing a coronavirus strand to see if squalamine can fight back against it would be worth a shot and could save thousands of people. If you have any questions feel free to email me

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 11:09:55 +0000
To: Cohen, Elizabeth
Subject: RE: Vaccine for new Chinese coronavirus in the works - CNN

I have not heard anything definite about the dynamics of the infection of the 14 healthcare workers.

-----Original Message-----

From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Tuesday, January 21, 2020 6:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Re: Vaccine for new Chinese coronavirus in the works - CNN

Tony –

Many thanks. Please let me know if there's anything else in particular you think we ought to be reporting today. We're trying to learn more about these 14 healthcare workers. Have you heard whether it was just one patient who infected all of them?

Cheers,
Elizabeth

> On Jan 21, 2020, at 12:51 PM, Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)> wrote:

>

> Elizabeth:

> Nice piece!

> Best,

> Tony

>

> -----Original Message-----

> From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>

> Sent: Tuesday, January 21, 2020 12:21 AM

> To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>

> Subject: Vaccine for new Chinese coronavirus in the works - CNN

>

> Tony - thank you for your help with this. Looking forward to speaking today to see if we've learned more about this virus.

>

> <https://www.cnn.com/2020/01/20/health/coronavirus-nih-vaccine-development/index.html>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:28:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: From Italy

Please set this up **IF** it is possible.

From: Michele Bocci <m.bocci@repubblica.it>
Sent: Saturday, January 25, 2020 8:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: From Italy

Hello, I'm a journalist from the Italian national newspaper La Repubblica and I'd like to have an interview with you about the new coronavirus. Just some question about it's nature and it's dangerousness.
Is it possible?

Thank you,
Michele Bocci

Il presente messaggio (inclusi gli allegati) contiene informazioni riservate esclusivamente al destinatario/ai destinatari indicato/i nel messaggio, ed è protetto dalla legge. La diffusione, distribuzione e/o la copia del contenuto del presente messaggio da parte di qualsiasi soggetto diverso dal destinatario è severamente vietata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei dati personali. Se non siete i destinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immediata comunicazione inviando un messaggio di ritorno all'indirizzo e-mail del mittente.

This message (including any attachments) contains confidential information intended only for the recipient(s) named above, and is protected by law. Any disclosure, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art. 616 c.p. and to the applicable data protection laws. If you are not the intended recipient, please delete this message and inform us immediately about the deletion by sending a message to the sender's e-mail address.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 15:54:54 +0000
To: Wayne Holman
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: 2019-nCOR: Could anti-IL6 be helpful if cytokine storm is driving the pathology in the sickest patients?

Thanks, Wayne.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Wayne Holman (b) (6)
Sent: Wednesday, January 29, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: 2019-nCOR: Could anti-IL6 be helpful if cytokine storm is driving the pathology in the sickest patients?

Hi Tony,
I share Wendy's view of the amazing work you and your team. Many thanks from a grateful nation.

The literature suggests that those who are asymptomatic have lower levels of cytokines and those who are highly symptomatic have something of a cytokine storm. In the CART field uses anti-IL6 monoclonals to treat the CRS. I wonder if anti-IL6 would work for these patients. The literature describes steroid use but perhaps IL-6 is more targeted, less immunosuppressive and more effective. I see literature describing IL-6 as key in SARS but not anti-IL6 use. The Lancet paper showed some modest change in the IL-6 levels in the 2019-nCoV patients relative to other cytokines however it could be a central mediator none-the-less. I know there is no easy answer.

Best Wishes,

Wayne

Wayne Holman, MD
Founder & CEO
Ridgeback Capital
Co-Founder
Ridgeback Biotherapeutics
www.ridgebackcap.com

(b) (6)

(b) (6)

Cytokine. 2019 Mar;115:13-23. doi: 10.1016/j.cyto.2018.12.008. Epub 2019 Jan 4.

Decoding the enigma of antiviral crisis: Does one target molecule regulate all?

[Mahmud-Al-Rafat A¹](#), [Majumder A²](#), [Taufiqur Rahman KM³](#), [Mahedi Hasan AM⁴](#), [Didarul Islam KM⁵](#), [Taylor-Robinson AW⁶](#), [Billah MM⁷](#).

Author information

Abstract

Disease fatality associated with Ebola, SARS-CoV and dengue infections in humans is attributed to a cytokine storm that is triggered by excessive pro-inflammatory responses. Interleukin (IL)-6 acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signaling, respectively. Hence, IL-6 is assumed to provide a target for a broad range of antiviral agents.

Available immunosuppressive antivirals are directed to control an often exaggerated pro-inflammatory response that gives rise to complex clinical conditions such as lymphocytopenia. It is known that IL-6, via its soluble receptor (sIL-6R), initiates a pro-inflammatory response while an anti-inflammatory response is triggered by the membrane-bound IL-6 receptor (IL-6R). Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling. In this review, we propose that the tumour necrosis factor- α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes.

Copyright © 2018 Elsevier Ltd. All rights reserved.

KEYWORDS:

ADAM-17; Antiviral; Cytokine storm; Dengue; Ebola; IL-6; Pro-inflammatory response; SARS-CoV; Virus

DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the individual or entity to which it is addressed and may contain information that is confidential or legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately and permanently delete this message and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:00:26 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: coronavirus vaccine
Attachments: Codagenix-NewCoV.pptx

FYI

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, January 23, 2020 10:00 PM
To: Casetti, Cristina (NIH/NIAID) [E] (b) (6)>
Subject: FW: coronavirus vaccine

Please take a look at this and respond to this person one way or another.

-----Original Message-----

From: J. Robert Coleman (b) (6)
Sent: Thursday, January 23, 2020 9:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>, Casetti, Cristina (NIH/NIAID) [E]
(b) (6)
Subject: Re: coronavirus vaccine

Dear Dr. Fauci

Thank you for responding to Dr. Norton, I am sure you are being pulled in many different directions.

(b) (4)

Thank you for your time and I look forward to hearing from NIAID. Best Regards, Robert Coleman

On Thu, Jan 23, 2020 at 7:08 PM (b) (6)> wrote:

>
> Thank you so much! We need all the smartest minds (like yours) we can focus on this issue, I suspect with trepidation.
>
> I am fine but working too hard. I know you know that syndrome too!
>
> I trust all is well with you too.
>

> All my best,

>

> Larry

>

>

>

> From: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>

> Sent: Thursday, January 23, 2020 6:04 PM

> To: Norton, Larry/President's Office [REDACTED] (b) (6)>

> Cc: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>

> Cassetti, Cristina (NIH/NIAID) [E] [REDACTED] (b) (6)>

> Subject: [EXTERNAL] RE: coronavirus vaccine

>

>

>

> Larry:

>

> Thanks for the note. Have them send me some material and I will forward it to the appropriate people here at NIAID. I hope that all is well with you.

>

> Best regards,

>

> Tony

>

>

>

> Anthony S. Fauci, MD

> Director

> National Institute of Allergy and Infectious Diseases Building 31,

> Room 7A-03

> 31 Center Drive, MSC 2520

> National Institutes of Health

> Bethesda, MD 20892-2520

> Phone: [REDACTED] (b) (6)

> FAX: (301) 496-4409

> E-mail: [REDACTED] (b) (6)

>

> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

>

>

>

>

>

> Please note that this e-mail and any files transmitted from Memorial Sloan Kettering Cancer Center may be privileged, confidential, and protected from disclosure under applicable law. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any reading, dissemination, distribution, copying, or other use of this communication or any of its attachments is strictly prohibited. If you have received this communication in error, please notify the sender immediately by replying to this

- > message and deleting this message, any attachments, and all copies and
- > backups from your computer.

--

J. Robert Coleman, PhD, MBA
Chief Executive Officer
Co-founder, Codagenix, Inc.
3 Bioscience Park Drive
Farmingdale, NY 11735-0176
Phone: (b) (6)
(b) (6)

This e-mail (and any attachment) is intended solely for the use of the individual or entity to which it is addressed, and may contain proprietary, confidential or privileged information of Codagenix, Inc. and/or its subsidiaries. If you are not the intended recipient of this e-mail, or responsible for delivering this e-mail to the intended recipient, you are hereby notified that any dissemination, distribution, copying or other action taken with respect to this e-mail is strictly prohibited. If you have received this e-mail in error, please notify the sender immediately and permanently delete the original and any copy.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:41:56 +0000
To: (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: from Dame Jillian Sackler

Dear Dame Sackler:

Thank you for your note. As you have probably already heard, the Chinese authorities have closed down the wet markets that sell exotic animals for consumption and are encouraging the population to avoid such consumption.

Best regards,
Tony

From: (b) (6)
Sent: Friday, January 24, 2020 2:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: from Dame Jillian Sackler

Dear Dr. Fauci,

We met when you delivered the inaugural opening of The DJS Distinguished Lecture on Global Health Issues at the Foreign Policy Association. Thank you again. Of course the Sackler name has been completely destroyed - due to fake news: I have no opioid money, my husband Arthur had nothing to do with this scandal or any other nefarious behavior, he was a magnificent man.

Anyway, I have been involved with China for years, and have wondered why pathogens such as the Wuhan Coronavirus all seem to begin in China, considering India and other countries maintain unhygienic practices. I just read that Chinese health officials believe it originated at a market selling exotic live animals for food, such as crocodiles, rats, peacocks (more than 100 kinds of wildlife), they think the culprits may be snakes or bats. Perhaps your or another US health leader can pressure China to ban the merchandising and eating of wild animals.

Kind regards and happy Chinese Lunar New Year.

Dame Jillian Sackler

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 15:55:42 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Assistance/Guidance

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hank Safferstein (b) (6) >
Sent: Wednesday, January 29, 2020 9:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Assistance/Guidance

Dear Dr. Fauci,

I hope this email finds you well.

(b) (4)

I was hoping to schedule a call with the appropriate person at NIAID to discuss in further detail.

Appreciate your help and thank you

Hank

--

Hank Safferstein, Ph.D., J.D., M.B.A.

CEO
Generian
Executive in Residence
Pittsburgh Life Sciences Greenhouse
2425 Sidney Street
Pittsburgh, PA 15203

(b) (6) Direct
(b) (6) Mobile
412-770-1276 Fax
(b) (6) Email
www.plsg.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 15:34:31 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Attachments: JAMA - Viewpoint on 2019 n-CoV - Paules, Marston and Fauci - 01-21-2020.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:55:37 +0000
To: Ali, Imran X. -ND
Subject: RE: Coronavirus..... Holy Cross Grad....

Imran:

Unfortunately, I am too swamped to do this right now. Sorry.
Best,
Tony

From: Ali, Imran X. -ND <Imran.X.Ali.-ND@abc.com>
Sent: Friday, January 24, 2020 11:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Coronavirus..... Holy Cross Grad....

Greetings Dr. Fauci,

I hope you remember me. This is Imran Ali the Holy Crow Graduate who has been inspired by your work throughout the years. We met on several occasions and you were interviewed for my podcast. We have been in touch ever since you gave me your autographed photo way back in 1999.

I know that you are extremely busy right now doing what you do best informing the public and our lawmakers in the Senate today. As you can see I am a contributor to ABC News as a freelancer. I was wondering if you could reply briefly to the following questions that I could include in an article that I can send to my editor for consideration next week:

1. SO FAR WE HAVE 63 PATIENTS UNDER INVESTIGATION FROM 22 STATES WITH 2 TESTING POSITIVE AS OF FRIDAY JAN 24TH, 11 ARE NEGATIVE, HOW WORRIED SHOULD THE AMERICAN PUBLIC BE?
2. CORONAVIRUS HAS BEEN AROUND FOR MANY YEARS BUT WHAT MAKES THIS STRAIN DIFFERENT?

3. DURING THE EBOLA OUTBREAK WE ONLY HAD ABOUT 700 PEOPLE ARRIVING TO THE US EVERY DAY BUT NOW WE HAVE ALMOST 10,000 PEOPLE COMING FROM CHINA EVERY DAY.... IS THERE ANY USE IN CURTAILING FLIGHTS?

4. JUST LAST YEAR USAID HAS CUT FUNDING TO THE "PREDICT" PROGRAM THAT WAS INSPIRED BY THE 2005 H5N1 BIRD FLU SCARE, WOULD THIS PROGRAM BE HELPFUL IN BETTER UNDERSTANDING THE CORONA VIRUS?

5. FINALLY, IN A RECENT ARTICLE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION IT WAS MENTIONED THAT BACK WHEN THE SARS VIRUS OUTBREAK A DNA VACCINE TOOK ABOUT 20 MONTHS TO DEVELOP BUT SINCE THEN WE HAVE MRNA VACCINE TECHNOLOGY, HOW QUICKLY COULD WE POTENTIALLY SEE A VACCINE FOR THIS CORONAVIRUS STRAIN?

Thank you very Dr. Fauci for your time if you are able to answer these questions.... I totally understand if you are busy and need to defer this as this is an article that I am volunteering not necessarily assigned at the moment

Sincerely,

Imran

Imran Ali MD MS MPH

Physician Fellow ABC News Medical Unit

Office [212-456-2632](tel:212-456-2632)

Cell [REDACTED] (b) (6)

Email Imran.X.Ali.-ND@abc.com

Personal Email: [REDACTED] (b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 16:06:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Informal coronavirus teleconference, 29 January, 19.00 CET

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. (b) (6)
Sent: Wednesday, January 29, 2020 10:45 AM
To: Redfield, Robert R. (CDC/OD) <(b) (6)>; (b) (6);
(b) (6); David Heymann <(b) (6)>;
(b) (6); Chris.Elias (b) (6);
(b) (6); Fauci, Anthony
(NIH/NIAID) [E] <(b) (6)>; (b) (6);
(b) (6); COX, Paul Michael (b) (6); SHOC (b) (6); GREIN, Thomas
(b) (6);>
Cc: GHEBREYESUS, Tedros Adhanom (b) (6);>; SCHWARTLANDER, Bernhard F.
(b) (6);>; MINHAS, Raman (b) (6)
Subject: Informal coronavirus teleconference, 29 January, 19.00 CET

Dear colleagues,

Dr Tedros would like to take the opportunity to informally discuss with you the ongoing 2019 novel coronavirus.

We are planning to host a teleconference today at 19.00 CET and will provide a dial-in number with a passcode.

If you face any difficulties with the dial-in number, please provide us with a contact number and we will attempt to dial you in.

Best,

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 15:42:16 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Speak with Dr. Fauci on the coronavirus?

Done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Tuesday, January 21, 2020 5:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: Speak with Dr. Fauci on the coronavirus?

Sent from my iPhone

Begin forwarded message:

From: Eileen O'Reilly <eileen@axios.com>
Date: January 20, 2020 at 8:17:07 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>
Subject: Speak with Dr. Fauci on the coronavirus?

Hi Patricia:

Hope you had a nice holiday weekend.

Would Dr. Fauci have 10 minutes on Tuesday to speak about what we now know about the coronavirus linked to Wuhan?

Thanks,

Eileen O'Reilly, Axios

(b) (6)

eileen@axios.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:18:43 +0000
To: Gallo, Robert
Subject: FW: GVN

Sorry. Pressed "send" too soon. Let us discuss this next time we get together.
Best,
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, January 23, 2020 10:17 PM
To: Gallo, Robert <[REDACTED]> (b) (6)
Subject: RE: GVN

Bob:
Thanks for the note.

From: Gallo, Robert <[REDACTED]> (b) (6) >
Sent: Thursday, January 23, 2020 4:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: GVN

Hi Tony,

I want you to know GVN is very active internationally in the new coronavirus problem via its respiratory Watch Group.

[REDACTED] (b) (4)

Please let me know if you wish to discuss further.

Thanks and with my very best wishes,

Bob

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:19:56 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Wired article on Wuhan coronavirus

Please set up a call with this person. It can wait until next week.

From: Michele Cohen Marill [REDACTED] (b) (6)
Sent: Thursday, January 23, 2020 3:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Wired article on Wuhan coronavirus

Dr. Fauci,

I'm a writer with Wired, and I'm interested in writing about the Wuhan coronavirus and particularly about the issue of super spreaders and the potential they pose to greatly increase transmission. (I know that both SARS and MERS had important incidents of super spreading.) I would love to get your perspective on this issue. A key question is how to detect super spreaders—yet it seems like that is still not well-understood. I was also intrigued with a couple of points raised in your JAMA article—particularly, why are most coronaviruses so benign that we call them “the common cold” but then in recent years we are having outbreaks of much more serious disease? And how quickly could a vaccine be produced—and how effective would it likely be?

Would you be available to talk in the next few days? (This afternoon would be awesome, if that's possible. Or perhaps tomorrow late morning (10:30 or 11-ish?) or midday? Or please let me know if a different time would work.)

Here's a bit of my background: I'm a health and medical writer based in Atlanta and a regular contributor to Wired, Health Affairs, and Medscape. I have also written for Stat, Nature Medicine, and WebMD magazine, among other publications. Here are a couple of recent articles for Wired: <https://www.wired.com/story/new-tests-use-epigenetics-to-guess-how-fast-youre-aging/> and <https://www.wired.com/story/why-a-promising-potent-cancer-therapy-isnt-used-in-the-us/>. More info about me is available on my website, www.michelemarill.com.

Thanks so much for your help!
-Michele

Michele Cohen Marill
Journalist/Writer
(404) 636-6021 (office)
[REDACTED] (b) (6) (cell)
[REDACTED] (b) (6)
www.michelemarill.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:01:02 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY
Attachments: WHO Bridge Calling Information.docx

Can you listen in on this? It overlaps with an AMA call.

From: GPMB Secretariat <gpmbssecretariat@who.int>
Sent: Friday, January 24, 2020 9:39 AM
To: As Sy Elhadj (b) (6); Brundtland Gro Harlem (b) (6); Dzau Victor (b) (6); Chris.Elias (b) (6); Farrar Jeremy (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Fore Henrietta (b) (6); Gao Fu (b) (6); Gashumba Diane (b) (6); Kaag Sigrid (b) (6); Ilona Kickbusch (b) (6); Skvortsova Veronika (b) (6); Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)
Cc: MAHJOUR, Jaouad (b) (6); MINHAS, Raman (b) (6); Toomas Palu (b) (6); Pate Muhamed (b) (6); RYAN, Michael J. (b) (6); SCHWARTLANDER, Bernhard (b) (6); Alex Harris (b) (6); Alveberg, Benedikte Louise (b) (6); Chiaki NOGUCHI (b) (6); Esveld Marja (b) (6); Esveld Marja (b) (6); Esveld Marja (b) (6); Gonggrijp Mette (b) (6); Julie.HALL <(b) (6)>; Kanarek Morgan (b) (6); Marston, Hilary (NIH/NIAID) [E] <(b) (6)>; Oleg Sonin (b) (6); Omar Abdi (b) (6); Amelie RIOUX (b) (6); Tore Godal <(b) (6)>; GABEDAVA, Tsira (b) (6); ROSS, Alex (b) (6); Banks Lynn (b) (6); Block Bruce (b) (6); Conrad Jane (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>; Del Sol Dinia (b) (6); Diao Fay (b) (6); Elena Kirsanova (b) (6); Gahungu Zacharie (b) (6); Harikumar M K (b) (6); Harikumar M K (b) (6); Kabagire Christine (b) (6); KITA Yosuke (b) (6); Miller de Vega Teresa (b) (6); MURIUKI, Hilda Wairimu (b) (6); Muzenda Sindiso (b) (6); Sarah Beimir (b) (6); YU Bai (b) (6)
Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY
Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.

As co-chairs of the GPMB we therefore suggest to hold a **teleconference** of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on **Monday 27 January at 1400-1500 Geneva time**. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 18:30:52 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: update on coronavirus?

Indeed, it happened 15 minutes after I sent you the e-mail. Embargoed until 3:00 PM ET

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Tuesday, January 21, 2020 1:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: update on coronavirus?

Thanks. Larry just gave me a heads up that your last sentence may have come true in WA.

Sent from my iPhone

On Jan 21, 2020, at 5:13 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Francis:

Thanks for the note. There is definite person-to-person transmission. 15 health care workers were infected in a Wuhan Hospital. We do not know about the degree of "sustained" person-to-person transmission. There have been 298 cases reported as of this AM with 6 deaths. The number is likely larger and is growing by the hour. We have already started working on a vaccine for the 2019 n-CoV. We are partnering with the Moderna Company using their mRNA vaccine

platform. We should be in Phase 1 trials (unless there are unforeseen issues) within 3 months. We are also pursuing any cross-reactivity of mAbs that we developed for SARS to see if they could be used as therapeutics for n-CoV. Other drugs such as remdesivir and ritonavir have been tried with MERS and may be useful. We would however, need the isolates (we just have sequence) to test these. We are already screening entries from China at JFK, LAX and SFO. I would not be surprised if just like SARS and MERS we ultimately see an imported case in the USA.

Hope that this is helpful.

Best,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Tuesday, January 21, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: update on coronavirus?

Hi Tony,

I will be in a Davos session on Thursday where response to the coronavirus outbreak will be a topic. Paul Stoffels will be there, as will Tedros.

What's now the best information about person-to-person transmission and mortality risk? Can you give me a quick precis of what the US is doing about risks of the illness coming to our shores? What do we know about possible therapies? And what is the plan to utilize the fastest possible platform to work on a vaccine?

Thanks, and sorry to hit you with this!

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:28:35 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Interview on coronavirus

Please have me call him tomorrow.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Thursday, January 23, 2020 12:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Interview on coronavirus

Hi Dr. Fauci: How are you? I have a few more questions that I think you could really help with. WHO has been saying this is a much quicker, more thorough and more transparent reaction than with SARS. We're trying to put together some early information about when the coronavirus first came to light, what the responses were, and what kinds of action were taken. Would you have some time to talk about this today or tomorrow? I'd just want to get some details about what you heard and when; I'm sure you've been on the case for a while. Thanks and regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell [REDACTED] (b) (6)
<http://www.bloomberg.com>
<http://www.bloomberg.com/prognosis>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:03:10 +0000
To: Paules, Catharine
Cc: Marston, Hilary (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Dear Prof. Anthony Fauci, here is a request from MIT Technology Review (Chinese)

Please respond to this person.

From: Tao Sun [REDACTED] (b) (6)
Sent: Friday, January 24, 2020 2:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Dear Prof. Anthony Fauci, here is a request from MIT Technology Review (Chinese)

Dear Prof. Anthony Fauci,

I am Tao Sun, a reporter from Beijing. I am currently writing reports for the MIT Technology Review (Chinese) .

JAMA published your article Coronavirus Infections—More Than Just the Common Cold, and Xinhua News Agency reported this article. Here are some questions I would like to ask you.

1 Some people think that it is not necessary to develop a new vaccine against SARS or coronavirus in Wuhan. The reason is that, firstly, there is no commercial interest to pharmaceutical manufacturers, and secondly, such outbreaks may not return after the extinction.
What do you think of these views?

2 For the Wuhan virus vaccine being developed, the epidemic is likely to be eliminated after three months, so is it still necessary to develop a vaccine?

3 You can talk about SARS. How much does a vaccine against SARS actually play?

Looking forward to your reply.

--

TAO SUN

DEEPTTECH MIT Technology Review

[REDACTED] (b) (6)

suntao@mittrchina.com

7th FL, Tower AB Office Park, 10 Jintong West Road, Chaoyang District, Beijing

<http://www.mittrchina.com>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 23:58:30 +0000
To: Routh, Jennifer (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Media Inquiry

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Monday, January 27, 2020 10:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> Billet, Courtney (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Stover, Kathy (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Media Inquiry

Dr. Fauci –

I have drafted responses to Radio Free Asia for your review. Please let me know if you have edits. I will share the final version with the reporter on your behalf and I will note the responses are attributed to you.

Can we make medicine and vaccine against that virus? And if so, how long do you think is it going to take?

NIAID, part of the U.S. biomedical research agency NIH, has mobilized a research response to 2019-nCoV that builds on experience with SARS-CoV, MERS-CoV and other emerging pathogens. Scientists are continuing basic research to characterize the novel virus and understand how it causes disease, as well as developing diagnostics, vaccines and treatments.

We have begun early stage development of an mRNA (messenger RNA) vaccine for 2019-nCoV. mRNA vaccines direct the body's cells to express a protein to elicit a broad immune response including high levels of neutralizing antibodies. The expressed protein is designed based on knowledge of the virus structure, but the platform does not contain live or inactivated virus. The mRNA platform can be quickly adapted and manufactured efficiently. NIAID and its industry partner Moderna anticipate the 2019-nCoV vaccine will be ready for the first stage of clinical testing in the coming months.

Do you think It will be even more lethal if that virus spread in a country with poor health environment such as North Korea?

At this stage it is difficult to predict how the virus will spread and cause disease in different regions. Experts around the globe are working to understand key epidemiological transmission features of 2019-nCoV and to characterize the severity and spectrum of disease. Certainly, a robust public health system that can effectively diagnose, isolate and care for patients and trace contacts is critical to controlling an emerging infectious disease.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, January 26, 2020 9:57 PM
To: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>
Cc: Routh, Jennifer (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Media Inquiry

Please have Jen prepare a response for me.

From: Albert Hong <honga@rfa.org>
Sent: Friday, January 24, 2020 10:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Media Inquiry

Hi,

I'm Albert Hong a reporter of the Radio Free Asia in Washington DC. I'm writing about new virus, called 2019 novel coronavirus (2019-nCoV). I want to ask you..

- 1)Can we make medicine and vaccine against that virus?
- 2)And if so, how long do you think is it going to take?
- 3)Do you think It will be even more lethal if that virus spread in a country with poor health environment such as North Korea?

Thank you and I'll be looking forward your comment.

Best,
Albert

Albert Hong

Broadcaster
Radio Free Asia- Korean Service
2025 M Street, NW., Washington DC 20036
Office (202) 266-4091

CONFIDENTIAL COMMUNICATION

This e-mail message is intended only for the use of the addressee and may contain information that is privileged and confidential. Any unauthorized dissemination, distribution, or copying is strictly prohibited.

If you receive this transmission in error, please contact network@rfa.org.

Visit us at www.rfa.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 21:48:41 +0000
To: Alice Park
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Time request

I called and left voice mail

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alice Park <alice.park@time.com>
Sent: Tuesday, January 21, 2020 2:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Time request

Hi Dr. Fauci -- hope all is well, and happy new year!

I'm writing, as you can imagine, about the emerging coronavirus cases, w/the first reported case in the US (brought from Wuhan). I wanted to speak to you more generally about coronaviruses, what we know and how it typically transmits, what we've learned since SARS and MERS, and what if any specific challenges these viruses pose in terms of developing treatments or vaccines against them. Happy to talk whenever you have a few minutes, today or tomorrow. Best, Alice

PLEASE NOTE NEW PHONE NUMBER

Alice Park

~~TIME~~

(b) (6)

alice.park@time.com

@aliceparkny

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:32:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Hi Dr. Fauci - JAMA piece

Please set up a call.

From: Michelle Cortez (Cortez,Michelle) <mcortez@bloomberg.net>
Sent: Thursday, January 23, 2020 11:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Hi Dr. Fauci - JAMA piece

Hi Dr. Fauci -

I just read your JAMA piece on the importance of preparedness given the new coronavirus.

I'm wondering if you have a moment to discuss the effort, both before and since the latest outbreak. We are working on a Tick Tock of the situation and I think that effort - done before the latest virus emerged - would be a key piece.

Thanks so much -
Michelle
[REDACTED] (b) (6)

Michelle Fay Cortez | Health-Science-Medical Technology | [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:05:09 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: Wuhan accelerated vaccine development- Codagenix

Please handle this. Thanks.

From: Wayne Koff [REDACTED] (b) (6)>
Sent: Thursday, January 23, 2020 10:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Erbeding, Emily (NIH/NIAID) [E] [REDACTED] (b) (6) Steffen Mueller
[REDACTED] (b) (6)
Subject: Wuhan accelerated vaccine development- Codagenix

Tony, Emily



All the best,

WK

Wayne C. Koff, PhD
President and CEO
Human Vaccines Project
One Penn Plaza, Suite 6178
New York, NY 10119

Phone: (b) (6)
Email: (b) (6)
Website: www.humanvaccinesproject.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 00:48:07 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Continuous Temperature Monitoring

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ruth Phillips (b) (6) >
Sent: Tuesday, January 28, 2020 4:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Continuous Temperature Monitoring

Dear Dr. Fauci,

Blue Spark Technologies is the inventor of a wearable patient temperature monitoring patch called TempTraq (www.temptraq.healthcare). TempTraq is a soft, comfortable patch worn under the arm that provides a continuous patient temperature feed to a smart device or directly to a hospital's monitoring station and/or EHR via Bluetooth.

We currently partner with Doctors Without Borders to support their Ebola clinic in Butembo, DRC and Malaria clinics in Tanzania. University of Rochester Medical Center has also begun to use TempTraq in their Malaria clinics in Zambia and Malawi.

Several clinical trials were conducted that show that TempTraq can:

- Accurately monitor patient temperature
- Detect neutropenic fevers in oncology patients **up to three hours earlier than the standard of care**
- Enable remote patient fever monitoring that can enable earlier discharge for BMT Patients

With the recent Coronavirus outbreak, we were interested in getting your thoughts about the use of TempTraq for those patients that need remote monitoring. I would love to set up a call to discuss further. Please let me know if there is a good time to connect.

Sincerely,
Ruth

Ruth Phillips BSN, MS, OCN, BCMAS
Director, Medical Affairs

(b) (6)

(b) (6)

<https://temptraq.healthcare/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 23:13:09 +0000
To: Siegel, Marc
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Question

Marc:

Thanks for the note. Am stuck for a while in DC with the coronavirus situation. I will let you know about any future possibility of my coming up there.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Siegel, Marc (b) (6)
Sent: Wednesday, January 22, 2020 7:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: Question

Just quoted you on Fox and Friends.

We want to know if you might be interested in coming to NYU to give Grand Rounds sometime over the next several weeks - on this coronavirus and vaccine candidate.

Grand Rounds are Wednesday mornings at 8 AM

It would be a great honor and pleasure to have you here.

We would of course cover all expenses and your fee.

Hope you will consider.

Marc

Sent from my iPhone

On Jan 22, 2020, at 5:52 AM, Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)> wrote:

[EXTERNAL]

Marc:

You certainly can quote me.

Best regards,

Tony

From: Siegel, Marc [REDACTED] (b) (6)>
Sent: Tuesday, January 21, 2020 10:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Re: Question

thanks Tony!

hope I can quote you!

From: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Tuesday, January 21, 2020 10:00:21 PM
To: Siegel, Marc
Subject: RE: Question

[EXTERNAL]

Marc:

Thanks for the note. We are already working on a vaccine for the 2019 n-CoV. We have the sequence of the virus and are employing an mRNA vaccine platform in collaboration with the Moderna Company. We hope to have the candidate in Phase 1 trials within 3 months. You might remember that we actually developed a DNA vaccine for SARS (another coronavirus pathogen) several years ago and brought it through Phase 1 trials showing safety and immunogenicity. We never developed it further since the SARS outbreak was completely stopped by good public health measures. Bottom line is that there is a good chance that over time, we will develop a vaccine for this virus.

Best regards,

Tony

-----Original Message-----

From: Siegel, Marc [REDACTED] (b) (6)>
Sent: Tuesday, January 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Question

Tony

Any chance of a vaccine for this coronavirus?

I believe they were testing one in dogs.

Marc

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:09:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

OK. Have Steve sit in for us and de-brief us. You do the Moderna meeting.

From: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, January 26, 2020 10:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

It looks like it overlaps with the Moderna meeting. I will participate in whichever you tell me to (of course), but Steve Smith can listen into GPMB (and has been following/meeting with secretariat etc).

From: Anthony Fauci <(b) (6)>
Date: Sunday, January 26, 2020 at 10:01 PM
To: Hilary Marston <(b) (6)>
Subject: FW: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Can you listen in on this? It overlaps with an AMA call.

From: GPMB Secretariat <gpmbssecretariat@who.int>
Sent: Friday, January 24, 2020 9:39 AM
To: As Sy Elhadj <(b) (6)>; Brundtland Gro Harlem <(b) (6)>; Dzau Victor <(b) (6)>; Chris.Elias <(b) (6)> Farrar Jeremy <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> Fore Henrietta <(b) (6)> Gao Fu <(b) (6)>; Gashumba Diane <(b) (6)>; Kaag Sigrid <(b) (6)>; Ilona Kickbusch <(b) (6)> Skvortsova Veronika <(b) (6)>; Suzuki Yasuhiro <(b) (6)>; Vega Morales Jeanette <(b) (6)>; Vega Morales Jeanette <(b) (6)>; VijayRaghavan Krishnaswamy <(b) (6)>
Cc: MAHJOUR, Jaouad <(b) (6)>; MINHAS, Raman <(b) (6)>; Toomas Palu <(b) (6)>; Pate Muhamed <(b) (6)>; RYAN, Michael J. <(b) (6)>; SCHWARTLANDER, Bernhard F. <(b) (6)>; Alex Harris <(b) (6)>; Alveberg, Benedikte Louise <(b) (6)> Chiaki NOGUCHI <(b) (6)>; Esveld Marja <(b) (6)>; Esveld Marja <(b) (6)>; Esveld Marja <(b) (6)>; Gonggrijp Mette <(b) (6)>; Julie.HALL <(b) (6)>; Kanarek Morgan <(b) (6)>; Marston, Hilary (NIH/NIAID) [E] <(b) (6)> Oleg Sonin <(b) (6)>; Omar Abdi <(b) (6)>; Amelie RIOUX <(b) (6)>; Tore Godal <(b) (6)>

GABEDAVA, Tsira <(b) (6)>; ROSS, Alex <(b) (6)>; Banks Lynn
(b) (6)>; Block Bruce <(b) (6)>; Conrad Jane
(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> Del Sol Dinia
(b) (6)>; Diao Fay <(b) (6)> Elena Kirsanova
(b) (6)>; Gahungu Zacharie <(b) (6)>; Harikumar M K
(b) (6)>; Harikumar M K <(b) (6)>; Kabagire Christine
(b) (6)>; KITA Yosuke <(b) (6)>; Miller de Vega Teresa
(b) (6)>; MURIUKI, Hilda Wairimu <(b) (6)>; Muzenda Sindiso
(b) (6)>; Sarah Belmir <(b) (6)> YU Bai <(b) (6)>

Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.

As co-chairs of the GPMB we therefore suggest to hold a **teleconference** of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on **Monday 27 January at 1400-1500 Geneva time**. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 00:49:52 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: accelerated pathway to a coronavirus vaccine development
Attachments: career highlights.docx, CV GIM 2019.doc

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George Moonsammy (b) (6)
Sent: Wednesday, January 29, 2020 8:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: accelerated pathway to a coronavirus vaccine development

Dear Dr. Fauci:

I am writing you for two reasons;

- a. Congrats to you and your team for the recent publication of the corona virus, very clear and concise.

(b) (4)

(b) (4)

George Moonsammy, PhD

M: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 02:46:58 +0000
To: Burklow, John (NIH/OD) [E]
Subject: RE: Press interviews

John:

Thank you for your kind note. It is much appreciated.
Best regards,
Tony

From: Burklow, John (NIH/OD) [E] <[REDACTED] (b) (6)>
Sent: Friday, January 24, 2020 2:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Press interviews

Hi, Dr. Fauci—

I know it goes without saying, but you do such a great job in your TV interviews on the Wuhan coronavirus! You deftly handle any question they throw at you, and they run the gamut!

John

John Burklow
Associate Director for Communications and Public Liaison
National Institutes of Health
1 Center Drive/Building 1
Room 344
9000 Rockville Pike
Bethesda, MD 20892
Phone [REDACTED] (b) (6)
Cell: [REDACTED] (b) (6)
[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 10:46:12 +0000
To: Corey MD, Larry
Subject: RE: 702 / confidential

(b) (5), (b) (4)

From: Corey MD, Larry <[REDACTED]> (b) (6)
Sent: Sunday, January 26, 2020 10:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: RE: 702 / confidential

(b) (5), (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Sent: Sunday, January 26, 2020 7:16 PM
To: Corey MD, Larry <[REDACTED]> (b) (6)
Subject: RE: 702 / confidential

[REDACTED] (b) (5)

From: Corey MD, Larry <[REDACTED]> (b) (6)
Sent: Sunday, January 26, 2020 5:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: 702 / confidential

Tony

(b) (5), (b) (4)

(b) (5), (b) (4)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 15:32:26 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- BBC News - Taped on camera - Corona virus
Attachments: RE: Interview request: BBC News, Wuhan coronavirus

Producer: Lindle Markwell
Organization: BBC News
lindle.markwell@bbc.co.uk, Tel: [REDACTED] (b) (6)
Subject: Wuhan coronavirus
Deadline: 1/31

Hi Patty,

If Dr. Fauci has free time on Friday, the BBC would like to send a small crew to do a 30-minute interview in his office. This would be taped for a TV segment. Is there a time when he could make this work?

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 18:53:42 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: Bloomberg TV Asia Daybreak (Live Skype hit at 6:30 pm ET)
Attachments: FW: Interview request: Wuhan Coronavirus, RE: Interview request: Wuhan Coronavirus, RE: Interview request: Wuhan Coronavirus

Jonah Davis
Bloomberg TV—Bloomberg Daybreak Asia
(b) (6)
Topic: Wuhan Coronavirus
jdavis57@bloomberg.net

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Jan 2020 16:19:25 +0000
To: Fauci, Anthony (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Meeting with Nicki Lurie and Jerry Keusch re GPMB
Attachments: RE: time to discuss GPMB, RE: time to discuss GPMB, RE: time to discuss GPMB, Re: time to discuss GPMB

Jerry cell phone is (b) (6)

From: Nicole Lurie (b) (6)
Sent: Thursday, January 16, 2020 1:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Cc: Keusch, Gerald T <(b) (6)>; Dzau, Victor J. (b) (6)
Subject: time to discuss GPMB

Hi Tony and Hilary-

As you know from Victor, Jerry and I have been asked to write the chapter on the R&D ecosystem for the GPMB. We're in the process of putting together an early framing of this. But, its clear that our first stop needs to be to talk with you both, to get your input about any draft framing, issues you think need to be highlighted for the Board, progress, gaps, etc. We'd love to come out to NIAID sometime in the next two weeks and sit down with you. Might you be able to suggest some potential times--Jerry will try to fly down for the day. For me, other than Wednesday mornings when I have clinic, I can be pretty flexible. Many thanks, in advance, and we very much look forward to seeing you both.

With warmest regards,
Nicki and Jerry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 23:06:19 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - FOX Sean Hannity
Attachments: RE: [EXTERNAL] Fwd: Fox News request

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 20:27:05 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: KPBS San Diego Public Radio & TV (taped via zoom with awwad)
Attachments: RE: ON AIR: Interview request: coronavirus outbreak

Shalina Chatlani
Science and Technology Reporter, KPBS
Work: 619-594-8142 **Cell:** (b) (6)

Shalina Chatlani
KPBS San Diego Public Radio & TV
(b) (6) | schatlani@kpbs.org
Subject: coronavirus vaccine research
Deadline: 6pm ET

Hi Patty,

This science reporter is asking for an update on NIAID coronavirus vaccine research in the form of a taped video conference to take 20 min max. The video would broadcast on KPBS Evening Edition, and the audio would broadcast on the local radio station as well. She has a tight deadline of 6pm ET tonight, but if a spokesperson is only available tomorrow, she is open to taping an interview then.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 21:16:04 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: i24 news - israeli news corona virus interview - (LIVE HIT BY LANDLINE PHONE
7:05 pm ET)
Attachments: Corona virus interview with Dr. Fauci

Interview is with Michelle Mikori

Adriana Guzman (booking agent)

i24NEWS Live Tonight

(b) (6)

(b) (6)

Topic: Wuhan coronavirus

Deadline: 7:00 or 9:00 EST

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 13:52:22 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- Call with Richard Hatchett CEPI re Coronavirus (B. Graham)
Attachments: RE: My notes from WHO SAG call this morning

Belated best wishes for 2020 and I hope this finds you well. In case helpful, I just wanted to share my notes from the WHO call this morning, which was convened on short notice and before US working hours, in light of the dramatic increase of cases and new cases in Beijing and South Korea over the weekend. On the call we also heard about new cases in Shanghai. I joined a bit late so am not sure if Hilary was on that call.

(b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 20:53:19 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOlD - Print Interviews - several calls
Attachments: RE: Interview request: Washingtonian Magazine, Wuhan coronavirus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 19:12:12 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: The TODAY SHOW - pre tape 7:00 am - 7:15 am ET
Attachments: RE: TODAY Request Tomorrow 1/31, RE: TODAY Request Tomorrow 1/31, RE: TODAY Request Tomorrow 1/31, image001.png

I'm adding my colleagues here, Jane Marie and Tracy. They will handle the logistics of this!

Our contact number will be our control room, (b) (6)

Thank you!
Clare

CLARE E. HILER | NBC NEWS | 212-664-3639 | (b) (6)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 00:22:46 +0000
To: Howard Bauchner
Cc: Phil Fontanarosa; Paules, Catharine; Marston, Hilary (NIH/NIAID) [E]; Fauci, Anthony (NIH/NIAID) [E]
Subject: Viewpoint
Attachments: Viewpoint on 2019 n-CoV - Paules, Marston and Fauci - 01-21-2020.docx

Howard:

As you may have noticed, I am in the middle of the activity associated with the 2019 novel CoV that has hit China and now (yesterday) has reached the United States. Even though the situation is evolving rapidly and is a moving target, I believe that we need to comment on this. I know that others are sending commentaries into other journals including the *New England Journal of Medicine*. My first choice is you guys and so I am sending this to you to see if you feel that we should do a Viewpoint at this time even though it is early in the game. I would hate to see us get scooped by others who are not involved, as we are knee-deep in this. What do you think? Many thanks.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 03:07:58 +0000
To: NIAID OD AM
Subject: FW: Tin-cupping for the 2020 International Summit in Genetics and Genomics
Attachments: ISHGG 2019_Agenda[1].pdf, ISHGG 2019_DIR report_Final[1][1].pdf, Annual Report 2018 10072019_Final[1].pdf
Importance: High

Let us discuss and obviously do this.

From: Kastner, Daniel (NIH/NHGRI) [E] (b) (6) >
Sent: Tuesday, January 21, 2020 9:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Kaur, Manjit (NIH/NHGRI) [E] (b) (6); Solomon, Ben (NIH/NHGRI) [E] (b) (6)
Subject: Tin-cupping for the 2020 International Summit in Genetics and Genomics
Importance: High

Hi Tony,

I hope all is well with you. I'm writing in my capacity as Scientific Director of the NHGRI to thank you for your generous support of the 2019 International Summit in Genetics and Genomics. Last year we hosted 34 participants from low to middle-income countries (LMICs, as defined by the World Bank in 2019) for this month-long program. To date, we have trained 105 healthcare professionals from 43 different countries. Please see attached details, including the most recent report and last year's agenda.

In short, the purpose of this trans-NIH initiative is to advance the field of Genetics and Genomics in resource-poor countries. The Summit also helps extend the reach of the NIH to the global community.

To continue the program in 2020, I'm hoping that you will extend your previous support of \$20,000/year, and would appreciate if you would let us know if this is something that you are able and willing to do, so that we can work on documentation and logistics. In 2020 we hope to host 40 trainees. Each selected participant costs \$20,000 to cover expenses such as travel, housing, and meals. We appreciate any amount we receive from you; sponsoring at least one full participant would be ideal.

Please let us know if you have any questions or if we can help in any way. I am cc'ing Manjit Kaur, who administers the program, and Ben Solomon, the new Clinical Director of NHGRI.

With my very best wishes,

Dan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 18:18:44 +0000
To: Stacy Christiansen
Cc: Marston, Hilary (NIH/NIAID) [E]; Paules, Catharine; Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Urgent: JAMA Viewpoint on HCoV
Attachments: JAMA - VP - Coronavirus - Paules, Martson, Fauci.pdf

Stacy:

Here it is. Very minor edits.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stacy Christiansen <Stacy.Christiansen@jamanetwork.org>
Sent: Wednesday, January 22, 2020 12:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Subject: Urgent: JAMA Viewpoint on HCoV
Importance: High

Hi Dr Fauci and Dr Marston.

Attached is your Viewpoint on the n-CoV. We would really like to publish it tomorrow morning.

Is it possible for you to review very quickly today? In the next hour or 2?

Thanks so much

Stacy

Stacy L. Christiansen, MA
Managing Editor, *JAMA*
Chair, *AMA Manual of Style*



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 03:08:42 +0000
To: NIAID OD AM
Subject: FW: Invitation to present at the SD/CD meeting on Feb. 5
Attachments: SD-CDAgenda2-5-2020.docx

Let us discuss.

From: Wyatt, Richard G (NIH/OD) [E] (b) (6)
Sent: Thursday, January 30, 2020 9:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Gottesman, Michael (NIH/OD) [E] (b) (6); Holland, Steven (NIH/NIAID) [E] (b) (6); Kleinman, Joe (NIH/OD) [E] (b) (6)
Subject: Invitation to present at the SD/CD meeting on Feb. 5

Tony:

The Scientific Directors have asked if you could possibly give a brief scientific update on the new coronavirus and the status of the outbreak at their meeting with the Clinical Directors next Wednesday, Feb. 5 (draft agenda attached). They will be meeting in Wilson Hall, 9 -11 AM, and we are flexible on timing.

(b) (5)

It would be frankly great if you had a few minutes to brief the SDs and CDs, but I know your schedule is overly full right now. If you can't do this, would you please recommend a colleague who might be able to fill in?

Thanks.

Richard

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 23:22:56 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: CONFIRMNNG GPMB Board Teleconference, Monday, 27 January, re: novel coronavirus
Attachments: WHO Bridge Calling Information.docx, GPMB Teleconference Agenda 27 January.pdf

Let us discuss.

From: GPMB Secretariat <gpmbssecretariat@who.int>
Sent: Sunday, January 26, 2020 6:13 PM
To: As Sy Elhadj (b) (6); Brundtland Gro Harlem (b) (6); Dzau Victor (b) (6); Chris.Elias (b) (6); Farrar Jeremy (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> Fore Henrietta (b) (6); Gao Fu (b) (6); Gashumba Diane (b) (6); Kaag Sigrid (b) (6); Ilona Kickbusch (b) (6); Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)
Cc: MAHJOUR, Jaouad (b) (6); MINHAS, Raman (b) (6); Toomas Palu (b) (6); Pate Muhamed (b) (6); RYAN, Michael J. (b) (6); SCHWARTLANDER, Bernhard F. (b) (6); Alex Harris <(b) (6)> Alveberg, Benedikte Louise (b) (6); Chiaki NOGUCHI <(b) (6)> Esveld Marja (b) (6); Esveld Marja (b) (6); Esveld Marja (b) (6); Gonggrijp Mette (b) (6); Julie.HALL (b) (6); Kanarek Morgar (b) (6); Marston, Hilary (NIH/NIAID) [E] <(b) (6)> Omar Abdi (b) (6); Amelie RIOUX (b) (6); Tore Godal (b) (6); GABEDAVA, Tsira (b) (6); ROSS, Alex (b) (6); Banks Lynn (b) (6); Block Bruce (b) (6); Conrad Jane (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> Del Sol Dinia <(b) (6)> Diao Fay (b) (6); Gahungu Zacharie (b) (6); Harikumar M K (b) (6); Harikumar M K (b) (6); Kabagire Christine (b) (6); KITA Yosuke (b) (6); Miller de Vega Teresa (b) (6); MURIUKI, Hilda Wairimu <(b) (6)> Muzenda Sindiso (b) (6); Sarah Belmir (b) (6); YU Bai (b) (6)
Subject: CONFIRMNNG GPMB Board Teleconference, Monday, 27 January, re: novel coronavirus
Importance: High

Dear GPMB Board Members,

We are confirming the teleconference tomorrow, **Monday 27 January 2020, 1500-1600 Geneva Time.**

Please find attached the agenda (replicated below) and for ease of reference the call-in numbers and participant code.

Please let us know if you have any questions

Thank you very much
GPMB Secretariat (on behalf of the co-Chairs)

GPMB Teleconference on the 2019-novel Coronavirus outbreak

Monday, 27 January 2020

15.00-16.00 Geneva time [li](#)

15.00 – 15.10 1. Welcome and Roll call _

-
15.10 – 15.30 Updates on the Novel 2019-Coronavirus outbreak
2. Prof George Gao, Director, China CDC (10 min)

3. Dr. Mike Ryan, Executive Director, WHO/WHE (10 minutes)

-
15.30 – 16.00 4. Discussion/Actions from the Board (30 minutes)

- **Possible statement**

16.00 Adjourn

From: GPMB Secretariat

Sent: Friday, January 24, 2020 4:44 PM

Subject: RE: URGENT TIME CORRECTION -- GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Importance: High

Dear GPMB Board members

We apologize -- please note there is a **TIME CORRECTION** for the call this **Monday 27 January. The call is at 1500-1600 Geneva time**

The call in details remain the same.

Thank you very much
GPMB Secretariat

From: GPMB Secretariat

Sent: Friday, January 24, 2020 3:39 PM

To: 'As Sy Elhadj' (b) (6); 'Brundtland Gro Harlem' (b) (6); 'Dzau Victor'

(b) (6); 'Elias Chris' < (b) (6) 'Farrar Jeremy'
(b) (6) 'Fauci Anthony' < (b) (6) 'Fore Henrietta'
(b) (6); 'Gao Fu' (b) (6); 'Gashumba Diane' (b) (6); 'Kaag
Sigrid' (b) (6); 'Kickbusch Ilona' (b) (6); 'Skvortsova Veronika'
(b) (6); 'Suzuki Yasuhiro' (b) (6); 'Vega Morales Jeanette'
(b) (6); 'Vega Morales Jeanette' (b) (6); 'VijayRaghavan
Krishnaswamy' (b) (6)
Cc: MAHJOUR, Jaouad < (b) (6); 'Minhas Raman' (b) (6); 'Palu Toomas'
(b) (6); 'Pate Muhamed' (b) (6); RYAN, Michael J.
(b) (6); 'Schwartlander Bernhard' (b) (6); 'Alex Harris'
(b) (6) 'Alveberg Benedikte L.' (b) (6); 'Chiaki
NOGUCHI' (b) (6); 'Esveld Marja' (b) (6); 'Esveld Marja'
(b) (6); 'Esveld Marja ' (b) (6) 'Gonggrijp Mette '
(b) (6); 'Hall Julie' (b) (6) 'Kanarek Morgan'
(b) (6); 'Marston Hilary' (b) (6) 'Oleg Sonin '
(b) (6); 'Omar Abdi' (b) (6); 'Rioux Amelie'
(b) (6); 'Tore Godal' (b) (6); GABEDAVA, Tsira (b) (6)
'ROSS, Alex' < (b) (6); 'Banks Lynn' (b) (6); 'Block Bruce'
(b) (6); 'Conrad Jane' (b) (6); 'Conrad Patricia' < (b) (6)
'Del Sol Dinia' (b) (6); 'Diao Fay' < (b) (6) 'Elena Kirsanova '
(b) (6); 'Gahungu Zacharie' (b) (6); 'Harikumar M K'
(b) (6); 'Harikumar M K' (b) (6); 'Kabagire Christine'
(b) (6); 'KITA Yosuke' (b) (6); 'Miller de Vega Teresa'
(b) (6); 'Muriuki Hilda Wairimu' (b) (6); 'Muzenda Sindiso'
(b) (6) 'Sarah Belmir' (b) (6); 'YU Bai' < (b) (6)>

Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.

As co-chairs of the GPMB we therefore suggest to hold a **teleconference** of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on **Monday 27 January at 1400-1500 Geneva time**. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As

[\[i\]](#) Please refer to email planning for the call to find call-in information.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 23:04:22 +0000
To: (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: coronavirus vaccine

Larry:

Thanks for the note. Have them send me some material and I will forward it to the appropriate people here at NIAID. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6) >
Sent: Thursday, January 23, 2020 11:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: (b) (6)
Subject: coronavirus vaccine

I know you must be bombarded with stuff right now. (b) (4)

(b) (4)

Larry

Larry Norton, MD, FASCO, FAACR
Senior Vice President, Office of the President
Medical Director, Evelyn H. Lauder Breast Center
Norna S. Sarofim Chair of Clinical Oncology
Department of Medicine

Memorial Sloan Kettering Cancer Center

300 E. 66th Street, New York, NY 10065

T (b) (6) (Admin) T (b) (6) (Clinical) F 646.888.4924
(b) (6)

www.mskcc.org

Please note that this e-mail and any files transmitted from Memorial Sloan Kettering Cancer Center may be privileged, confidential, and protected from disclosure under applicable law. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any reading, dissemination, distribution, copying, or other use of this communication or any of its attachments is strictly prohibited. If you have received this communication in error, please notify the sender immediately by replying to this message and deleting this message, any attachments, and all copies and backups from your computer.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 03:49:18 +0000
To: Corey MD, Larry
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Talk today

Please handle this. I am literally drowning in coronavirus stuff. I was in the Situation Room of the White House for about 4 – 5 hours today.

-----Original Message-----

From: Corey MD, Larry [REDACTED] (b) (6) >
Sent: Tuesday, January 28, 2020 10:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)> Barasch, Kimberly (NIH/NIAID) [C] [REDACTED] (b) (6)
Subject: RE: Talk today

Ok understand ; looks like this Coronavirus has traction and is likely to stay around ; if they report 4500 there must be 20,000 at least and almost all person to person. Is the virus stable genetically therefore maximally adapted ?

(b) (4), (b) (5)

Ok that's my 3 cents worth.

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Tuesday, January 28, 2020 7:27 PM
To: Corey MD, Larry [REDACTED] (b) (6) >

Cc: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)> Barasch, Kimberly (NIH/NIAID) [C] [REDACTED] (b) (6)
Subject: RE: Talk today

I will be tied up tomorrow as I was today with coronavirus. Please work with Patty about squeezing something in later in the day.

-----Original Message-----

From: Corey MD, Larry [REDACTED] (b) (6)
Sent: Tuesday, January 28, 2020 1:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)> Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Talk today

[REDACTED] (b) (4), (b) (5)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 00:05:57 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Coronavirus talk work

The Tuesday afternoon before the talk on Wednesday, we need to make a slide showing the total number of cases and deaths.

From: Lerner, Andrea (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Sent: Saturday, January 25, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Coronavirus talk work

Dear Dr. Fauci,

Spoke with Hilary, who told me you are looking at the coronavirus talk currently and let her know of a few edits. FYI, I also asked the Weddles to make slides of (just for consideration):

[REDACTED] (b) (5)

I won't add/change slides to the talk without talking to you first because I don't want to mess things up!

[REDACTED] (b) (6) fully wired, [REDACTED] (b) (6) but otherwise available. Should we touch base this afternoon to discuss additional edits/thoughts? Phone or email, whatever you prefer.

Sincerely

Andrea

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892
Cell: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 22:14:02 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: RE: Coronavirus: Oy vey

John:

Can you call me at (b) (6). It will take only a minute.
Thanks,
Tony

-----Original Message-----

From: Mascola, John (NIH/VRC) [E] <(b) (6)>
Sent: Monday, January 20, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Graham, Barney (NIH/VRC) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Coronavirus: Oy vey

Tony,

One item to point out is that while this falls exactly into Barneys predicted framework for pandemic response; i.e. a new Betacoronavirus - there are some risks to success.

Barney and team know how to express MERS and SARS viral spikes - using structural information to introduce a key stabilizing mutation. We think the same mutation will apply here - but we need to express the protein and test.

We think the likelihood of success is high enough - that we should move full speed ahead to make the mRNA.

We can stop by to update you in more scientific detail if useful

John

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Monday, January 20, 2020 1:32 PM
To: Jon LaPook <(b) (6)>
Cc: amb@cbsnews.com; Kevin Finnegan <kpf@cbsnews.com>; Leigh Winick <WinickL@cbsnews.com>; Angelica Fusco <fuscoa@cbsnews.com>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> Mascola, John (NIH/VRC) [E] <(b) (6)>; Graham, Barney (NIH/VRC) [E] <(b) (6)>; Folkers, Greg (NIH/NIAID) [E] <(b) (6)>
Subject: RE: Coronavirus: Oy vey

Jon:

We are working with the Moderna company to put the gene for the spike protein of the 2019 n-CoV into an mRNA platform to develop a vaccine to go into Phase 1 trials. We did it with Zika with DNA in 3.25 months. We can probably go from sequence to Phase 1 with the mRNA platform in about 2 months. We are doing this at the Vaccine Research Center that you have previously visited. We can certainly arrange for you to visit some time and see directly what we are doing.

Best regards,
Tony

-----Original Message-----

From: Jon LaPook <(b) (6)>
Sent: Monday, January 20, 2020 1:21 PM

To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: amb@cbsnews.com; Kevin Finnegan <kpf@cbsnews.com>; Leigh Winick <WinickL@cbsnews.com>;
Angelica Fusco <fuscoa@cbsnews.com>
Subject: Coronavirus: Oy vey

Hi Tony,
Deja vu all over again.
Of course, I'm following along closely. If there is an opportunity for me to get an inside look at what you and your team are doing, please let me know.

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 03:50:07 +0000
To: Jon LaPook
Subject: RE: All Fauci, all the time! Thanks again.

Will do.

-----Original Message-----

From: Jon LaPook (b) (6)
Sent: Tuesday, January 28, 2020 10:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: All Fauci, all the time! Thanks again.

Thanks so much, Tony. That means a lot coming from you! PLEASE ping me when you are next in NYC with time for a meal.

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 28, 2020, at 10:46 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

You did a great job on the interview with your colleagues on CBS This Morning.

-----Original Message-----

From: Jon LaPook (b) (6)>
Sent: Tuesday, January 28, 2020 8:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: All Fauci, all the time! Thanks again.

[https://pbs.twimg.com/profile_images/1147114353679843329/W3nIPg4K_normal.png] CBS This Morning (@CBSThisMorning<<https://twitter.com/cbsthismorning?s=11>>) 1/28/20, 8:25 AM<<https://twitter.com/cbsthismorning/status/1222148703126982657?s=11>> The @CDCgov<<https://twitter.com/@CDCgov>> has issued its strongest travel warning, urging Americans to avoid all nonessential travel to China.

@CBSNews<<https://twitter.com/@CBSNews>> Chief Medical Correspondent Dr. Jon Lapook (@DrLaPook<<https://twitter.com/@DrLaPook>>) joins us to discuss the ongoing research of the coronavirus. [pic.twitter.com/TI0GEjnrSA](https://t.co/TI0GEjnrSA)

Download<https://twitter.com/download?ref_src=MailTweet-iOS> the Twitter app

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 23:03:19 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6); Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: ASM Biothreats session





Let us discuss this tomorrow.

From: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Sent: Monday, January 20, 2020 3:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: ASM Biothreats session

For discussion. Next Wednesday (the 29th), you are scheduled to give a 20 min/5 q&a talk at ASM Biothreats as part of a session entitled "Biothreats: How Prepared are We?" We had planned to do an Ebola Tale of Two Outbreaks talk. The organizers are asking if you can include the Wuhan virus in your talk. A few options here, (b) (5).

(b) (5)

As you consider, here are the recent talks you have given at ASM BioD. Despite the title, the 2017 talk was actually more of five prez talk, not the usual pandemic preparedness talk.

-  2015-02-11 ASM Biodefense and EID Mtg - Ebola in 2014-2015, perfect storm
-  2016-02-10 ASM Biodefense Meeting -- Zika Virus, a Pandemic in Progress
-  2017-02-07 ASM Biothreats Pandemic Preparedness - Learning from Experience
-  2019-01-31 ASM Biothreats Conference - Chasing Influenza

From: "Bloom, Marshall (NIH/NIAID) [E]" (b) (6)
Date: Monday, January 20, 2020 at 12:47 PM
To: Patricia Conrad <(b) (6)> Hilary Marston <(b) (6)>

Cc: "Bloom, Marshall (NIH/NIAID) [E]" (b) (6)>

Subject: ASM Biothreats session

Patty and Hilary,

The organizers of the conference would like ASF to devote part of his talk next Wednesday morning to the emerging Wuhan coronavirus and what NIAID is doing to respond even at this early date. Is this a possibility?

I saw the CNN interview from his office and it looked very nice.

Thanks very much.

Marshall

Division of Intramural Research

Chief, Biology of Vector-borne Viruses Section

Laboratory of Virology

Rocky Mountain Laboratories

National Institute of Allergy and Infectious Diseases

National Institutes of Health

903 South 4th Street

Hamilton, MT 59840

PHO: (b) (6)

Cell: (b) (6)

email: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:20:25 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus antibodies

Please handle.

From: Andrew Bradbury [REDACTED] (b) (6)
Sent: Tuesday, January 28, 2020 11:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Coronavirus antibodies

Dear Dr. Fauci

I read your recent viewpoint in JAMA with great interest.

[REDACTED] (b) (4)

Best wishes

Andrew

Andrew Bradbury, CSO | Specifica Inc.

Land [REDACTED] (b) (6)
Cell [REDACTED]

Office:
1512 Pacheco Street, Suite A203
Santa Fe NM 87505

Laboratory:
NMC Biological Laboratory
100 Entrada Drive
Los Alamos NM 87544

www.Specifica.bio

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential,

proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 00:54:05 +0000
To: (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus concerns on campus

Kent:

Thanks for the note. The students will almost certainly go through enhanced screening at a USA airport upon entry. They will receive educational material telling them what they should be doing. If you want the details of this, you should contact the CDC. The key person in charge of this at CDC is Dr. Martin Cetron.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Wednesday, January 29, 2020 9:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Coronavirus concerns on campus

Tony,

It was reassuring hearing you on NPR and other news programs.

With students from American, Georgetown and George Washington University being told to return from China due to Coronavirus, what protocols should be in place on campus and in the neighborhood?

An article in today's Washington Post said some students have been quarantined for two weeks before starting classes in China. Should they do the same before they join their classmates here? Most of the Georgetown, GW and AU students probably live on campus, but some live in the neighborhood.

https://www.washingtonpost.com/world/asia_pacific/coronavirus-china-live-updates/2020/01/29/d49b9194-423b-11ea-b503-2b077c436617_story.html#link-SRBFEBXQM6MXN24FB2MVDQF5E

What are the appropriate quarantine protocols? Who is responsible for setting up the protocols? Should we start wearing masks? Are we prepared for this?

Keep up the good work.

Kent Slowinski

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 00:28:40 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: update on coronavirus?

Embargoes are becoming a joke. CNN and NY Times both broke it.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Tuesday, January 21, 2020 2:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: update on coronavirus?

And that embargo clearly didn't hold!

Sent from my iPhone

> On Jan 21, 2020, at 7:30 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:
>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 03:01:39 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: coronavirus

NIAID inquiries, please.

From: Randy Cron, M.D. (b) (6) >
Sent: Friday, January 24, 2020 4:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: coronavirus

Hi Dr. Fauci:

I wonder if therapy (anti-interferon-gamma, rhIL-1R antagonist) for cytokine storm syndromes will benefit patients with the current coronavirus outbreak.

[An interferon-gamma-related **cytokine storm** in SARS patients.](#)

Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY.
J Med Virol. 2005 Feb;75(2):185-94.

[Delayed induction of proinflammatory **cytokines** and suppression of innate antiviral response by the novel Middle East respiratory syndrome **coronavirus**: implications for pathogenesis and treatment.](#)

Lau SK, Lau CC, Chan KH, Li CP, Chen H, Jin DY, Chan JF, Woo PC, Yuen KY.
J Gen Virol. 2013 Dec;94(Pt 12):2679-90.

[Current and future developments in the treatment of virus-induced hypercytokinemia.](#)

Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV.
Future Med Chem. 2017 Feb;9(2):169-178.

[Pathogenic human **coronavirus** infections: causes and consequences of **cytokine storm** and immunopathology.](#)

Channappanavar R, Perlman S.
Semin Immunopathol. 2017 Jul;39(5):529-539.

[Severe acute respiratory syndrome **coronavirus** ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC.](#)

Siu KL, Yuen KS, Castaño-Rodríguez C, Ye ZW, Yeung ML, Fung SY, Yuan S, Chan CP, Yuen KY, Enjuanes L, Jin DY.
FASEB J. 2019 Aug;33(8):8865-8877.

Sincerely,

Randy

Randy Q. Cron, MD, PhD

Professor of Pediatrics & Medicine
Arthritis Foundation, Alabama Chapter, Endowed Chair
Director, Division of Pediatric Rheumatology
Children's Hospital of Alabama/
University of Alabama at Birmingham
Children's Park Place N., Ste. G10
1601 4th Avenue South
Birmingham, AL 35233

Tel.: [REDACTED] (b) (6)

Email: [REDACTED] (b) (6)

FAX: (205) 638-2875

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 23:42:59 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]
Subject: RE: For review (due to HHS for White House by 8:30 tonight): press conference talking points
Attachments: Talking Points for NIAID Director Dr. Fauci - press conference - 01-28-2020.docx

Here it is with my minor edits. Thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6) >
Sent: Monday, January 27, 2020 6:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Billet, Courtney (NIH/NIAID) [E] <(b) (6)> Stover, Kathy (NIH/NIAID) [E] <(b) (6)> Folkers, Greg (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Subject: For review (due to HHS for White House by 8:30 tonight): press conference talking points

Dr. Fauci –

You will be making brief remarks at the HHS press conference tomorrow. HHS has requested your talking points by 8:30 tonight. (They are really just a placeholder for the White House to have something and so they are not surprised by any news). I have attached proposed points and pasted them below.

Please let me know if you have edits. I will send the final version to HHS tonight.

Thanks,
Jen

Talking Points for NIAID Director Anthony S. Fauci, M.D.

HHS Press Conference on Coordinated Public Health Response to 2019 Novel Coronavirus

(b) (5)

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 04:10:15 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Coronavirus Expert Needed For Romper Article

NIAID inquiries, please.

From: Lindsay Mack <(b) (6)>
Sent: Friday, January 24, 2020 2:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Coronavirus Expert Needed For Romper Article

Hello Dr. Anthony S. Fauci,

I'm writing an article for Romper about the coronavirus, and I need some input from an expert. Would you respond to the following questions via email by the end of day this Monday, Jan 27? I will be happy to include info about your work in the piece as well.

What exactly is the coronavirus, and why has it been such a news story lately?

Are there any precautions against coronavirus that people in the US should take now? For the most part, is coronavirus not worth stressing about, or should people be on alert about this virus?

What do you wish more people knew about coronavirus in general?

Thank you,

Lindsay Mack

www.romper.com

Romper is a part of the [Bustle Media Group](#), the largest premium publisher reaching millennial women. Nearly 80 million readers a month rely on the Bustle Media Group for info about everything from pop culture to relevant social interests.

--

Lindsay Mack
[Freelance Writer](#)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 00:09:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: interview request: LA Times Emily Baumgaertner

Done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Monday, January 27, 2020 7:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: interview request: LA Times Emily Baumgaertner

Sent from my iPhone

Begin forwarded message:

From: "Routh, Jennifer (NIH/NIAID) [E]" <(b) (6)>
Date: January 27, 2020 at 6:58:01 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)> NIAID FOG <fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: interview request: LA Times Emily Baumgaertner

This is a different LA Times request—please send this one for ASF consideration rather than prior Melissa Healy request. Emily said she will patch in Melissa to the same line if they need to. Emily said she is available on her cell below tonight.

Emily Baumgaertner, MPH

Los Angeles Times

Cell: [REDACTED] (b) (6)

Her note: I hope you're well. I'd love to speak briefly by phone with Dr. Fauci regarding what would need to be done in the event that coronavirus isn't quickly contained. Lots of experts discussing what it would look like to accelerate vaccine development and scale up protective work quickly -- but it would be excellent to ask the expert! Around the rest of the day.

Jennifer Routh [E]

News and Science Writing Branch

Office of Communications and Government Relations

National Institute of Allergy and Infectious Diseases (NIAID)

NIH/HHS

31 Center Drive Room 7A17C

Bethesda, MD 20892

Direct: [REDACTED] (b) (6)

[REDACTED] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 00:47:25 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: RE: Wuhan sample

You and Barney should initiate and if there is any resistance, let me know and I will speak with Bob. I will also mention casually to Bob that you guys are trying to work with his people to accomplish this, just to give him a heads-up.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] (b) (6)
Sent: Tuesday, January 21, 2020 7:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Graham, Barney (NIH/VRC) [E] (b) (6)>
Subject: RE: Wuhan sample

Agree. Do you want me an Barney to initiate or do you want to involve Bob Redfield?

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Tuesday, January 21, 2020 7:32 PM
To: Mascola, John (NIH/VRC) [E] (b) (6)>
Subject: RE: Wuhan sample

We should talk with the CDC about (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520

National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] (b) (6) >
Sent: Tuesday, January 21, 2020 2:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> Graham, Barney (NIH/VRC) [E]
(b) (6) >
Subject: Wuhan sample

<https://www.nytimes.com/2020/01/21/health/cdc-coronavirus.html>

Tony,

(b) (5)

John

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 04:11:25 +0000
To: Arnold Vera
Subject: RE: Coronavirus infections (CoVs)

At least 14 days.

-----Original Message-----

From: Arnold Vera <[REDACTED] (b) (6)>
Sent: Friday, January 24, 2020 6:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Coronavirus infections (CoVs)

Dear Dr.Faucy,

Thank you for the excellent information regarding CoVs. Do you recommend for a quarantines time of person expose and arriving at USA from epidemic areas .Thank you , very much. Arnold Vera, MD., MSc.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 00:39:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: [EXTERNAL] Fwd: Fox News request

Done

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>
Sent: Monday, January 27, 2020 7:28 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> Woloshin, Stephanie <stephanie.woloshin@FOXNEWS.COM>
Subject: RE: [EXTERNAL] Fwd: Fox News request

Hi Patricia!

Copying my colleague Stephanie.

We wanted to confirm Dr. Fauci's titles for his name banners. Also would you mind sending over a few talking points about the virus/treatment etc?

Thanks,
Hayley

From: Caronia, Hayley
Sent: Monday, January 27, 2020 6:21 PM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: RE: [EXTERNAL] Fwd: Fox News request

Yes! I have all of that info. Thanks!!

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Monday, January 27, 2020 6:19 PM
To: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: RE: [EXTERNAL] Fwd: Fox News request

Great- Dr. Fauci will be ready at 9:40 pm ET for the hit - thank you – reconfirming address is [REDACTED] (b) (6) Dr. Fauci's home phone is [REDACTED] (b) (6) and cell is [REDACTED] (b) (6)

Also adding him here on email.

Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>
Sent: Monday, January 27, 2020 6:15 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Re: [EXTERNAL] Fwd: Fox News request

All confirmed for tonight. I spoke with the truck operator and he knows to call upon arrival.
Thanks so much!

HAYLEY CARONIA "HANNITY"

C: (b) (6) o O: [212.301.3275](tel:212.301.3275)

On Jan 27, 2020, at 4:58 PM, Caronia, Hayley <hayley.caronia@foxnews.com> wrote:

Yes! If anything changes I will let you know. It's 95% firm. Just have to have Sean confirm after radio. Thanks for your patience!!

Sent from my iPhone

On Jan 27, 2020, at 4:56 PM, Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> wrote:

Thank you – still 9:40 pm ET live hit with Sean Hannity?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>

Sent: Monday, January 27, 2020 4:49 PM

To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>

Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)

Subject: Re: [EXTERNAL] Fwd: Fox News request

The truck operator is named Oran: (b) (6)

HAYLEY CARONIA "HANNITY"

C: (b) (6) o O: [212.301.3275](tel:212.301.3275)

On Jan 27, 2020, at 4:18 PM, Caronia, Hayley <hayley.caronia@foxnews.com> wrote:

Sure, I'll have them call upon arrival. Thanks!

HAYLEY CARONIA "HANNITY"

C: [REDACTED] (b) (6) O: [212.301.3275](tel:212.301.3275)

On Jan 27, 2020, at 4:10 PM, Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)> wrote:

Ok Thank you

Dr. Fauci's home phone is [REDACTED] (b) (6) and cell is [REDACTED] (b) (6). Will you call when the truck is outside?

My cell in case you need me is [REDACTED] (b) (6)

Thank you.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>

Sent: Monday, January 27, 2020 4:03 PM

To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <[REDACTED] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] <[REDACTED] (b) (6)>
Subject: RE: [EXTERNAL] Fwd: Fox News request

Hi!

As of right now, Dr. Fauci will be in the D block at 9:40 PM ET. There will be a quick one minute reporter hit before the interview.

D BLOCK - CORONAVIRUS SCARE // HOW TO CONTAIN THE CORONAVIRUS?
FOX NEWS: CDC: 110 SUSPECTED CORONAVIRUS CASES IN US UNDER INVESTIGATION, NUMBER 'WILL ONLY INCREASE'
<https://www.foxnews.com/health/cdc-110-suspected-coronavirus-cases-in-us-under-investigation-number-will-only-increase>

NY TIMES: AS CORONAVIRUS FEARS INTENSIFY, EFFECTIVENESS OF QUARANTINES IS QUESTIONED
<https://www.nytimes.com/2020/01/26/world/asia/coronavirus-wuhan-china-hubei.html>

FOX NEWS: CORONAVIRUS CAN BE SPREAD DURING INCUBATION PERIOD, CHINESE OFFICIAL CLAIMS
<https://www.foxnews.com/health/coronavirus-spread-during-incubation-period-chinese-official-claims>

TRACE GALLAGHER REPORTER HIT ((LA BUREAU))
THEN...
GUEST: DR. ANTHONY FAUCI, DIRECTOR OF THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES ((DC BUREAU))

From: Caronia, Hayley
Sent: Monday, January 27, 2020 2:54 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] <[REDACTED] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] <[REDACTED] (b) (6)>
Subject: Re: [EXTERNAL] Fwd: Fox News request

Amazing. Booking it now. Thank you!

Will send over hit time as soon as I can.

HAYLEY CARONIA "HANNITY"
C: [REDACTED] (b) (6) o O: [212.301.3275](tel:212.301.3275)

On Jan 27, 2020, at 2:48 PM, Conrad, Patricia (NIH/NIAID) [E] <[REDACTED]> (b) (6)
wrote:

Wow...ok that would be great.

Address is [REDACTED] (b) (6)
[REDACTED] (b) (6)

Please send us your crew name and cell numbers and hit time as soon as possible.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives. without defect.

This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. Any content of this message and its attachments that does not relate to the official business of Fox News or Fox Business must not be taken to have been sent or endorsed by either of them. No representation is made that this email or its attachments are without defect.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 04:14:57 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus epidemic in China
Attachments: Viruses Presentation 012220.pdf

Please handle. Thanks.

From: Kucuk, Omer [REDACTED] (b) (6)
Sent: Friday, January 24, 2020 9:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: omer kucuk [REDACTED] (b) (6)
Subject: coronavirus epidemic in China

Dear Dr. Fauci,

My friend Kieu Hoang is a business man with companies in Los Angeles and Shanghai. Kieu has a nutritional product that has remarkable anti-viral activity (see attached) and could potentially benefit people with coronavirus infection. He is willing to provide the product which is produced at his FDA approved GMP facility in Los Angeles.

If you are interested, I would be happy to give you Kieu's contact information.

All the best,

Omer

Ömer Küçük, MD

Professor of Hematology-Oncology and Urology
Correll Chair in Genitourinary Cancer
Director, Emory Integrative Health and Medicine Center
Director, Multidisciplinary Genitourinary Oncology Group
Chief, Genitourinary Medical Oncology Service
Leader, Prostate Cancer Research Program
Georgia Research Alliance Distinguished Scientist
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Atlanta, GA 30322

Email: [REDACTED] (b) (6)
Mobile: [REDACTED] (b) (6)

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution

or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact the sender by reply e-mail message and destroy all copies of the original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 00:40:25 +0000
To: Johnson, Richard Allen, M.D.
Subject: RE: 01.27 Monday

Dick:

Very busy. I hope that you are well.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Richard Allen, M.D. (b) (6)
Sent: Monday, January 27, 2020 6:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> (b) (6)
Subject: 01.27 Monday

Hi, Tony,

You must be busy. I am expecting to see you on the news discussing coronavirus outbreak.

Best wishes,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 03:02:28 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: interview request: coronavirus AND HIV

Done.

From: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Tuesday, January 21, 2020 1:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: FW: interview request: coronavirus AND HIV

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Sent: Tuesday, January 21, 2020 1:12 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)> NIAID FOG <fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: interview request: coronavirus AND HIV

Betsy McKay
Wall Street Journal
[REDACTED] (b) (6)
betsy.mckay@wsj.com

Betsy would like to speak with ASF after 3 p.m. today about

1. Novel coronavirus (she is aware of CDC call)
2. HIV papers coming out in Nature tomorrow (see attached)

Laura Leifman can provide additional information on the Nature papers as requested – I believe we are issuing a news release about this research tomorrow.

For awareness, if ASF would like to speak with Betsy, we're going to send this as two separate clearance requests for organizational purposes.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 03:36:28 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: News - Germ/Virus Containment

Please handle.

From: [REDACTED] (b) (6) >
Sent: Wednesday, January 29, 2020 1:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: News - Germ/Virus Containment

Hi Dr. Fauci,

I have been following the news and some interviews with yourself. I was hoping you would be willing to speak with me about our technology?

We have the only GERM CONTAINMENT TECHNOLOGY of it's kind.

The ongoing Coronavirus and FLU viruses pose a significant threat to public health globally and here in the US.

We have the most powerful solution to minimize infection and maximize protection against SARS, EBOLA, FLU, and all types of germs and viruses.

With local 3rd party tested efficacy of 100%, no other technology anywhere can yield this result or sustainable 24/7/365 protection.

XTIO2 is a world exclusive containment technology with self-cleaning functions that can help minimize the risk of cross-contamination in hospitals, planes, public transportation, elevators, and public places.

XTIO2 technology works by forming an invisible protective layer on mostly ALL material surfaces (plastic, steel, glass, fabric, paper, walls, etc...). It is green, sustainable, and has yielded up to 100% efficacy proven by SGS LABS (US).

I look forward to hearing from you and sending you an information file for your review.

Thank you,

Michael Holbert

Cleancoating LLC
2522 State Rd., BLDG ISPBC
Bensalem, PA 19020
<http://www.cleancoating.us>

Email: (b) (6)

Direct: (b) (6)

Mobile: (b) (6)



DISCLAIMER

This e-mail message is intended for sole use of the above named recipient(s). If you are not the intended recipient, you may not review, copy or forward this e-mail message. If you have received this communication incorrectly, please notify Clean Coating Technologies LLC immediately via e-mail or phone and delete the message accordingly.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 13:08:59 +0000
To: Howard Bauchner
Subject: RE: Thank You

Howard:

Thank you for your kind note. Much appreciated.
Best regards,
Tony

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Saturday, January 25, 2020 5:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>
Subject: Thank You

Tony

Can't thank you enough for getting in touch and submitting the coronavirus piece.

60,000 views in less than 2 days. Suspect will pass 100,000 views this week.

NYT and others doing a great job on the quarantine, deaths, etc – but this piece provides the science.

Again, many thanks – not sure any one else could have written it with such clarity.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 03:38:28 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: ASM Biothreats 2019-nCoV

Please handle. Thanks.

From: Boltz David (b) (6) >
Sent: Wednesday, January 29, 2020 2:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: ASM Biothreats 2019-nCoV

Dear Dr. Fauci,

My is David Boltz and I am a virologist at IIT Research Institute. I am attending the ASM Biothreats conference and want to thank you for the informative and up to date talk this morning about the novel coronavirus (2019-nCoV). I agree that the number of cases is likely 10-100X what has been reported.

Your presentation reminded me of a game my son plays called Plague Inc as the outbreak of the 2019-nCoV appears to be playing out like the game. If you are not familiar with the game, in the game the player is pathogen trying to infect the world's population. To achieve your goal, you make the pathogen more transmissible and increase the types and severity of clinical symptoms while the governments of the world shut down airports and perform research to study the pathogen and make a vaccine. Once the vaccine is made, the pathogen/player loses. Thus far, the current real life efforts to contain the spread of the virus and develop the vaccine would ultimately stop the pathogen in the game.

(b) (3) (A), (b) (4)

Thank you for time.

Best Regards,

David A. Boltz, Ph.D
Senior Virologist
IIT Research Institute
10 West 35th Street
Chicago, IL 60616
Ph: (b) (6)
(b) (6)

The information contained in this e-mail and any attached documents are confidential, may be privileged, and are intended solely for the persons or entities to whom the e-mail is addressed. Unauthorized review, use, disclosure, or copying of this communication, or any part thereof, is strictly prohibited and may be unlawful. If you have received this e-mail in error, please return the e-mail and attachments to the sender and delete the e-mail and attachments and any copy from your system.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 18:51:42 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Interview with Dr. Fauci about novel coronavirus spreading in China

I called and left voice mail

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Saturday, January 25, 2020 1:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Fwd: Interview with Dr. Fauci about novel coronavirus spreading in China

Sent from my iPhone

Begin forwarded message:

From: "Oplinger, Anne (NIH/NIAID) [E]" <(b) (6)>
Date: January 25, 2020 at 1:08:09 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: Fwd: Interview with Dr. Fauci about novel coronavirus spreading in China

Patty. See below for asf. Wants phone call before Monday if possible.

Anne A. Oplinger
NIAID News Branch
National Institutes of Health
Sent from my iPhone
Any typos are yours to keep.

Begin forwarded message:

From: "Sheikh, Knvul" <knvul.sheikh@nytimes.com>

Date: January 25, 2020 at 12:52:47 PM EST

To: [REDACTED] (b) (6)

Subject: Interview with Dr. Fauci about novel coronavirus spreading in China

Hi Anne,

My name is Knvul Sheikh and I'm a science reporter at The New York Times. I was hoping to speak with Dr. Anthony Fauci about the coronavirus currently spreading in China and a few other countries.

I'm interested in understanding the human backstory of how U.S. scientists got involved in ID'ing the virus and/or developing a test to diagnose the new virus. I understand Chinese scientists posted the genetic sequence of the virus on an NIH database sometime on Friday night, Jan. 17, so I wanted to ask Dr. Fauci about the next steps that his team took to understand the nature of the new virus.

Please let me know if he has time to speak over the phone tomorrow or early Monday morning. I'm on a tight deadline, trying to get some context for a story by Monday morning, Jan. 27.

Thanks and best regards,
Knvul

—

Knvul Sheikh

(Pronunciation: kah-vl shake)

Science & Health Reporter



620 Eighth Avenue
New York, NY 10018

[REDACTED] (b) (6)
knvul.sheikh@nytimes.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 04:08:57 +0000
To: Grady, Christine (NIH/CC/BEP) [E]
Subject: FW: POTUS: Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China.

With the POTUS.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, January 29, 2020 11:05 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: POTUS: Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China.



Donald J. Trump ✓
@realDonaldTrump



Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China. We will continue to monitor the ongoing developments. We have the best experts anywhere in the world, and they are on top of it 24/7!



7:06 PM - Jan 20, 2020 - Twitter for iPhone

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 02:26:08 +0000
To: Daniel Bednarik
Cc: Casseti, Cristina (NIH/NIAID) [E]
Subject: RE: Hello and Idea

Dan:

Thanks for the note. I will pass this on to our program people. All is well here. I hope the same for you.

Best regards,

Tony

From: Daniel Bednarik [REDACTED] (b) (6) >
Sent: Monday, January 27, 2020 1:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Hello and Idea

Dear Tony:

It has been a long time since we last communicated. I listened carefully to your NPR interview this morning which was very clear and I think understandable by the lay public. This triggered a thought, which might be a long shot. The coronaviruses typically express a viroporin or pH-sensitive ion channel that is required for budding of new particles and sometimes for de novo infection. There is evidence that the SARS-CoV is inhibited by amantadine, that age old drug used to block the M2 channel in flu. By analogy, could one also consider amantadine prophylactically for this virus?

I hope you are well; I often interact with [REDACTED] (b) (6).

Best,

Dan Bednarik

--

Daniel Bednarik, Ph.D.
Senior Vice President
Molecular Engineering & Protein Design
NexImmune, Inc.
9119 Gaither Road
Gaithersburg, MD 20877
Phone: [REDACTED] (b) (6)
Email: [REDACTED] (b) (6)
Web: www.neximmune.com



NexImmune, Directing T cell function to restore natural immunity

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 20:09:24 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus talk work

OK. I just saw this. I have 650 e-mails in my in box. I will connect with you later today or sometime tomorrow. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Saturday, January 25, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] <(b) (6)>
Subject: Coronavirus talk work

Dear Dr. Fauci,

Spoke with Hilary, who told me you are looking at the coronavirus talk currently and let her know of a few edits. FYI, I also asked the Weddles to make slides of (just for consideration):

(b) (5)

I won't add/change slides to the talk without talking to you first because I don't want to mess things up!

(b) (6), fully wired, (b) (6) but otherwise available. Should we touch base this afternoon to discuss additional edits/thoughts? Phone or email, whatever you prefer.

Sincerely

Andrea

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892
Cell: [REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 04:10:06 +0000
To: Aaron Weddle
Cc: Conrad, Patricia (NIH/NIAID) [E]; Greg Folkers ([REDACTED] (b) (6))
Subject: FW: POTUS: Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China.

Please call me or Greg about what we can do with these pictures to make slides and prints for framing. Thanks.

From: Folkers, Greg (NIH/NIAID) [E] ([REDACTED] (b) (6))
Sent: Wednesday, January 29, 2020 11:05 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: POTUS: Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China.



Donald J. Trump ✓
@realDonaldTrump



Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China. We will continue to monitor the ongoing developments. We have the best experts anywhere in the world, and they are on top of it 24/7!



7:06 PM - Jan 20, 2020 - Twitter for iPhone

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 Nov 2019 20:32:29 +0000
To: vince@leavittpartners.com
Cc: mike@leavittpartners.com; Greg Folkers (GFOLKERS@niaid.nih.gov); Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Insight
Attachments: jama_marston_2017_vp_170145.pdf

Vince:

Thanks for the note. I am attaching a pdf of a paper that I wrote in the *Journal of the American Medical Association* that addresses the role of biomedical research in pandemic preparedness. In addition, I have inserted into this e-mail a few graphics that describe the relationship between NIH, FDA, and industry in developing countermeasures such as drugs and vaccines. Finally, I include a link below of some of my recent testimonies on this precise subject. I believe that these will supply you with all of the information that you need. If you would still like to chat after you go through this material, please let me know.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.



JAMA. 2017;318(18):1757-1758. doi:10.1001/jama.2017.15033

The Critical Role of Biomedical Research in Pandemic Preparedness

[Hilary D. Marston, MD, MPH¹](#); [Catharine I. Paules, MD¹](#); [Anthony S. Fauci, MD¹](#)

And some of my recent testimony <https://www.niaid.nih.gov/news-events/congressional-testimony>

These graphics might be helpful



From: Vince Ventimiglia <vince@leavittpartners.com>
Sent: Monday, November 4, 2019 11:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Cc: Mike Leavitt <mike@leavittpartners.com>
Subject: Insight

Doctor, good morning.

The Governor has been asked to consider writing a short oped or paper describing the drug/vaccine development ecosystem, and the respective roles of NIH, industry, academia, and other players in that enterprise. Would you or a designee have a few moments to elaborate on your view of the appropriate role of NIH, or to point us toward statements you have made to this effect?

As we address biodefense product development, and efforts to expand NIH work in this area, we'd value your sense of the optimal collaboration.

Thanks for your time,

Vince Ventimiglia
Leavitt Partners

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 6 Nov 2019 19:09:06 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Attachments: Letter of invitation to WHO DG Tedros to write Introductory Chapter.doc, Draft Introduction to Emergency Response Research Book - with Fauci tracked changes.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 04:22:42 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: Hi, potential off-label for the Coronavirus (Resveratrol)

Please handle.

From: David Lee (b) (6)
Sent: Wednesday, January 29, 2020 7:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Hi, potential off-label for the Coronavirus (Resveratrol)

Hi Dr Anthony Fauci

I won't take up too much of your time. I'm David, a general science enthusiast and I want to let you know something regarding the Coronavirus in case interested (and if not readily known)

There are some papers floating around where Resveratrol (molecule from wine), that has been shown to be effective against the 2001 SARS and 2012 Mers, but in vitro.

Resveratrol and sars:

<https://www.sciencedirect.com/science/article/pii/S0223523406001437?via%3Dihub>

And a paper where it was good against Mers:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307780/#!po=0.877193>

It has also been noted by a biologist and Professor in Genetics David Sinclair

<https://twitter.com/davidasinclair/status/1221177622157307904?s=21>

whether it can work against the 2019 version of SARs (as it is 75% similar to the 2001 version), and in vivo, not sure.

But letting you know in case, because Resveratrol is readily available in Chemists over the counter and is safe to use already, so if wanted to test it with humans with the latest Coronavirus, conceptually could be quite fast.

But understand could be a niche, non-standard approach

Also If you are already aware if this, my bad

Thanks for your time

Regards,

David

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:07:51 +0000
To: Rebecca Harris
Subject: RE: NPR today; [REDACTED] (b) (6)

Pneumonia vaccines should be given to everyone over 65 years of age or older should receive the pneumococcus vaccine no matter where they are or where they travel.

From: Rebecca Harris [REDACTED] (b) (6) >
Sent: Monday, January 27, 2020 10:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [REDACTED] (b) (6) >
Subject: Re: NPR today; [REDACTED] (b) (6)

Tony,

Thank you so much! I can't tell you how appreciative I am. [REDACTED] (b) (6) was in China last time he basically described it as a huge "outdoor spittoon!" He said the sanitary conditions, street food vendors, and intense crowds were not to be believed. And Hangzhou is a 'small city'...only 8 million people!

I just looked at the CDC website - have they increased the level to 3 now?
<https://wwwnc.cdc.gov/travel/notices/warning/novel-coronavirus-china>

[REDACTED] (b) (6)

In closing, thank you again. I hope the work to find a vaccine is moving along. Are you all recommending pneumonia vaccines as a precautionary matter for people who travel even if not to China? Keep up the great work!

Warm regards,
Rebecca

Rebecca U. Harris

[REDACTED] (b) (6)

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] < [REDACTED] (b) (6) >
Sent: Monday, January 27, 2020 9:21:48 PM
To: Rebecca Harris [REDACTED] (b) (6)
Subject: RE: NPR today; [REDACTED] (b) (6)

Rebecca:

Thanks for the note. The CDC has a Level 2 alert for all of China (such as Hangzhou) which means enhanced precautions and a level 3 for Wuhan, which means only essential travel. However, the State department is evacuating all of their staff from Wuhan, which tells you something. Given the evolving nature of the situation and the possibility of an explosive outbreak, (b) (6) I would recommend that he not go. I hope that this is helpful.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Rebecca Harris (b) (6)

Sent: Monday, January 27, 2020 4:51 PM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: NPR today; (b) (6)

Dear Dr. Fauci:

I heard you on NPR this morning and was so very impressed with your knowledge of the coronavirus, the work being done to contain the disease, and your astute comment that the CDC has not been 'invited' to assess the situation.

(b) (6)

(b) (6)

I would so value your input.

My sincere thanks - keep up the great work.

Rebecca Harris

Rebecca U. Harris

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 13:00:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

See my edits in **red**. You can forward these to her.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Tuesday, January 21, 2020 4:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: FW: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Do you want to edit this?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Deatrick, Elizabeth (NIH/NIAID) [C] [REDACTED] (b) (6)>
Sent: Tuesday, January 21, 2020 4:47 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: FW: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Patty,

See below—Tanya Lewis, at Scientific American, has asked if ASF can review the transcript of their convo. Let me know if there's anything I can do to help.

Best,
Elizabeth

From: Tanya Lewis <tlewis@sciam.com>
Sent: Tuesday, January 21, 2020 4:43 PM
To: Deatrick, Elizabeth (NIH/NIAID) [C] [REDACTED] (b) (6)
Subject: Re: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Elizabeth,

I just spoke with Dr. Fauci—thanks for arranging the call on short notice! I don't usually do this, but I had some problems with my recording software, so I wondered if I could run the transcript of my interview by Dr. Fauci to make sure I copied everything correctly. Can you ask Dr. Fauci to review it for accuracy only? (We may edit the conversation slightly for length and clarity, but it will be pretty close to this):

Do we know how the U.S. patient contracted the virus? The earliest cases appeared to be people who had been to a seafood market in Wuhan, but there have since been documented cases of human-to-human transmission.

He [the patient] was not in any market where there may have been an animal reservoir, and he does not recall coming into contact with someone who was ill. That's not surprising— **often people contract respiratory infections without knowing the definite exposure source.** But he was in Wuhan.

Do you suspect the virus is transmitted via a respiratory route?

A respiratory infection is almost certainly transmitted through droplets. Respiratory spread is a very good guess. We have **definitively proven that the virus entered through the respiratory tract,** but it is highly likely. When you have symptoms of fever, cough, infiltrates in the lung, and respiratory [symptoms]... historically, respiratory is the route.

How similar or different is the virus from other Coronaviruses such as SARS and MERS?

First of all, it's a Coronavirus, the same family as SARS. It has some of the same molecular homology as SARS. It's closer to SARS than it is to MERS. But it isn't overwhelmingly close.

Do we know the mortality rate of the new virus?

It's a moving target. It's a rough estimate. If you look at the number of cases, it's around 300. There have been six deaths so far. That's about 2 percent mortality. But we have not identified all the cases. We're only seeing the ones who are hospitalized. If there are asymptomatic infections, the mortality rate would be much less. Among symptomatic people, the mortality rate is around 2 percent. It was 10 percent with SARS, and 30-35 percent with MERS. It may be less virulent than those two, or it may evolve. It's too early to know.

Aren't the symptoms of this viral infection similar to many other types of respiratory infection? How can you tell them apart?

It's a syndromic and epidemiological association. If somebody comes into an emergency room in Washington with a respiratory illness and they haven't been to China, they probably have the flu or some other virus. But if they came from Wuhan, [it's likely to be the new Coronavirus]. The symptoms are very common to a number of viruses, though, so it's [based on] epidemiology.

How are the patients with this virus being treated?

It's mostly symptomatic treatment. There are experimental antivirals that have been used *in vitro* and *in vivo*. If [the patients] need antibiotics **for complicating bacterial infections**, you give them antibiotics. If they need to be put on a respirator, they're put on a respirator. Most [patients] in China are doing well. But a proportion of them are very ill, and are on respirators.

How long will it be before we have a vaccine for this virus?

We've already started to develop a vaccine. We got the [genetic] sequence from the Chinese. We're partnering with a company called Moderna to develop a messenger RNA-based platform for a vaccine. We will likely have a candidate in **early phase 1 trials for safety in** about three months. That doesn't mean we will have **a vaccine ready for use in three months; even in an emergency, that would take a year or more.**

Is the most likely source of this virus an animal market in Wuhan?

It almost certainly came from an animal. Almost certainly.

How common are Coronaviruses, and how often do they jump from animals to humans?

Coronaviruses represent 10-30 percent of common colds. Over the last 18 years, we've had three coronaviruses from animal reservoirs: SARS, MERS, and now this. There could be several intermediary hosts, but at least with SARS and MERS, the primary host is thought to be a bat. [We don't know what the primary host is for this virus yet.]

Thanks very much,

Tanya

--

Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell # [REDACTED] (b) (6)

From: Administrator <tlewis@sciam.com>

Date: Tuesday, January 21, 2020 at 1:25 PM

To: "Deatrck, Elizabeth (NIH/NIAID) [C]" <(b) (6)>

Subject: Re: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Elizabeth,

Thanks for getting back to me. I don't have a hard deadline, but as this is a quickly evolving topic, I'd like to file something fairly soon. I am aware of the CDC telecom this afternoon, and plan on listening in. But I'm still interested in speaking with Dr. Fauci if he's available.

Best,
Tanya

--

Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell #: (b) (6)

From: "Deatrck, Elizabeth (NIH/NIAID) [C]" <(b) (6)>

Date: Tuesday, January 21, 2020 at 1:01 PM

To: Administrator <tlewis@sciam.com>

Subject: RE: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Tanya,

Thank you for reaching out to NIAID. I'll be checking with Dr. Fauci to see if he's available for an interview tomorrow morning, or late this afternoon. Do you have a hard deadline tomorrow you're working to meet?

Also, in case you're unaware, the CDC is having a telebriefing on this topic later this afternoon—it may answer some of your questions (see attachment for details). If you're still interested in a call afterwards, we'd be happy to work on that for you.

Best,
Elizabeth

From: Tanya Lewis <tlewis@sciam.com>

Sent: Tuesday, January 21, 2020 12:41 PM

To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>

Cc: Deatrck, Elizabeth (NIH/NIAID) [C] <(b) (6)>; Oplinger, Anne (NIH/NIAID) [E] <(b) (6)>

Subject: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Dear NIAID press officers,

I'm a news editor at Scientific American, and I'm reporting a story on the ongoing outbreak of a new coronavirus from China. I'm writing to request an interview with Dr. Fauci, or someone else in your agency who is an expert on this topic, or coronaviruses in general. I'm hoping to file my story no later than noon ET tomorrow. Let me know if you can set something up for this afternoon (anytime except 2-3 ET), or first thing tomorrow morning. Thanks!

Best regards,

Tanya

--

Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell #: (b) (6)

DISCLAIMER: This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage mechanism. Springer Nature America, Inc. does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of Springer Nature America, Inc. or one of their agents. Please note that neither Springer Nature America, Inc. or any of its agents accept any responsibility for viruses that may be contained in this e-mail or its attachments and it is your responsibility to scan the e-mail and attachments (if any).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 8 Nov 2019 21:22:42 +0000
To: STEWART SIMONSON
Cc: Marston, Hilary (NIH/NIAID) [E];Higgs, Elizabeth (NIH/NIAID) [E];Sorenson, Robert (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: Request for Tedros
Attachments: Draft Introduction to Emergency Response Research Book- 11.08.2019.docx, Letter to DG Tedros - 11-08-2019.pdf

Stewart:

I am hoping you can help gauge Tedros' interest in co-authoring with me an introduction for a new textbook on response research. NIAID staff are spearheading this effort, having recognized the growing global interest in the topic and the need for practical standards to guide the field. Given his leadership in this area, I can think of no one better suited to introduce the volume.

Recognizing the many demands on his time, he should of course feel free to decline – that is why I wanted to route through you and not send to him directly. If he does accept, I tried to make it as straightforward a task as possible and took the liberty of drafting text (attached). Should he decide to co-author this with me, he should feel free to send any edits or comments over email.

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 20:45:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: ASM Biothreats - Coronavirus talk for 1/29

It is now marked as "1st FINAL" in the OD folder. Hilary is in the loop.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, January 25, 2020 3:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Re: ASM Biothreats - Coronavirus talk for 1/29

Dr Fauci,

Sounds good. (b) (6) but otherwise available to assist. As I said in other email, I will wait to hear further from you.

Andrea

Sent from my iPhone

> On Jan 25, 2020, at 3:07 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

>

> I understand that you are (b) (6) and so I do not want to bother you. I will get to the talk later in the day or tomorrow AM and then I will e-mail you about the way forward. Thanks.

>

> Anthony S. Fauci, MD

> Director

> National Institute of Allergy and Infectious Diseases Building 31,

> Room 7A-03

> 31 Center Drive, MSC 2520

> National Institutes of Health

> Bethesda, MD 20892-2520

> Phone: (b) (6)

> FAX: (301) 496-4409

> E-mail: (b) (6)

> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

>

> -----Original Message-----

> From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)

> Sent: Friday, January 24, 2020 6:22 PM

> To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

> Subject: ASM Biothreats - Coronavirus talk for 1/29

>

> Dear Dr. Fauci,

>

> I know you will need a little bit more time over the weekend to look at the talk. Let me know what edits or thoughts you have and I will be available over the weekend to discuss things with you!

>

> Sincerely

> Andrea

>

> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 10:55:58 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: URGENT GPMB: Message on behalf of the Co-Chairs: Statement on 2019-nCoV
Attachments: GPMB Statement on 2019 nCoV.pdf

FYI and let us discuss.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Thursday, January 30, 2020 4:43 AM
To: (b) (6); Gro (b) (6); Dzau Victor <(b) (6); Chris.Elias (b) (6); Farrar Jeremy (b) (6); Fauci, Anthony (NIH/NIAID) [E] <(b) (6) Fore Henrietta (b) (6) Gao Fu (b) (6); Gashumba Diane (b) (6); Kaag Sigrid (b) (6); Ilona Kickbusch (b) (6); Skvortsova Veronika (b) (6) Suzuki Yasuhiro (b) (6); Vega Morales Jeanette (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)
Cc: SCHWARTLANDER, Bernhard F. (b) (6); FALL, Ibrahima Soce (b) (6) MAHJOUR, Jaouad (b) (6) MINHAS, Raman (b) (6); Toomas Palu (b) (6); 'Pate Muhamed' (b) (6); RYAN, Michael J. (b) (6); 'Alex Harris' (b) (6); Alveberg, Benedikte Louise (b) (6); 'Chiaki NOGUCHI' (b) (6) 'Esveld Marja' (b) (6); 'Gonggrijp Mette ' (b) (6); Julie.HALL (b) (6) 'Kanarek Morgan' (b) (6); Marston, Hilary (NIH/NIAID) [E] <(b) (6) 'Oleg Sonin ' (b) (6); 'Omar Abdi' (b) (6); Amelie RIOUX (b) (6) Tore Godal' <(b) (6) GABEDAVA, Tsira (b) (6); ROSS, Alex (b) (6) 'Banks Lynn' (b) (6); 'Block Bruce' (b) (6) 'Conrad Jane' (b) (6); Conrad, Patricia (NIH/NIAID) [E] <(b) (6) 'Del Sol Dinia' (b) (6); 'Diao Fay' (b) (6); 'Elena Kirsanova ' (b) (6) 'Gahungu Zacharie' (b) (6); 'Harikumar M K' (b) (6); 'Harikumar M K' (b) (6); 'Kabagire Christine' (b) (6); 'KITA Yosuke' (b) (6); 'Miller de Vega Teresa' (b) (6); MURIUKI, Hilda Wairimu (b) (6); 'Muzenda Sindiso' (b) (6); 'Sarah Belmir' (b) (6) 'YU Bai' (b) (6); Scott Dowell (b) (6); 'Kanarek Morgan' (b) (6) STERN, Gabriella (b) (6); LOEWENBERG, Samuel Richard <(b) (6)>
Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Statement on 2019-nCoV
Importance: High

Dear Board members,

Thank you for your rapid response and participation in the teleconference call and feedback to the draft statement on the 2019 n-CoV outbreak.

Please find attached the final statement which reflects all of your comments. It is supportive of countries' and WHO's critical efforts for further immediate preparedness and response, and calls for urgent actions to strengthen global preparedness and response to this outbreak.

We encourage you to circulate the Statement through your channels.

The Statement will be uploaded to the GPMB website, and the Secretariat is circulating to various media. You may wish to use the original hashtag from our report #AWorldatRisk in social media posts.

As media will reach out to the Secretariat, please let the Secretariat know of your willingness to be interviewed in the coming days (the Secretariat will screen requests and coordinate with you/your staff).

Please also note that WHO is convening the IHR Emergency Committee later this afternoon.

Thank you for your continued engagement.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:08:58 +0000
To: Paules, Catharine
Subject: RE: Reply regarding email sent to Dr. Fauci

Very little 😞

From: Paules, Catharine <[REDACTED]> (b) (6)
Sent: Monday, January 27, 2020 9:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: RE: Reply regarding email sent to Dr. Fauci

Just saw you on the news. Hope you are getting some sleep in all this.

From: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Date: January 27, 2020 at 9:16:45 PM EST
To: Paules, Catharine <[REDACTED]> (b) (6)
Subject: RE: Reply regarding email sent to Dr. Fauci

== CAUTION: External Sender ==
This message came from outside of Penn State Health & College of Medicine.
Please use caution when opening attachments or links.

Thanks, Cat

From: Paules, Catharine <[REDACTED]> (b) (6)
Sent: Monday, January 27, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] <[REDACTED]> (b) (6); Conrad, Patricia (NIH/NIAID) [E] <[REDACTED]> (b) (6); Billet, Courtney (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: FW: Reply regarding email sent to Dr. Fauci

Just FYI—this was the gentleman you asked me to respond to and here is the response below. Thanks much, Cat

From: Paules, Catharine
Sent: Monday, January 27, 2020 4:54 PM
To: [REDACTED] (b) (6)
Subject: Reply regarding email sent to Dr. Fauci

Hello Mr. Sun,

Thank you very much for reaching out to Dr. Fauci with your questions and for reading the manuscript in JAMA. Please see the links below to two publications that I think will help address some of your questions and highlight the importance of vaccine development (and other countermeasure development) in response to emerging viral pathogens.

<https://jamanetwork.com/journals/jama/fullarticle/2676502>

<https://jamanetwork.com/journals/jama/fullarticle/2656224>

In regard to the novel coronavirus, this situation is evolving rapidly so it is difficult to make predictions regarding the scope and duration of this outbreak. Vaccine development remains a key priority at this time.

Thank you very much for reaching out,

Catharine

Catharine I. Paules MD

Assistant Professor, Infectious Diseases

Penn State University College of Medicine, Milton S. Hershey Medical Center

500 university drive Hershey PA 17033

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:21:23 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Any coronavirus update?

Francis:

You can use any of the information in my 01/21/2020 e-mail. There are close to 500 cases (440 at last count) and 9 deaths. Mortality remains at around 2% for people who are recognized with sx's. No evidence at present regarding asymptomatic infections. In addition to the ORD and ATL airports plus JFK, LAX and SFO, DHS will work out funneling people coming from China to USA through these 5 airports. Also, CDC has elevated their Travel Alert to Level 2, which means enhanced precaution. Level 1 is business as usual and Level 3 is only essential travel.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Wednesday, January 22, 2020 8:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Burklow, John (NIH/OD) [E] <(b) (6)>; Myles, Renate (NIH/OD) [E] <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] <(b) (6)>
Subject: Any coronavirus update?

Hi Tony,

I'm doing a Swiss Radio interview at 4 pm in Davos (10 am EST). It's supposed to be wide-ranging about many issues in biomedical research, but I'd be surprised if they don't bring up the coronavirus situation.

Stephane Bancel sent me a heads up (just forwarded to you) that Moderna was announcing their collaboration with NIH on an RNA based vaccine development, as you told me yesterday. Just so I'm clear, is there anything in your message from 1/21 11:13 AM that I should NOT mention? And is there anything new in the last 24 hours other than screening at Chicago and Atlanta airports?

Thanks for all your help on this!

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 10:57:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Skype Interview requests of Arirang TV in Seoul

Please handle.

From: 김효선 (b) (6) >
Sent: Thursday, January 30, 2020 3:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Skype Interview requests of Arirang TV in Seoul

Hello. My name is Hyosun kim and I'm a writer at Arirang TV, based in Seoul, Korea.

I am writing to you because I'd love to have you as a guest on my show.
The show, titled <Peace & Prosperity>, is a 30-minute pre-recorded segment that focuses on inter-Korean issues and denuclearization negotiations on the Korean Peninsula.

Below is our program site link.

http://www.arirang.com/Tv2/Tv_Home.asp?PROG_CODE=TVCR0863&MENU_CODE=102722

This week's topic is the new coronavirus.

I would like to say the importance of cooperation between the Korean and Chinese governments.

And I contacted you because I needed medical explanation for the new coronavirus.

Would you be free for a 10-minute Skype interview on

February 3 (monday) or February 4 (tuesday) ?

I look forward to hearing from you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:14:38 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers (GFOLKERS@niaid.nih.gov)
Subject: FW: Invitation to write a Perspective for Cell

Let us discuss.

From: Narasimhan, Sri Devi (ELS-CMA) <srnarasimhan@cell.com>
Sent: Monday, January 27, 2020 4:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Invitation to write a Perspective for Cell

Dear Tony,

I hope all is well. I had the great pleasure of meeting you in person when you were the keynote speaker at our Cell Symposium on Emerging and Re-emerging Viruses in 2017. You then gave a wonderful talk that covered AIDS to Zika and your experiences across different outbreaks, administrations and the challenges you encountered.

I realize I am writing to you in the middle of a yet another outbreak but you have such a broad, unique and valuable perspective on the complexity and multifaceted nature of dealing with these situations that I think would be of very broad interest and value to the scientific community. I'd love Cell to be the platform for this communication - it could be focused more on the Wuhan coronavirus or a broader perspective on outbreak to management and everything in between where you focus on common threads as well as unique challenges.

This could be a more long-term article for Cell if your hands are full right now but I'd love to know if you would be interested in writing for us.

My best wishes,
Sri.

Sri Devi Narasimhan, PhD
Deputy Editor, Cell
Cell Press/Reed Elsevier

50 Hampshire St., Cambridge, MA 02139
snarasimhan@cell.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:46:51 +0000
To: Phil.Fontanarosa@jamanetwork.org
Subject: RE: JAMA20-0602 Decision Letter - Please Confirm Receipt

Received!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Phil.Fontanarosa@jamanetwork.org <Phil.Fontanarosa@jamanetwork.org>
Sent: Wednesday, January 22, 2020 8:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Lupe.Morales@jamanetwork.org
Subject: JAMA20-0602 Decision Letter - Please Confirm Receipt

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

January 22, 2020

Dr Anthony S Fauci
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520

RE: Coronavirus Infections: More Than Just the Common Cold

Dear Dr Fauci:

We have completed our review of your manuscript and are considering accepting it for publication in JAMA. However, acceptance will not be final until we receive all of the items described in this letter.

Do NOT send a revised version of your manuscript at this time.

After receipt of all of the items, your manuscript is accepted with the understanding that its contents, all or in part, have not been published elsewhere and will not be published elsewhere in print or electronic format without the consent of the editor.

We are planning to publish your article online ahead of print. Any information you may receive about the proposed publication date of your article is tentative and should be kept confidential. Shortly before publication, the publication date can be confirmed. Prepublication distribution of the accepted manuscript without permission is prohibited.

Please note that the news media should not release any information about your article until it is published. If you need help in coordinating press conferences or releases, please contact the JAMA Network Media Relations Department at mediarelations@jamanetwork.org or 312-464-JAMA (312-464-5262).

We sincerely appreciate your submitting the manuscript for our consideration and look forward to seeing it in JAMA.

Sincerely yours,

Phil B Fontanarosa, MD, MBA
Executive Editor, JAMA
Email: Phil.Fontanarosa@jamanetwork.org
Phone: (312) 464-2457
Fax: (312) 464-5824

Lupe Morales
Editorial Assistant, JAMA
Email: Lupe.Morales@jamanetwork.org
Phone: 312.464.2457
Fax: 866.460.7052

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

EDITOR'S REQUIREMENTS

Authorship Forms

Each author will be sent an email with instructions for submitting the Authorship Forms, with information about authorship responsibility, funding and conflicts of interests, and a publishing agreement.

Author Conflict of Interest Disclosures

Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, up-to-date, and reported in the Acknowledgment section of the manuscript in a manner that is consistent with that reported in the disclosures of potential conflicts of interest section of the JAMA's Authorship Form.

Our policy requires that all authors disclose:

Any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present);

Any relevant financial activities outside the submitted work (during the 3 years prior to submission);

And any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

Potential conflicts of interest include but are not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. For example, authors of a manuscript about hypertension should report all financial relationships they have with all manufacturers of products used in the management of hypertension, not only those relationships with companies whose specific products are mentioned in the manuscript.

Authors without potential conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests. If you are uncertain about what constitutes a relevant financial interest or relationship, please let me know. Each author will be sent an email with further instructions for submitting the Authorship Form, which includes the ICMJE Disclosure of Potential Conflicts of Interest section.

All financial and material support for the research and/or the work reported in the manuscript should be clearly and completely identified in the Acknowledgment.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 10:58:02 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview Request on Novel Coronavirus

Please handle.

From: 박현영 <park.hyunyoung@joongang.co.kr>
Sent: Thursday, January 30, 2020 3:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Interview Request on Novel Coronavirus

Dear Dr. Fauci,

I am Senior Washington Correspondent with The JoongAng Ilbo and JTBC news network, the largest media group in South Korea.

I would like to schedule an interview regarding Novel Coronavirus 2019, how it spreads and how to fight it.

Topics I would like to discuss are how dangerous this virus is, what is the best way to prevent it in local communities and whether patients without symptoms can transmit the disease.

Yesterday CDC announced it won't quarantine 200 Americans flown home from Wuhan, China. Japan has followed the same path. However, South Korea, Australia, France and UK governments decided to quarantine evacuees for 14 days in independent facilities. Why are governments' responses different and what is the optimal choice?

Currently S. Korea has 4 confirmed cases which is not very many, but the nation is split on where evacuees should be quarantined after they're airlifted later this week. Nobody wants them closeby.

I hope this interview could be an informative reference to our readers who seek scientific information on the new virus.

I am based in Washington DC. When scheduled our team can visit NIH. I hope to hear from you soon. Thank you.

Best regards,
Hyun Young

Hyun Young PARK
Washington Correspondent
The Joongang Ilbo & JTBC Broadcasting Network
Mobile: [REDACTED] (b) (6)
Office: (202) 347-0122

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:35:01 +0000
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: RE: Statement on new coronavirus

Paolo:

The JAMA article is still the best summary of what is going on.

Best,
Tony

From: Lusso, Paolo (NIH/NIAID) [E] (b) (6)
Sent: Monday, January 27, 2020 9:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Statement on new coronavirus

Dear Tony,

I am sorry we haven't been able to meet recently, but I can imagine how busy you must be with the Wuhan virus. In this respect, I have received a request from the Italian Ambassador through the scientific attache', Dr. Gilli, who was enquiring if NIH has released any official statement on the new coronavirus situation. Is there any such statement or other material I can send them other than your JAMA article? Please, let me know. Thanks!

All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: (b) (6) (personal)

(b) (6) (lab)

Fax: (301) 480-5291

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious

Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:48:00 +0000
To: Paules, Catharine;Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: JAMA20-0602 Decision Letter - Please Confirm Receipt

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Phil.Fontanarosa@jamanetwork.org <Phil.Fontanarosa@jamanetwork.org>
Sent: Wednesday, January 22, 2020 8:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Lupe.Morales@jamanetwork.org
Subject: JAMA20-0602 Decision Letter - Please Confirm Receipt

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

January 22, 2020

Dr Anthony S Fauci
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520

RE: Coronavirus Infections: More Than Just the Common Cold

Dear Dr Fauci:

We have completed our review of your manuscript and are considering accepting it for publication in JAMA. However, acceptance will not be final until we receive all of the items described in this letter.

Do NOT send a revised version of your manuscript at this time.

After receipt of all of the items, your manuscript is accepted with the understanding that its contents, all or in part, have not been published elsewhere and will not be published elsewhere in print or electronic format without the consent of the editor.

We are planning to publish your article online ahead of print. Any information you may receive about the proposed publication date of your article is tentative and should be kept confidential. Shortly before publication, the publication date can be confirmed. Prepublication distribution of the accepted manuscript without permission is prohibited.

Please note that the news media should not release any information about your article until it is published. If you need help in coordinating press conferences or releases, please contact the JAMA Network Media Relations Department at mediarelations@jamanetwork.org or 312-464-JAMA (312-464-5262).

We sincerely appreciate your submitting the manuscript for our consideration and look forward to seeing it in JAMA.

Sincerely yours,

Phil B Fontanarosa, MD, MBA
Executive Editor, JAMA
Email: Phil.Fontanarosa@jamanetwork.org
Phone: (312) 464-2457
Fax: (312) 464-5824

Lupe Morales
Editorial Assistant, JAMA
Email: Lupe.Morales@jamanetwork.org
Phone: 312.464.2457
Fax: 866.460.7052

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

EDITOR'S REQUIREMENTS

Authorship Forms

Each author will be sent an email with instructions for submitting the Authorship Forms, with information about authorship responsibility, funding and conflicts of interests, and a publishing agreement.

Author Conflict of Interest Disclosures

Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, up-to-date, and reported in the Acknowledgment section of the manuscript in a manner that is consistent with that reported in the disclosures of potential conflicts of interest section of the JAMA's Authorship Form.

Our policy requires that all authors disclose:

Any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present);

Any relevant financial activities outside the submitted work (during the 3 years prior to submission);

And any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

Potential conflicts of interest include but are not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. For example, authors of a manuscript about hypertension should report all financial relationships they have with all manufacturers of products used in the management of hypertension, not only those relationships with companies whose specific products are mentioned in the manuscript.

Authors without potential conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests. If you are uncertain about what constitutes a relevant financial interest or relationship, please let me know. Each author will be sent an email with further instructions for submitting the Authorship Form, which includes the ICMJE Disclosure of Potential Conflicts of Interest section.

All financial and material support for the research and/or the work reported in the manuscript should be clearly and completely identified in the Acknowledgment.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Dec 2019 18:21:00 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CSIS Health Security Commission Final Report Released
Attachments: CSIS Ending The Cycle of Crisis and Complacency_11.22.pdf

Let us discuss. I may need to take a look at the report as well as attend the dinner. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephen Morrison <SMorriso@csis.org>
Sent: Wednesday, December 18, 2019 12:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)> Anna Carroll <ACarroll@csis.org>; Samantha Stroman <SStroman@csis.org>
Subject: CSIS Health Security Commission Final Report Released

Hi Tony,

I hope this email finds you well. I am pleased to share that, in late November, the [CSIS Commission on Strengthening America's Health Security](#) released its final report, [Ending the Cycle of Crisis and Complacency in U.S. Global Health Security](#). We are extremely grateful for all of the time and input you have given to the Commission over the past year and a half.

The report proposes seven strategic recommendations to replace the cycle of crisis and complacency that has long plagued health security preparedness with a doctrine of continuous prevention, protection, and resilience. The Commission settled on what it believes to be cost-

effective, proven, commonsense recommendations that can draw support from across the political divide.

The report calls on Congress and the administration to adopt the following integrated package of critical actions:

1. Restore health security leadership at the White House Security Council.
2. Commit to full and sustained multi-year funding for the Global Health Security Agenda to build partner capacity.
3. Establish a Pandemic Preparedness Challenge at the World Bank to incentivize countries to invest in their own preparedness.
4. Ensure rapid access to resources for health emergencies.
5. Establish a U.S. Global Health Crises Response Corps.
6. Strengthen the delivery of critical health services in disordered settings.
7. Systematically confront two urgent technology challenges: the need for new vaccines and therapeutics and the public health communications crisis.

We would welcome the opportunity to brief you on the report, should that be of interest to you. In particular, we would be interested in meeting to discuss the recently established National Influenza Vaccine Task Force and its forthcoming five-year plan. The Commission report includes a recommendation to increase investment in universal flu vaccine development, and we plan to write a follow-up policy brief on the issue of pandemic and seasonal influenza. We are eager to align this policy brief with the work of the Task Force.

Lastly, on Tuesday, February 4, we will host a by-invitation dinner discussion following the fourth and final private meeting of the Commission. The dinner will be a high-level dialogue between the Commission and executive branch leaders on advancing the recommendations of the Commission's final report. Dr. John J. Hamre, President and CEO of CSIS, will attend the dinner, along with Commission Co-Chairs Kelly Ayotte and Julie Gerberding. We expect many members of the Commission to join as well, including Members of Congress. We would be delighted to have you participate, and we hope you can join us.

Best Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 02:07:20 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: FW: AlphC: Medical Modelling/Historical Travel Modelling and (2019-nCoV) spread

Please take a look and respond if appropriate.

From: Shafin Valla <shafin@alphc.com>
Sent: Saturday, January 25, 2020 2:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Stephen Baruch [REDACTED] (b) (6)>
Subject: AlphC: Medical Modelling/Historical Travel Modelling and (2019-nCoV) spread


Dr. Anthony Fauci,

Please see below and we can talk. I have also left a voicemail at [REDACTED] (b) (6)

We reach out to you based on the current issues with nCov. Our medical modelling is new knowledge to the field and we share this with you.

Alphabet Communication (AlphC) creates an email for every physical address in the world. A message sent to the email of the address connects you to all occupants. You have the unique ability to map the global population. Every email created is unique and cannot be duplicated (similar to a fingerprint/DNA). We are at the cusp and new age for the Internet. Travel patterns can now be mapped providing medical models and instant connectivity based on needs. Historical and current locations of travellers (places of visit, neighbours, etc), we can provide vast opportunities and fill gaps current technologies have not addressed.

Here is a quick illustration below.



In summary:

- Every Passenger has an address
- These can be graphically mapped instantly to exact address in the world (travel itinerary)
- Their destinations mapped
- Passengers that sat in their vicinity, possible infections can be mapped
- Authorities can then have a graphic-mapped-areas of possible areas of infection
- The infection can be mapped to the origin (exact-address) and at-risk neighbors identified
- At risk population at the new addresses can also be identified
- Graphic display of each address with infection, quarantined areas, suspect sites of infection
- Rural addresses can also mapped and high-rise building to the unit number.
- 80% of the population has a cell. This is where the message gets sent as text with 100% penetration.
- All this information is captured before we board a flight.
- Hence everything auto populates and can be activated by CDC or NIH or designated authority

Feel free to connect ...

Shafin Valla

Alphabet Communication (AlphC)

shafin@alphc.com

1.647.836.7867

<https://www.linkedin.com/in/shafin-valla-b99ba6181/>

On Fri, Jan 24, 2020 at 11:58 PM Stephen Baruch (b) (6) > wrote:

Shafin, please consider reaching out to Dr. Anthony Fauci. He is the US point person for the 2019 novel coronavirus . Your company's capability to efficiently track and communicate with people who may have been exposed could be a real interest to him and his colleagues.

Stephen

Dr. Stephen B. Baruch, MBCI, CBCP

The Baruch Group, Disaster Preparedness....Business Continuity

Tel: 650-279-2556

Twitter: <http://twitter.com/bcpexpert>

LinkedIn: <http://www.linkedin.com/in/stephenbaruch>

Facebook: <http://www.facebook.com/TheBaruchGroup>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:36:11 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Level of interest @ NIAID: Chemo-prophylaxis/treatment by drug reprofiling for coronavirus.

Please handle.

From: Dr. Farhan Subhani [REDACTED] (b) (6)
Sent: Monday, January 27, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Level of interest @ NIAID: Chemo-prophylaxis/treatment by drug reprofiling for coronavirus.

Dear Dr. Fauci,

I am drug discovery/reprofiling consultant with clinical medicine background. I'm aware that NIAID is interested for vaccine of coronavirus new strain but vaccine will take years. So, at this time, chemo-prophylaxis is best option [REDACTED] (b) (4)

[REDACTED] (b) (4)

Looking forward for your response.

Kind regards

Dr. Farhan UI Haq Subhani (M.B.,B.S)
Independent Drug Discovery/Reprofiling Consultant
email: [REDACTED] (b) (6)
Cell/WhatsApp: [REDACTED] (b) (6)
Lahore, Pakistan.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:59:05 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Authorship Form Needed for JAMA20-0602

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cheryl.Sykes@jamanetwork.org <Cheryl.Sykes@jamanetwork.org>
Sent: Wednesday, January 22, 2020 8:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Authorship Form Needed for JAMA20-0602

January 22, 2020

Dear Dr Fauci:

Your manuscript, Coronavirus Infections: More Than Just the Common Cold, is being considered for possible publication in JAMA. Meanwhile, please complete the Authorship Form.

Click on the link below to access the electronic authorship form. You will be required to enter your password. If you are unable to locate your password please click the "Unknown/Forgotten password" link.

Please do not share this email with anyone.

<https://manuscripts.jama.com/cgi-bin/main.plex?el=A6e5BMng1A4BtRQ3w6A3E1F7A4A9ftdszp7SLUByqn9I47YfWJZAZ>

This form must be completed online. Each author needs to complete Section 1: Author Responsibility, Criteria, and Contributions; Section 2: Disclosure of Potential Conflicts of Interest, Section 3: Publishing Agreement, and Section 4: Confirmation. The corresponding author also needs to complete Section 1A.

Acknowledgement.

After completing the sections online, type your name as it appears on the top of the form and date into Section 4: Confirmation. A digital signature is not required. Click the submit button on the form display screen to save the authorship form in the manuscript submission system.

Instructions for Authors are available online at:

<http://jamanetwork.com/journals/jama/pages/instructions-for-authors>

Sincerely yours,

Cheryl R. Sykes
Supervisor, JAMA
Phone: 312.464.4416
Email: Cheryl.Sykes@jamanetwork.org

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 02:13:08 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: ASM Biothreats coronavirus talk, 20 min, 1/29

I would like to include slides 3.4, and 5. Thanks.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Saturday, January 25, 2020 7:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] <(b) (6)> Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: ASM Biothreats coronavirus talk, 20 min, 1/29

Dear Dr. Fauci,

I have gone through the slides labeled "1st FINAL" in the OD drive and made the noted edits. I will also update the map slides as we see what happens over the weekend,.

Regarding demographics, there is a Lancet paper detailing demographics and clinical information for 41 patients, and 2 reports (1 from the Hubei Province Health Commission, 1 from the Chinese Health Commission) reviewing demographics and limited clinical information for a total of 24 patients who died. I could not find an age range for all severe cases, or for all deaths reported.

Slides 1-4 in this deck are possibilities for the demographics and clinical information. Slide 5 in this attachment can possibly update slide #61 on cities quarantined in the presentation. Cc'ing Greg and Hilary as well for ideas and input, and in case they are aware of sources that I didn't find!

Let me know what you think,

Andrea

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:36:50 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Disinfecting Against NovoCorona Virus
Attachments: ncnovoviruspaper, danolyte200126.pptx

Please handle.

From: Robert Jackson (b) (6)
Sent: Monday, January 27, 2020 8:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Don Peterson (b) (6)
Subject: Fwd: Disinfecting Against NovoCorona Virus

Dr Anthony Fauci Director of National Institute of Allergy and Infectious Diseases

Dr. Fauci,

Please note the forwarded email and the attachments. I believe we have an effective, economical and environmentally safe technology that can be a first line of defense against the coronavirus outbreak. You are well aware infected individuals may remain asymptomatic for days and it will be months before an effective vaccine can be found and dispensed. This technology can disinfect contaminated environments effectively covering all surfaces and is hypoallergenic. It also includes a solar powered system so that power outages and remote regions of the world can use the unit.

We hope to hear from you soon so that we can join with your current plan of action against this epidemic.

Highest Regards,

Dr. Jackson
Clinical Consultant Danolyte Global




Robert Wayne Jackson, **DO, FACOI**
President & Founder
Premier Specialty Network
3610 Buttonwood Drive, Suite 200
Columbia, MO 65201
Office : [\(573\) 231-9022](tel:5732319022)
Office Fax: (573) 886-8901
Cell: (b) (6)
(b) (6):

'If the purpose of your heart is pure then anything is possible'

This electronic communication is from **PSN** (Premier Specialty Network) and is confidential, privileged and intended only for the use of the recipient named above. If you are not the intended recipient or the employee or agent responsible for delivering this information to the intended recipient, unauthorized disclosure, copying, distribution, or use of the contents of this transmission is strictly prohibited.

If you have received this message in error, please notify the sender immediately at the following email address: administrator@psnmo.net or by calling [573-886-8904](tel:573-886-8904) or [573-231-9022](tel:573-231-9022). Emails originating from psnmo.net are **HIPAA** compliant. Documentation on file. Additional documentation encryption may be included.

----- Forwarded message -----

From: **Don Peterson**  (b) (6) >
Date: Sun, Jan 26, 2020 at 11:00 AM
Subject: Disinfecting Against NovoCorona Virus
To: < (b) (6) >
Cc: Bob Jackson MD < (b) (6) >

Dear Dr. Van-Kerhove,

Attached please find a few slides that explain the capabilities of hypochlorous acid in eliminating pathogens on various surfaces. Hypochlorous acid sprayed using our electrostatic spraying technology could help contain the corona virus. The virtue of electrostatic spraying is that every surface with a negative charge would be uniformly coated with HOCl insuring complete coverage and improving efficacy throughout the sprayed environment.

We would propose shipping several HOCl generators to key sites where large amounts of 500ppm HOCl could be deployed. We also propose shipping drums of HOCl to port cities to spray inbound and outbound passenger aircraft and other sites where people gather who may have been exposed to the virus.

My colleague, Dr. Robert Jackson is copied here and could serve as a clinical consultant on this effort.

We hope to hear from you soon.

Sincerely,
Don Peterson

Don Peterson
 (b) (6)
 (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:59:35 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: JAMA20-0602 Decision Letter - Please Confirm Receipt

Read carefully

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Phil.Fontanarosa@jamanetwork.org <Phil.Fontanarosa@jamanetwork.org>
Sent: Wednesday, January 22, 2020 8:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Lupe.Morales@jamanetwork.org
Subject: JAMA20-0602 Decision Letter - Please Confirm Receipt

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

January 22, 2020

Dr Anthony S Fauci
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520

RE: Coronavirus Infections: More Than Just the Common Cold

Dear Dr Fauci:

We have completed our review of your manuscript and are considering accepting it for publication in JAMA. However, acceptance will not be final until we receive all of the items described in this letter.

Do NOT send a revised version of your manuscript at this time.

After receipt of all of the items, your manuscript is accepted with the understanding that its contents, all or in part, have not been published elsewhere and will not be published elsewhere in print or electronic format without the consent of the editor.

We are planning to publish your article online ahead of print. Any information you may receive about the proposed publication date of your article is tentative and should be kept confidential. Shortly before publication, the publication date can be confirmed. Prepublication distribution of the accepted manuscript without permission is prohibited.

Please note that the news media should not release any information about your article until it is published. If you need help in coordinating press conferences or releases, please contact the JAMA Network Media Relations Department at mediarelations@jamanetwork.org or 312-464-JAMA (312-464-5262).

We sincerely appreciate your submitting the manuscript for our consideration and look forward to seeing it in JAMA.

Sincerely yours,

Phil B Fontanarosa, MD, MBA
Executive Editor, JAMA
Email: Phil.Fontanarosa@jamanetwork.org
Phone: (312) 464-2457
Fax: (312) 464-5824

Lupe Morales
Editorial Assistant, JAMA
Email: Lupe.Morales@jamanetwork.org
Phone: 312.464.2457
Fax: 866.460.7052

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

EDITOR'S REQUIREMENTS

Authorship Forms

Each author will be sent an email with instructions for submitting the Authorship Forms, with information about authorship responsibility, funding and conflicts of interests, and a publishing agreement.

Author Conflict of Interest Disclosures

Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, up-to-date, and reported in the Acknowledgment section of the manuscript in a manner that is consistent with that reported in the disclosures of potential conflicts of interest section of the JAMA's Authorship Form.

Our policy requires that all authors disclose:

Any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present);

Any relevant financial activities outside the submitted work (during the 3 years prior to submission);

And any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

Potential conflicts of interest include but are not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. For example, authors of a manuscript about hypertension should report all financial relationships they have with all manufacturers of products used in the management of hypertension, not only those relationships with companies whose specific products are mentioned in the manuscript.

Authors without potential conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests. If you are uncertain about what constitutes a relevant financial interest or relationship, please let me know. Each author will be sent an email with further instructions for submitting the Authorship Form, which includes the ICMJE Disclosure of Potential Conflicts of Interest section.

All financial and material support for the research and/or the work reported in the manuscript should be clearly and completely identified in the Acknowledgment.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 03:29:22 +0000
To: Awwad, David (NIH/NIAID) [C]
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Thanks.

From: Awwad, David (NIH/NIAID) [C] [REDACTED] (b) (6)
Sent: Saturday, January 25, 2020 9:28 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Subject: Re: CTV NEWS CHANNEL INTERVIEW REQUEST

Here is the clip from today.

https://mobile.twitter.com/RobynCurnowCNN/status/1221236930576297984?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet

Sent from my iPhone

On Jan 25, 2020, at 9:21 PM, Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6) > wrote:

Thx

Sent from my iPhone

On Jan 25, 2020, at 9:13 PM, Awwad, David (NIH/NIAID) [C] [REDACTED] (b) (6) > wrote:

I will be onsite by 7:25am for 7:30am test.

David

Sent from my iPhone

On Jan 25, 2020, at 8:09 PM, Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)> wrote:

Firm for 8 am tomorrow. See below.

Sent from my iPhone

Begin forwarded message:

From: "Taylor, Brooke" <brooke.taylor@bellmedia.ca>

Date: January 25, 2020 at 7:57:59 PM EST

To: "Conrad, Patricia (NIH/NIAID) [E]" <(b) (6)> "Awwad, David (NIH/NIAID) [C]" <(b) (6)y>

Cc: "Lautenschlager, Tyson" <tyson.lautenschlager@bellmedia.ca>, "Pekoc, Ken (NIH/NIAID) [E]" <(b) (6)> "Oplinger, Anne (NIH/NIAID) [E]" <(b) (6)>, "Lalonde, Jared" <Jared.Lalonde@bellmedia.ca>

Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Hi Patricia,

The live hit will be at 8:00 a.m. ET. Our morning producer should do a connection test around 7:30 a.m.

ET, our control room will connect around 7:55 a.m. ET.

Correct, Andrea Bain is the anchor doing the interview.

I have a pronouncer in the script for his last name 😊

Thanks!

Brooke

From: Conrad, Patricia (NIH/NIAID) [E] [[mailto:\(b\) \(6\)](mailto:(b) (6)@bellmedia.ca)]

Sent: Saturday, January 25, 2020 7:41 PM

To: Taylor, Brooke; Awwad, David (NIH/NIAID) [C]

Cc: Lautenschlager, Tyson; Pekoc, Ken (NIH/NIAID) [E]; Oplinger, Anne (NIH/NIAID) [E]

Subject: [EXT]RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Good evening:

Just touching base to reconfirm:

- 1) Live hit will be at 8:00 am ET – when will you connect via skype?
- 2) Andrea Bain will do the interview
- 3) Pronunciation of Fauci is Fow-chee – rhymes with grouchy
- 4) Will you test connection in advance and what time?

Thank you

-patty

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 5:47 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Awwad, David (NIH/NIAID) [C] [REDACTED] (b) (6)>
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>; Pekoc, Ken (NIH/NIAID) [E] [REDACTED] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Will do, thank you!

From: Conrad, Patricia (NIH/NIAID) [E] [[@mailto:\[REDACTED\] \(b\) \(6\)](mailto:[REDACTED] (b) (6))]
Sent: Friday, January 24, 2020 5:30 PM
To: Taylor, Brooke; Awwad, David (NIH/NIAID) [C]
Cc: Lautenschlager, Tyson; Pekoc, Ken (NIH/NIAID) [E]; Oplinger, Anne (NIH/NIAID) [E]
Subject: [EXT]RE: CTV NEWS CHANNEL INTERVIEW REQUEST

If there are any changes over the weekend please email all here and my cell is [REDACTED] (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[REDACTED] (b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 5:16 PM
To: Awwad, David (NIH/NIAID) [C] <[REDACTED] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>; Pekoc, Ken (NIH/NIAID) [E] [REDACTED] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Great, thank you so much!

Best,

Brooke

From: Awwad, David (NIH/NIAID) [C] [REDACTED] (b) (6)
Sent: Friday, January 24, 2020 5:15 PM
To: Taylor, Brooke; Conrad, Patricia (NIH/NIAID) [E]
Cc: Lautenschlager, Tyson; Pekoc, Ken (NIH/NIAID) [E]; Oplinger, Anne (NIH/NIAID) [E]
Subject: [EXT]RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Skype ID: Live:niaidithelp or niaidithelp@outlook.com

My cell is [REDACTED] (b) (6)

David Awwad, Contractor
Customer Services Branch, NIH\NIAID\OCICB
NTT DATA Services Federal, LLC
Phone: ([REDACTED])
[REDACTED] (b) (6)

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 5:12 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>; Pekoc, Ken (NIH/NIAID) [E] [REDACTED] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [REDACTED] (b) (6)>; Awwad, David (NIH/NIAID) [C] [REDACTED] (b) (6)
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Great, let's confirm this for Sunday, January 26 at 8:00 a.m. ET.
Dr. Fauci will be on with our anchor Andrea Bain.

Thanks!
Brooke

From: Conrad, Patricia (NIH/NIAID) [E] [[mailto:\[REDACTED\] \(b\) \(6\)](mailto:[REDACTED] (b) (6)@nihs.gov)]
Sent: Friday, January 24, 2020 5:06 PM
To: Taylor, Brooke
Cc: Lautenschlager, Tyson; Pekoc, Ken (NIH/NIAID) [E]; Oplinger, Anne (NIH/NIAID) [E]; Awwad, David

(NIH/NIAID) [C]

Subject: [EXT]RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Dr. Fauci can be available on Sunday 1/26 at 8:00 am ET for your skype interview. IF this works – please confirm asap and we will send you the connection info.

Thanks.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>

Sent: Friday, January 24, 2020 2:51 PM

To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>

Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>

Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Hi Patricia,

This would be done via FaceTime or Skype, whichever you prefer.

I have lots of time available on Sunday, 8:00 a.m., 9:00 a.m., 10:00 a.m., 12:00 p.m., 4:00 p.m. or 6:00 p.m..

Let me know if any of those times work!

The interview will be between three and five minutes long.

Thanks!

Brooke

From: Conrad, Patricia (NIH/NIAID) [E] [[\(b\) \(6\)](mailto:(b) (6))]

Sent: Friday, January 24, 2020 2:50 PM

To: Taylor, Brooke

Subject: [EXT]FW: CTV NEWS CHANNEL INTERVIEW REQUEST

Hi Brooke

What is the timing for this? how long would the interview be and what is the location of your studio? Or is this something that can be done by skype – please provide more details. Thanks.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 2:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>
Subject: CTV NEWS CHANNEL INTERVIEW REQUEST

Hi Dr. Fauci,
I hope you're well!

I'm reaching out to see if you might have any availability **this Sunday, January 26th** to join us on air to talk about the coronavirus.

Let me know if you're available and we can set up a time!

Best,
Brooke

Brooke Taylor | Chase Producer | CTV News Channel
t 416-384-7400 | brooke.taylor@bellmedia.ca 9 Channel Nine Court
Toronto, ON M1S 4B5

<image001.jpg>

CTV is Canada's largest private broadcaster. CTV News Channel is the network's 24-hour, all news, specialty channel.

External Email: Please use caution when opening links and attachments / **Courriel externe:** Soyez prudent avec les liens et documents joints

External Email: Please use caution when opening links and attachments / **Courriel externe:** Soyez prudent avec les liens et documents joints

External Email: Please use caution when opening links and attachments / **Courriel externe:** Soyez prudent avec les liens et documents joints

External Email: Please use caution when opening links and attachments / **Courriel externe:** Soyez prudent avec les liens et documents joints

External Email: Please use caution when opening links and attachments / **Courriel externe:** Soyez prudent avec les liens et documents joints

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Jan 2020 21:48:24 +0000
To: Holland, Steven (NIH/NIAID) [E]
Cc: Lane, Cliff (NIH/NIAID) [E]
Subject: FW: Qiastat-DX

Steve:

Please take a look at this. It is very interesting and something that we might want to have.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Altan-Bonnet, Nihal (NIH/NHLBI) [E] (b) (6)
Sent: Wednesday, January 8, 2020 12:34 PM
To: Gallin, John (OD) [E] <(b) (6)>; Glass, Roger (NIH/FIC) [E] (b) (6) Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Qiastat-DX

Hi John, Roger and Tony

It was very nice meeting you last night.

I am just following up regarding that machine I mentioned that does quantitative multiplex QPCR on a number of pathogens in < 1hour.

Here is a link to a brief video regarding the machine:

<https://www.youtube.com/watch?v=5KrNgq1vNds>

I've listed all the pathogens that can be tested from a single sample below. The machine is in my lab on the 2nd floor of Bldg 50 (Room 2537), you or someone from your lab is welcome to come and play with it. It is incredibly simple to use.

The GI panel and Respiratory panel cassettes (though they were initially approved for stool and respiratory expectorates respectfully) work with really any biological fluid we've tested (cell culture materials, breast milk, diluted blood etc).

It's a great tool to quickly get a quantitative and qualitative snap shot of pathogen in your samples.

If you have any questions or like to try it out, just contact me.

Best

Nihal

GI Panel

14 bacteria

- Clostridium difficile toxin A/B
- Enteroaggregative E.coli (EAEC)
- Enteroinvasive E.coli (EIEC)/Shigella
- Enteropathogenic E.coli (EPEC)
- Enterotoxigenic E.coli (ETEC) lt/st
- Pathogenic Campylobacter spp. (C.jejuni, C.upsaliensis, C.coli)
- Plesiomonas shigelloides
- Salmonella
- Shiga-like toxin producing E.coli (STEC) stx1/stx2
- Shiga-like toxin producing E.coli (STEC) O157:H7
- Vibrio cholerae
- Vibrio parahaemolyticus
- Vibrio vulnificus
- Yersinia enterocolitica

4 parasites

- Cyclospora cayetanensis
- Cryptosporidium spp.
- Entamoeba histolytica
- Giardia lamblia

6 viruses

- Adenovirus F40/41
- Astrovirus
- Norovirus GI
- Norovirus GII
- Rotavirus A

Respiratory Panel

18 viruses

- Adenovirus
- Bocavirus
- Coronavirus 229E

- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus OC43
- human Metapneumovirus A/B
- Influenza A
- Influenza A subtype H1N1/2009
- Influenza A subtype H1
- Influenza A subtype H3
- Influenza B
- Parainfluenza virus 1
- Parainfluenza virus 2
- Parainfluenza virus 3
- Parainfluenza virus 4
- Respiratory Syncytial virus A/B
- Rhinovirus/Enterovirus

3 Bacteria

- Bordetella pertussis
- Legionella pneumophila
- Mycoplasma pneumoniae

Nihal Altan-Bonnet Ph.D
Senior Investigator
Head, Laboratory of Host-Pathogen Dynamics
National Heart Lung and Blood Institute
National Institutes of Health
9000 Rockville Pike
Bldg 50 Room 2537
Bethesda MD 20892 USA

phone : (b) (6)
email: (b) (6)